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Abstract
Nitazoxanide (NTZ) has been shownto be effective against a wide range of
pathogens including anaerobic bacteria, protozoan parasites and several viruses.
Previously postulated mechanisms of action cannot satisfactorily explain the
wide range ofactivity of this class of compounds, leading to the hypothesis that
there may be multiple mechanismsofaction.
The aim ofthis study wasto profile gross biological changes in response to, and
interactions with, the thiazolides that might relate to the thiazolides mechanism
of action and thus obtain data that might be useful in determining new or more
detailed information aboutthis class of compoundsbroad spectrum ofactivity.
In this study the cellular responses to nitazoxanide and the other thiazolides
against the intestinal parasite Giardia lamblia and against hepatitis C virus
(HCV) infected cells were investigated. A NTZ resistant strain of G. lamblia
was compared to the naturally occurring wild-type strain, initially using 2D
difference gel electrophoresis (DIGE) and quantitative real time PCR, and then
also using microarray data. Analysis of differentially expressed proteins and
genes indicated that regulation of the cell cycle, mitosis, and chromosomal
organisation is important to the resistant strain. Proteomic experiments in
particular indicated that protein metabolism,translational elongation and protein
folding were also modulated in the resistant strain. Several changes in
cytoskeletal proteins were also detected.
DIGE was also used to investigate the proteomic response of Huh7 cells
expressing a sub-genomic replicon of HCV to the thiazolides. Expression
changes in several heat shock proteins, particularly BiP, a protein responsible
for coordinating the unfolded protein response, indicated that stress responses in
the endoplasmic reticulum are important in the mechanism of action against
HCV. Modulation of several proteins with critical roles in the correct
functioning of HCV replication complexes were also detected upon treatment
with thiazolide.
Specific thiazolide-host protein interactions were also sought using tizoxanide
affinity chromatography with Huh7 cells. NAD(P)H quinone oxidoreductase |
(NQO1) was identified as a previously undiscovered binding partner to
tizoxanide (TIZ). It was then shown that several thiazolides inhibit NQO1 at
physiologically relevant concentrations, and using a combination of in vitro
enzyme kinetics and computational modelling of the active site, a putative
model for binding that resembles the interaction of dicoumarol with the active
site ofNQO1is also proposed.
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Chapter1
General Introduction
This introductory chapter provides information and contextthatis of particular
importance to the understanding of the subsequent chapters of this thesis. This
includes a review of past and current literature and also provides general
information about the organisms,diseases, cell types used in the study and also
a General Materials and Methods section that details methodologies that are
commonto more than one chapterorsection of this thesis.
This study is centered around a small molecule, anti-infective drug,
nitazoxanide (NTZ), that was discovered in 1980 by Euzebyet al. [1] (Figure
1.1) as an effective anti-helminthic in cats, dogs and sheep, yet NTZ remained
a relatively unknown compoundfor quite some time. Current records indicate
that prior to 1996 there were only three published references it NTZ,all
published in the years immediately after its discovery. In the decade that
followed, published research into the activity of NTZ increased markedly
(Figure 1.2), largely due to the discovery of its efficacy against several
parasites [2], a wide range of anaerobic and microaerophillic bacteria [3, 4]
and against Cryptosporidium parvum and G. lamblia [5-7]. However, aside
from the routine testing of NTZ for efficacy against new organisms, there was
no indication of how NTZ mightelicit its effects against such an unusually
broad range of pathogens. Another major factor contributing to the increase in
research into the thiazolides, particularly during 2008, was the discovery of
20
their anti-viral properties. Hepatitis B virus (HBV) and Hepatitis C virus
(HCV) [8-18] being the most prominent in the literature, however rotavirus,
norovirus and others are also mentioned [8, 19-22]. This discovery is of major
clinical importance, and has opened new possibilities for treatment of some
debilitating and/or deadly infections. Moreover, the failure of NTZs proposed
mechanisms of action against non-viral pathogens to adequately explain its
anti-viral activity has highlighted a significant gap in our knowledge. Activity
against such disparate pathogensis also one of several indications that multiple
mechanismsofaction are probable.
21
Figure 1.1. The structure of Nitazoxanide. Full chemical name 2-acetyloxy-N-
(5-nitro-2-thiazolyl) benzamide.
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retrieved from Web of Science SCI(ISI)
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Drugsrelating to this study
There are primarily two drugsthat relate to the present study, nitazoxanide and
metronidazole
Nitazoxanide (NTZ)
The primary compoundin this study, NTZ belongs to a class of drugs known
as the thiazolides. The core molecule consists of a thiazole moiety and phenyl
ring bound by a central peptide bond. Functional groups attached to one or
both of these ring structures affect the activity, specificity and efficacy of the
various drugs, andalso result in different names for the drugs. No standardised
naming system for the drugs has been developed, although TIZ, a deacetylated
form of NTZ is accepted to be referred to as such, as is the glucuronidated
form of TIZ, TIZ-glucuronide. Further derivations of the thiazolides have
generally acquired numerical names prefixed by ‘RM’that relate to the various
‘series’ that were synthesised by Liverpool’s Dept of Chemistry on behalf of
Romark Laboratories. These names and their structural arrangement can be
foundin the chapters in which they are used.
The mechanism ofaction ofnitazoxanide
For any drug, the mechanism ofaction is the specific biochemical means by
which that drug effects its activity. Understanding the mechanism of action of
new and novel drugsis of critical importance to establishing their immediate
and long-term safety, improving their efficacy, assessing the potential for the
23
developmentof resistance and even in simply developing our understanding of
biology as a whole.
In vivo interactions with the thiazolides appear to be complex. Differing
functional group modifications have different effects on the various activities
of the thiazolides. For example, Muller et al [23] found that carboxylation or
methylation of position 3 of the benzene ring, or methylation of position 5,
diminished or abrogated the activity of the thiazolides against G. lamblia
parasites. The same effect was observed upon substitution of the nitro group
with a bromine residue but bromination does not appear to affect activities
against Neospora caninum or Cryptosporidium parvum (unless also
methylated in position 3 of the benzene ring). This has led to the notion that
the thiazolides may possess two functionally distinct active centres, at the
benzene and nitrothiazole rings and also suggests different targets within the
different parasites. However, recent research by Hoffman et al. [24]
demonstrated a probable mechanism of action of NTZ in selected anaerobic
bacteria and Campylobacter jejuni via inhibition of pyruvate ferredoxin
oxidoreductase (PFOR) through targeting of its activated thiamine
pyrophosphate (TPP) cofactor. This proposed mechanism is in contrast to the
mechanism of metronidazole which undergoes nitroreduction by PFOR to
becomeactivated. This result was particularly interesting, since preventing the
interaction with an ‘activated’ cofactor required for the correct functioning of
several enzymes is likely to require more numerous and extensive genetic
changesthan, for example, a single base pair substitution resulting in reduced
affinity between enzymeandinhibitor.
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Whilst the discovery of a target in the anaerobic bacteria and parasites tested in
their study is of great significance, it remains unclear how this mechanism
could account for the efficacy against other organisms, particularly viruses
which do not posses these enzymes themselves, and thus the effect must either
be mediated through a componentof the viruses themselves, or through a host
factor. Evidence for the targeting of a host factor, was provided by an
investigation into inhibition of hepatitis C virus (HCV)replication. Korba et al
[25] inferred that since phenotypic resistance to NTZ could not be
experimentally transferred to a naive Huh7.5 cell line by transfer of viral
RNA,resistance must be conferred by the host. Although not conclusive, it
makes a compelling argument, and is a view increasingly shared amongst
members of the field. Unpublished research, personally communicated by
Romark Laboratories has suggested that tizoxanide (TIZ), the compound
believed to be the circulating active metabolite of NTZ, acts against HCV by
disrupting the dephosphorylation of EIF2a that occurs during a typical
infection. Or to state it conversely, TIZ action allows the phosphorylation of
EIF2a, by PERK/PKRto occur normally, leading potentially to a normal
induction of the unfolded protein response (UPR) and integrated stress
response (ISR). The UPR andISRareclosely related stress responses that are
normally employed in response to stress in the endoplasmic reticulum (ER).
Although the interplay between ER stress response mechanisms and HCVis
not fully characterised, HCV appears to both induce and control and ERstress
response to its own advantage. This is discussed further in Chapter 4. With
respect to HCV infection, the structure: activity relationship differs from other
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microorganisms;it appears that whilst the nitro position is important, it can be
substituted with other groups such as a sulphomethyl (SO2CH3) that makeit up
to ten times more effective against hepatitis C virus (HCV) but ineffective
against hepatitis B virus (HBV)in vitro. Bromination moderately reduced the
efficacy against both HCV and HBVandchlorination abrogated entirely the
anti-HCV effects [26].
The complexity of the interactions between the thiazolides, pathogens and
their hosts is by no meanslimited to interactions with PFOR and PKR. NTZ
also appears to inhibit the protein disulphide isomerase (PDI) of Neospora
caninum [27], howeverit is currently unknown how this mechanism might be
effected, and the authors hypothesise that this may not be the primary
mechanism of action. A novel nitroreductase of G. lamblia is also inhibited by
several thiazolides but the functional significance of this has not been fully
elucidated andits therapeutic efficacy against this parasite is unknown.
In vivo resistance to nitazoxanide
Since NTZ is often used when treatment with metronidazole has failed, data on
the potential for pathogenic resistance to NTZ is scarce and published
incidences of resistance in any normally susceptible pathogen appear to be
limited to laboratory induced resistance in G. lamblia [28]. Although
resistance to NTZ could be induced in an Huh7.5 HCVreplicon system,it is
believed that this is mediated via genetic alterations in host factors over
several generations of selective pressure and is thus unlikely to be of
26
widespread concern with regards to the development of resistance to drug
treatmentin the general population [29].
Metronidazole
The nitroimidazole antibiotic drug metronidazole (MET) is commonly used for
the treatment of giardiasis and a mechanism ofaction is believed to be known.
Pyruvate ferredoxin oxidoreductase (PFOR) reduces ferredoxin, which
subsequently transfers it’s electrons to the nitro group of MET,resulting in a
nitro group that is highly reactive and can form covalent adducts with both
protein and DNA [30-32]. Activation by PFORprovidesa neat explanation for
the spectrum ofactivity against anaerobic bacteria and parasites thatall respire
at low or absent concentrations of oxygen and use PFORto convert pyruvate
to acetyl coenzyme A during anaerobic glycolysis. This putative mechanism is
supported by the study of METresistant strains of pathogensthat are normally
susceptible to MET. In these METresistant strains, resistance is often
associated with reduced expression of PFOR [33, 34]. However, several years
after these observations, alternative models for METresistanceare still being
proposed. For example, Trichomonas vaginalis, which is widely believed to be
susceptible to METvia the aforementioned mechanism,has had an alternative
flavin-based mechanism of action recently proposed [35].
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Gardia lamblia
Hosts andprevalence
Giardia spp. is a micro aerophilic protozoan parasite that resides in the
duodenumofthe digestive tract [36]. It is a commonparasite in cats, dogs, and
sheep but it is also prevalent in human populations where it is mainly spread
through water supplies contaminated with cysts shed from faeces [37]. It can
cause a range of gastrointestinal symptoms, though diarrhoea is the primary
problem. Infections are generally chronic and self limiting, however
immunocompromised individuals who are already particularly susceptible to
infection, will likely require treatment [38, 39]. G. /amblia exists in a number
of clonal populations, referred to as assemblages, with different host
specificities. Humansare affected by two of the more zoonotic assemblages, A
(including the highly similar but distinct Al and A2 sub-assemblages) and B
[36]. The isolate used in Chapter 3, WB clone 6, is assemblage Al and is a
clone of an isolate acquired from duodenalaspirate of a 30-year-old American
male.
Phylogeny ofG. lamblia
Since the first recorded description of G. Jamblia in 1681 by van Leeuwenhoek
[40], its taxonomic and phylogenetic classification has been the subject of
somedebate. Being a flagellated, protozoan eukaryote, assigning a taxonomic
classification to G. lamblia based on its visible characteristics finds it in
located with species such as Leishmania spp., Trypanosoma spp. and
Trichomonas vaginalis [41]. G. lamblia is further placed in the order
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Diplomonadida, and the Family Hexamitidae. More recently however these
taxonomic classifications have been somewhat supplanted by modern
phlyogenetic methods relying on the genetic sequences of highly conserved
cellular elements such as the small subunit ribosomal RNAs, translation
elongation factor 2 and ATPase’s [42-44]. These classifications have proven
enlightening with regards to the evolutionary position of G. lamblia, which
places the parasite as an early branching eukaryote [36] (Figure 1.3), although
this is still hotly debated by some whoargue that the absence of mitochondria
but the presence of mitochondrial-like genes means that G. /amblia diverged
after a proposed endosymbiotic event that may haveled to the evolution ofthe
mitochondria, and that these mitochondria were lost as an adaptive change to
their low oxygen environment[45, 46].
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Figure 1.3. Phlogenetic tree comparing 61 ribosomal proteins. Taken from
Horizontal lengths are representative of evolutionary change. The scale bar
represents the numberof aminoacid changespersite
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Life cycle ofG. lamblia
G. lamblia has just two knownlife cycle stages, the vegetative trophozoite
stage and the infective cyst stage. Upon ingestion of cysts and subsequent
passage through the stomach,the acidic conditions therein cause excystation of
the parasite and subsequently, attachmentto the luminal face of the duodenum
occurs.It is here that the parasite replicates and exerts any activity that would
lead to diarrhoea and malabsorption. G. /amblia had long been believed to be
asexual, only dividing by mitosis; however there has been significant genetic
evidence to suggest that G. /amblia can, under the right conditions, undergo
sexual meiosis [47, 48] although this has still to be observed directly.
Eventually, the growing trophozoites will be exposed to biliary secretions,
which will lead some trophozoites to encyst and be passed into the
environment along with the faeces, and the infective cycle can recommence.
During growth, exchange of nutrients and other factors required for the
survival of the parasite and maintenance of the infection occurs via a
specialised attachment organelle on the ventral side of the parasite (often
referred to simply as the ventral disk), although the precise method of
attachmentis still the subject of some debate, it appears probably to be a
mixture of chemical interactions, and mechanical ‘sucking’ force, as evidenced
by the presence of contractile proteins such as actin, myosin and others [49].
The ventral disk (VD) is made up of a structure of microtubules and
microribbons, which are made up from tubulins, and a group of annexin-like
proteins referred to as the giardins. Several of these proteins have been
localized to these structures [50-53].
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Hepatitis C Virus (HCV)
Classification andrelationship to other viruses
HCVis an enveloped, positive sense, single stranded RNA virus (Group IV).
The sole member of the genus Hepacivirus, HCV belongs to the family
Flaviviridae along with animal pestiviruses (e.g. bovine viral diarrhoea virus)
and flaviviruses (e.g. yellow fever, dengue and tick-borne encephalitis viruses)
and share similar genome organisation. Unlike the Pestivirus and Flavivirus
which infect a broader variety of species however, HCV causesdisease only in
humans; though chimpanzees (Pantroglodytes) can be experimentally infected
[54] and have beenhistorically used as a the only available animal model.
Prevalence
WHOestimates for the worldwide prevalence of HCV infection are
approximately 3% (over 200 million based on 2009 population estimates) with
higher prevalence in countries in the Far East, Mediterranean countries and
certain areas in Africa and Eastern Europe. HCV is normally transmitted via
blood-blood contact, commonly throughthe use of shared injection equipment
by drug users or accidental needle sticks however symptoms mayarise so long
after the infection that it can be difficult to identify the source of infection.
Historically however HCV could be transmitted via blood transfusions before
screening measures were established to prevent this in the early 1990s.
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Genomeandviral replication
HCVenters the cell via clathirin mediated endocytosis [55], and uncoats to
release the viral RNA into the cytoplasm. An internal ribosome entry site
(IRES) in the genome of HCV then forms a complex with the various
components required for replication [56]. The HCV genomeis approximately
9.6 kilobases in length andis translated to a 3000 aminoacid polyprotein that
is further cleaved into at least 10 proteins by cellular and viral proteases: the
core p21/p19, envelope 1 (El), E2, p7, nonstructural (NS) 2, NS3, NS4A,
NS4B, NSSA, and NSSB. There is also evidence for expression of several
frame shifted ‘F proteins’ (also alternative reading frame proteins - ARFPs)
[57, 58] whose functions (if indeed there are any)arestill unknownalthough
there is the possibility that they may possess functions that have been
previously attributed to the core proteins.
Diseases
Although the immediate (acute) infection with HCV is asymptomatic in ~80 %
of cases [59], chronic infections (persisting for over 6 months) develop in 70-90
% of cases [60]. Like the acute infection, chronic infections are usually
asymptomatic but become evident when other ailments, including fibrosis and
cirrhosis of the liver and subsequently hepatocellular carcinomaarise.
Treatments
The current standard of care for patients harbouring infection with HCV is a
combination therapy consisting of pegylated interferon a and ribavirin, but a
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sustained viral response (SVR)is only achieved in approximately 50-55 % of
cases [61, 62]. Interferon a (IFN-a) acts by inducing the expression of over
300 genes that results in an anti-viral state in the cell [63]. However IFN-a
monotherapyhas only limited efficacy and typically achieves an SVRin less
than 20 % of patients after 6 months of therapy [64]. Ribavirin meanwhile also
has limited activity as a monotherapy; howeverit is able to augmentthe effects
of IFN treatment, raising the combined incidences of SVRs above 50 %.
Details of Ribavirin’s mechanism ofaction are still unclear although evidence
for several proposed mechanismsexist [65-69].
More recently, NTZ has been identified as a potential treatment for HCV
infection for use in combination with PEG-interferon/Ribavirin treatments and
is discussed in greater detail in Chapter 4. Other potential new treatments in
the pipeline are mainly specific inhibitors of viral enzymes [70] (e.g. the non-
structural protein inhibitors telaprevir [71] and boceprevir [72]).
The application ofreplicon systems
Efficient and reliable replication systems for HCV infection have been
historically difficult to find, however the discovery of a sub-genomic replicon
system [73] has provided a safe and efficient model for replication that has
become widespread tool in HCV research and furthermore has allowed specific
functions andinteractions of the various components ofHCV to be investigated.
Moredetails regarding the replicon system can be foundin chapter 4.
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About‘omic scale approaches
Amongst the more major advances in biology of recent years, the rise of
experimental techniques that possess the power to resolve and measure many
thousands of biological components (proteins, genes, metabolites etc.)
simultaneously has been amongst the most important. Many of these
techniques have collectively been suffixed with the term omics; proteomics,
genomics, transcriptomics and metabolomics being probably the most
common, and has cometo be synonymous with the study of a system in its
entirety (or a subsystem; e.g. all protein kinases are often referred to as the
kinome). Ignoring for a moment the methodological sampling biases of
individual techniques, one of the major challenges that is faced by any single
‘omics experiment(in particular transcriptomics and proteomics)is that only a
portion of the entire picture can be observed using that method. Thatis to say,
investigating the same system with different techniques (e.g. electrophoresis of
proteins vs. microarray) will often yield results with only moderate agreement
between them [74, 75]. It is for this reason that the central dogma [76, 77] is
clearly a vast oversimplification for the purposes of understanding and
modelling global cellular changes. Thus it is becoming increasingly apparent
that to obtain a more complete and accurate picture of the biology of a system
it is important to try to observe that system on multiple and complementary
levels at as accurate a resolution as possible. This has led to increased activity
in the field of systems biology where a more holistic approach is taken to
modelling a biological system.
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Proteomics
Proteins are generally attributed to be the “actors” of cellular functions reading
from a genetic “script” [78] and as result, of all of the global cellular profiling
techniques, proteomics probably possesses the greatest power to describe the
phenotype of an organism. Somewhat ironically however, high throughput
protein studies that can distinguish between thousands of protein species are
almost entirely reliant on the existence of prior sequence data, and particularly
for lesser studied organisms, genomic data and gene prediction algorithmsthat
predict probable proteins. This protein sequence data is searched using the ion
masses of peptides derived by mass spectrometry and is a powerful method for
the identification of proteins where the protein species is already described or
hypothesised. The alternatives to this method of identification are de novo
sequencing techniques, that although feasible on a smaller scale, are time
consuming in the case of Edman degradation ordifficult to interpret in the case
of tandem mass spectrometry peptide fragmentation data [79-81]. The
organisms used in this study both have completely sequenced genomesand so
protein species that are of interest can be rapidly identified using peptide and
peptide-fragmentation ion massdata.
In the human genome,there are estimated to be approximately 25’000 genes and
whilst many of these genes may be inactive depending on the tissue type or
environmental conditions, several will possess the potential for alternative
splicing before translation into proteins and a great manyofthese proteins will
further be subject to post translational modifications. This means that the
techniques employed in any proteomic study should have a very high resolving
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power to separate these from one another. Furthermore there are many other
challenges in attempting to globally measure proteins, including protein
solubility, their wide range of concentrations, protein stability and turnover. The
proteomic experiments in this study use 2D gel electrophoresis to separate
proteins according to charge, followed by mass, and in combination with
sensitive staining can routinely resolve and detect several thousand protein
species over greater than 3.5 orders of magnitude of concentration in a single
experiment.
Transcriptomics
Transcriptomic technologies such as microarray analysis, whole transcriptome
shotgun sequencing (WTSS) such as RNA-seq, and serial analysis of gene
expression (SAGE) haveestablished themselves as reliable and informative
techniquesfor profiling the expression of many thousands of genes in a sample.
These technologies should be seen as complementary to proteomic methods
since they can only describe the level of transcript in a sample and not the
protein that it might encode. Microarrays in particular however have certain
benefits over other global techniques and lack the statistical problems that are
faced by whole proteomeexperiments. This is thanks to the fact that knowledge
of the gene sequencesis a prerequisite for synthesis of the chip on which the
experiment is performed. Asa result, the results can bestatistically assessed on
the basis of a known population size and replicate experiments are easily
combined.
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The microarray method has changedlittle since its inception. Typically short
oligonucleotide sequences corresponding to each gene that is to be quantified
are synthesised and each unique sequenceis attached to the array in a defined
area. The total mRNA from a sample is purified and reverse transcribed to
cDNA,and samples from control and treatment labelled conditions are labelled
with different fluorescent dyes. These samples are hybridised to the
oligonucleotide array resulting in a fluorescent signal in the location where the
complementary sequence exists. The intensity of the signal corresponds to the
concentration of a particular cDNAspecies. The signals from control and treated
conditions are compared anddifferentially expressed genesare identified [82].
Newer technologies such as RNA-seq do not require prior knowledge of the
sequence beforehand, since both sequence and abundance information are
obtained at the time of analysis. This has led someto believe that microarrays
may soonbereplaced by these new technologies [83].
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Chapter2
General Materials and Methods
Any workthat attempts to discover drug targets faces a considerable challenge
as testing the activity of a drug against every protein species would be an
almost insurmountable task. This makes directing the search for targets highly
desirable. In this study, we havetried to use several complementary techniques
for directing the search for partners interacting with NTZ. One philosophy
used for targeting the search for important information that is shared amongst
several of the experiments in this study is the use of differential analysis. We
have used well established methods of affinity chromatography and two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE) but in both cases
have applied differential techniques that enable us to quickly and effectively
eliminate large amounts of ‘interfering’ data and honein on the data that will
hopefully provide us with useful information. This study also uses several
techniques that are shared amongst the different aspects of investigation.
Outlined below is an introduction to the theory supporting these shared
techniques, someoftheir strengths and weaknessesanddetails of the protocols
used whereit is common between sections ofthis thesis.
2D-difference gel electrophoresis (2D-DIGE)
The DIGE technique is a combination of 2-Dimensional gel electrophoresis
(2D-GE) enhanced by several other experimental and statistical measures
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intended to both minimise experimental variation that is common in 2D-GE
and reduce the required number of sample replicates for statistical
significance. DIGE is undoubtedly a very powerful state of the art technique,
but it is not without its inherent systematic limitations. Arguably the greatest
limitation results from using a 2D PAGE based separation technique to
distinguish between protein species. 2D PAGEbased separations are mainly
able to resolve proteins that are readily soluble in aqueous solutions. Whereas
in 1D SDS-PAGE where sample is added directly to the gel and the use of
SDS helps with solubility of some of the more hydrophobic species, IEF does
not permit the inclusion of detergents such as these due to the charges
imparted on the proteins. Membrane boundorprimarily lipid soluble proteins
are therefore likely to be underrepresented in 2D PAGE experiments
employing IEF as the first dimension separation. Other techniques such a 16-
BAC/SDS PAGE[84] have been developed that are particularly suited to the
application of resolving membrane proteins, and even 16-BAC/PAGE DIGE
experiments but these experiment lack the high resolution of traditional SDS
PAGE. Proteins with an extremepI will also be excluded based on the range
of the IEF separation. Co-migration of proteins on the gel can also
theoretically lead to ambiguity in assigning an identity or potentially mask
significant changes in abundancealso [85, 86]. The individual techniques that
comprise DIGE used are discussed below.
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Isoelectric Focussing
Isoelectric focussing separates proteins on the basis of their net charge at a
given pH. Proteins are solubilised and subsequently applied to a gel support
(IEF strip) that contains an immobilised pH gradient across its length. When a
voltage is applied across this support, proteins movein the direction that will
minimise the net charge across the length of the protein. Thus, a protein with a
net positive charge at a given pH will move towards the negative electrode
until the net charge of the protein becomeszero as a result of the pH. When the
proteins reach a point at which the net charge is zero, referred to as their pl,
the proteins stop moving. A range of different pH gradients are available that
give differing degrees of separation across different pH ranges, these might be
useful for example, to obtain a higher resolution separation of a small portion
of the proteome(e.g. pH 4-7), howeverthese narrow rangestrips, will result in
various portions of the proteome falling outside their range. Since the
experiments here are intended to encompassas broad a sample of the proteome
as possible, wide-range strips (pH 3—10 non-linear) are used throughout.
First dimension electrophoresis — Isoelectricfocussing method
Immobiline DryStrips (24 cm pH 3 — 10 NL) (GE Healthcare) were rehydrated
overnight using 450 pl of Rehydration solution (8 M urea, 2 % (w/v) CHAPS,
0.5 % (v/v) IPG buffer, 20 mM DTT and trace bromophenol). 150 pg of
protein (50 pg each from the Cy5, Cy3 and Cy2 labelled samples) were
combined as outlined in individual chapters. To maximise mass spectrometry
identifications for the G. lamblia WT vs NTZr/METr + NTZs/METr DIGE
4]
experiment (Chapter 3), 300 wg of unlabelled protein from undiluted WT4,
C42 and C51 samples (100 ug from each) was loaded onto gel number3. In
both the G. lamblia WT vs NTZr/METr DIGEand the HCV replicon DIGE
experiments 500 pg of protein was loaded onto a separate preparative gel.
Finally, samples were made upto a final volume of 100 pl (maximum volume
permitted for cup-loading). Samples were applied to the strips using the cup-
loading method and run overnight on an Ettan IPGphor II (GE Healthcare)
using the protocol outlined in table 2.1
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 Step Voltage Constant/Gradient Amount Hours/Volt Hours
1 500 Constant 1 Hours
2 1000 Gradient 5200 Volt hours
3 10000 Gradient 3 Hours
4 10000 Constant 4 Hours
Table 2.1. Isoelectric focusing protocol. Total time was approximately 15 hours.
In constant steps, voltage was maintainedatthe level indicated. In gradient steps
voltage wasincreased to the level specified over the time specified. Duration of
individual steps was determined by either a fixed duration of time (Hrs) or by
the specified numberofvolt hours elapsing.
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SDS PAGE (including 1D PAGE)
The conditions in the buffers used during SDS-PAGE experiments results in
denatured proteins, coated with SDS along their length. This coating is
uniform and so proteins are imbued with a negative charge that is proportional
to their size. Proteins are transferred to one end of a polyacrylamide gel also
containing SDS,in the case of 2D-PAGE,this is directly from an equilibrated
IEF strip. A charge is applied across the length of the gel and hence negatively
charged proteins are caused to movealong the gel towards the anode. As they
move, the polyacrylamide acts as a molecular sieve that retards higher
molecular weightproteins to a greater extent than those of smaller mass.
2nd dimension electrophoresis — SDS PAGE method
Acrylamide gels (12.5 % (w/v)) were cast simultaneously using the Ettan
DALT (GE Healthcare) gel caster and allowed to polymerise overnight.
DryStrips were equilibrated for 15 min in equilibration solution (50 mM Tris,
6 M Urea, 30 % (v/v) glycerol, 2 % (w/v) SDS, trace bromophenol blue, pH
8.8) containing first 0.5 % (w/v) dithiotreitol (DTT) then a further 15 min in
equilibration solution containing 4.5 % (w/v) iodoacetamide (IAA) at room
temperature. Strips were then placed on the top edge of the gels and sealed into
place using 0.5 % (w/v) agarose sealing solution also containing bromophenol
(trace amount). All gels were run in parallel using the Ettan DALTsix (GE
Healthcare) (8 W per gel, 20 °C, until the bromophenoldye front reached the
end of the gel, ~4.5 h).
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Cyanine dye labelling
In order to visualise the proteins on the PAGE gel, minimal labelling is
performed. Cy2, 3 and 5 are cyanine based fluorescent dyes that are size and
charge matched. These are covalently bound to lysine residues at a
concentration that causes approximately 3 % of lysine residues within a given
protein to becomelabelled and asa furtherresult of this ratio, it is statistically
likely that only a single lysine residue per protein will be labelled thus
improving linearity of the resulting fluorescent signal. This technique also has
the added advantage that mass spectrometric identifications can be made from
analytical gels (as opposed to those with preparative loads) if desired without
any modification to the search algorithms as 97 % of protein remains
unmodified. The addition of the CyDye does however meanthat, particularly
at lower molecular weights, the migration distance of the proteins will be
retarded. Therefore it is common, if analytical gels are to be used for mass
spectrometric identifications that a post stain is used so that the maximal
amount of protein can be excised from the gel. Minimal labelling has a
sensitivity that is approximately as sensitive as silver staining. A different
chemistry that involves the labelling of cysteines at higher concentrations of
CyDyes, or ‘saturation labelling’, is also used due to its high sensitivity
(approximately 125 pg of protein according to manufacturers specifications),
howeverthe linearity of the stain mentioned aboveis lost. As the dyesall have
been chosen because they have differing excitation and emission wavelengths,
multiple samples can be run on each gel, reducing the total number of gels
required for a statistically valid result, and further reducing variation. As the
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weaker of the fluors, Cy2 is usually used for the internal standard which is
discussed below.
CyDye™ minimallabelling method
Labelling was performed according to the CyDye™ minimal labelling
protocol (GE Healthcare) using a ratio of 400 pmol dye: 50 pg protein, onice,
in the dark for 30 min, before stopping the reaction with 1 mM lysine on ice
for 10 min. Labelled samples were then frozen at -20 °C until required.
Use ofa DIGE internal Standard
The accuracy of the DIGE technique is greatly improved by the use of a
pooled internal standard. This standard, made up from equal amounts of each
biological replicate, ensures that each individual protein is represented on each
gel. Thus if a protein appears to be down-regulated to the point of absence in
particular sample, reference to the standard can revealif this is indeed the case,
or if the spot is merely missing altogether as can sometimes happen.Inclusion
of the standard on every gel in the experiment also aids the automated
matching of the spot patterns. The improvement in accuracythat the internal
standard providesis furtherillustrated in Figure 2.1.
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Figure 2.1. Internal standard employed in DIGE improves accuracy of
quantitation by revealing gel to gel variations. Images represent the perceived
abundance of each protein spot in a hypothetical three channel DIGE
experiment. Table below the images describe how each protein spot would be
interpreted with and without an internal standard.
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Analysis ofDIGE exeperiments
The traditional method of using one biological replicate per gel, results in a
large number of images that must be matched and analysed. One way of
minimising variation in these gels is to run replicates at the same time, using
the same equipment, however practical considerations makethis difficult. By
multiplexing samples, the number of gels required is immediately halved, and
also ensures that spots can be matched within each gel easily as migration of
proteins in each sample/fluorescent channel is identical. Numerous software
packages have been developed, by several companiesthat largely share similar
capabilities and functions. We have used DeCyder 6.0 (GE Healthcare) for the
analysis of our gel images due to its easy integration with our hardware and
cost effective licensing. Gels are scanned at the three wavelengths of the dyes,
optimising the exposure time to increase the dynamic rangeofthe signal (the
Ettan Imageris capable of pixel values between 0 and 65500) and minimizing
the signal-to-noise (s/n) ratio. Images are subsequently loaded into DeCyder,
gel images are normalised between the internal standards, automatic spot
detection is performed, spot patterns are matched and modulation ofprotein is
calculated along with statistics for each protein. This workflowis illustrated in
Figure 2.2. Referencing the identities of the protein spots back to the gel image
can also often provide information about post translational modifications such
as phosphorylation, cleavage andalternative splicing.
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Figure 2.2 Modules, functions and workflow in the analysis of DIGE
experiments using DeCyder6.5.
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Image acquisition and analysis method
Images were acquired using an Ettan DIGE Imager (GE Healthcare) and Ettan
Imager software, according to the manufacturers standard protocol, which
maximises the dynamic range (pixel values ranging from 0 to a possible
65500) of the image without losing quantitative information (via “clipping” of
the signal). To quickly determine appropriate exposure times, a small area of
the gel expected to contain the most intense protein spots (based on small scale
tests) was scanned at each of three wavelengths corresponding to each of the
three CyDyes (or Sypro Ruby when scanning a preparative gel). Using the
“report view” page of the Ettan imager software the cursor was positioned
over the most intense area of the acquired image to obtain a pixel intensity
value. The exposure time for each channel of the image was increased or
decreased to obtain maximum pixel intensity values of between 30,000 and
50,000. When appropriate values were obtained for each channel, these values
wereused to scan each gelinits entirety.
To ensure better automatic matching, areas around the edges of the scanned
images not containing protein spots or heavily obscured by dye fronts were
cropped from the images, imported into DeCyder™ Software (GE Healthcare)
for spot detection and matching algorithms. Where the automatic matching
was unsuccessful, manual landmarking was performed and used to repeat the
spot matching. Levels of image filtration were also applied to remove
interfering signals such as dust particles from subsequent analysis. Dust could
be reliably detected as “spikes” with a steep slope and small area.
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Gels (and hence protein spots) were assigned to their correct treatment group
and protein spots with significant changes in their standardized log abundance
(-1.2 > fold change > 1.2, Student t-test p < 0.05) were marked for picking
from the preparative gel. The preparative gel was post-stained with Sypro
Ruby (Invitrogen) in order to identify areas of greatest spot intensity (which
differs from areas of greatest CyDye signal by a mass decrease equivalent to
the mass of a CyDye molecule).
Spotpicking andtryptic cleavage method
Spots assigned for picking were assigned to a ‘picklist’, a text file containing
the x,y coordinates of spots to be excised, relative to a pair of reference
markers. This file was uploaded to the Spot Picker (GE Healthcare) robot,
which was then used to excise spots from the gel and store them in 96-well
plates.
The following spot picking parameters were used in order to minimise loss of
 
gel plugs:
Parameter Amount
Prefill volume 100 pl
Aspirate volume 50 ul
Aspirate flow rate 20 ml.min’!
Dispense volume 150 pl
Dispense flow rate 30 ml.min"!
Jazz (side-to-side oscillation) 1.1 mm
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Plates containing gel ‘plugs’ were sealed and frozen until they were subjected
to tryptic digestion.
After thawing, water dispensed with the plugs during picking was removed
with a pipette tip. Plugs were destained for 10 min at 37 °C with 25 mM
ammonium bicarbonate, 50 % (v/v) acetonitrile (ACN). All liquid was then
replaced by 100 % (v/v) ACNfor 10 min at 37 °C. Solvent was then removed
and the plug allowed to air dry for 10 min. Ten ul of Trypsin solution (25 pg
trypsin diluted with 250 pl 50 mM acetic acid then diluted 1 in 10 with 25 mM
ammonium bicarbonate) was added and incubated at 37 °C for 1 hr followed
by the addition of a further 10 pl 25 mM ammonium bicarbonate and
incubation at 37 °C overnight. Digestion was stopped with 2 pul of 2.6 M
formic acid.
Mass Spectrometry using ESILC MS/MS (LTQ)
This study has used a highly sensitive and accurate mass spectrometer
throughout. The system used employs a nano LC separation of peptides which
ensures minimal diffusion of reversed phase separated peptides during
transport to the electrospray ionisation (ESI) source of the mass spectrometer.
In ESI, ionisation is achieved by applying a high voltage to the tip of a very
fine capillary tube, charging the surface of emerging droplets. These repelling
charges cause disruption of the surface tensions and lead to the evaporation of
solvents and breakdownof the droplets leaving charged ions in the gas phase
[87]. The invention of ESIis attributed to John B. Fenn, for which he waslater
awarded the Nobel Prize. The gas phase ions are drawn into the MS where
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they are contained by a linear quadrupole ion trap [88] and can beselectively
released from the trap according to their mass to charge ratio (m/z). Once a
peptide ion has been identified it is further fragmented in the ion trap and the
resulting fragment ions, whose masses correspond to the amino acid sequence
of the peptide, are measured.
Identification ofproteins by tandem mass spectrometry
Twenty ul of the tryptically digested solutions of peptides were transferred to
wells in 96-well plates, and increasing volumes of water (Chromanorm for
HPLC, VWR, England) were added to compensate for the evaporation that
might occur over the course of the analysis based on experimentally
determined rates of evaporation at 4 °C (Sanderson, S. J., personal
communication). Tandem MS data were acquired for the peptides using a
linear ion trap mass spectrometer (MS) equipped with an electrospray
ionization (ESI) source coupled online to a Dionex u3000 HPLC utilising a
cl8 reversed phase chromatography column for separation. Fifteen pl of
peptide solution were loaded onto a C18 TRAP column for concentration and
desalting, and subsequently loaded onto a cl8 reversed phase column
equilibrated with 97.9 % HO, 2 % acetonitrile (ACN) (v/v) and 0.1 % formic
acid (FA) (v/v), at 300 nl.min’’. Peptides were eluted using a gradient of ACN,
increasing from 2 % ACN (v/v) to a final concentration of 90 % ACN (v/v)
(90 % ACN, 9.9 % H20, 0.1 % FA (v/v)). Peptides were passed through a
PicoTip and ionised at 1.8 kV. Ionised peptides were analysed using the “Big
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Three — Triple Play” method which consists of three main stages, run in an
iterative manner.
0)
2)
3)
4)
Survey scan — A range of m/z values were quickly scanned for the
presence of peptides and the top three most intense peaks at a given
time point above a threshold of 20’000 were noted for analysis in step
Z
Zoom scan — For each ofthe above peaks, a high resolution scan over a
narrow m/z window was analysed to determine the precise mass/
charge, the charge state of the ion and the peak collision energy for
fragmentation in step 3
MS/MS -— using the information from step 2, each peptide was
fragmented to producea series of ion masses corresponding to different
randomly split peptide fragments. The differences in masses,
correspond to the mass of the amino acids in the chain, and the
sequencescan therefore be calculated from the acquired spectra.
Repeat steps 1-3 — Peptides analysed in the current round were
excluded from analysis for the next 60 seconds and therefore excluded
during the nextiteration of analysis
The results of the analysis were stored in .RAW format, and required further
processing before they could be used for further analysis. The frequency of
ms/ms scans over time was assessed using BioWorks Browser (Thermo
Scientific) and areas not containing useful data were excluded from
subsequent generation of .DTA files using Sequest [89]. .DTA files were then
concatenated using merge.pl, a perl program that converts .DTAfiles into the
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mascot generic format (.MGF) ready for searching against the appropriate
database. The resulting MGF file for each sample was searched against the
hypothetical ion masses as determinedbytheoretical tryptic digestion ofthe G.
lamblia genome sequence that can be found at G. lambliaDB[90] using the
MASCOTsearch engine [91]. Database searches were performed using a
dedicated in-house server, either individually using the standard ms/ms web
browser based interface or using the Mascot Daemonto automate the search.
In either case the following non-default parameters were used:
 Parameter Setting
Database:
Fixed modifications:
Variable modifications:
Enzyme
Maximum missed cleavages
Peptide charge
Peptide tolerance
MS/MStolerance
G. lamblia Annotated Proteins
Carbamidomethylation (C)
Oxidation (M)
Trypsin
1
1+, 2+ and 3+
+2.0 Da
+ 0.8 Da
 
Anoverall Mascotscore ofat least 50, and at least 70 % presence of b or y ion
series in any peptide was required for a positive match.
55
Aimsofthis study
This study aimedto use differential proteomic, transcriptomic and bioinformatic
techniques to profile the global cellular changes that occur in host and pathogen
cells in response to NTZ.It was hoped that these changes could be usedto gain
novel insights into the mechanism of action of NTZ. Specific molecular
interactants with the thiazolides and details of how these interactions may occur
are also sought.
In Chapter 3 of this study, transcriptomic, proteomic and_ bioinformatic
approachesare used to investigate changes in a NTZresistant strain of Giardia
lamblia. In Chapter 4 the DIGE technique is applied to a human cell line
expressing a subgenomic replicon of HCV, which has relevance to the new
hypotheses regarding NTZs efficacy being mediated through host cell targets.
Benefiting from excellent functional annotation, bioinformatic approaches are
also employed to describe the possible implications of the results of this
experiment. Global profiling techniques can only go so far to describing the
specific interactions of a drug andits targets, and therefore to attempt to answer
important questions about specific host cell targets of the thiazolides, affinity
chromatography is used in Chapter 5 to seek out proteins with binding
interactions with the thiazolides. The potential of this technique for discovering
potentially important informationis clearly demonstrated bythe identification of
a previously unidentified binding partner from human liver cells, NAD(P)H
Quinone Oxidoreductase 1 (NQO1). In Chapter 6, the nature ofthis interaction
is investigated in greaterdetail.
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Chapter 3
Proteomic and Transcriptomic Analysis of Resistance to NTZ in Giardia
lamblia.
Introduction
The Centre for Disease Control (CDC) in the U.S.A. estimates that there are
approximately 8 incidences of G. lamblia infection per 1000 people in the
U.S.A. every year, and the Health Protection Agency (HPA)reports a similar
proportion of reported cases in England, Wales and Northern Ireland.It is not
in developed countries however that giardiasis represents a major clinical
problem. In third-world countries, the prevalence of infection can be over 50
% in some populations, putting the world-wide total in the order of hundreds
of millions (approx. 250 million infections, 500000 symptomatic according to
World Health Organization estimates for 1992) [92]. In these areas, death
resulting from dehydration and malnutrition due to diarrhoea is the main cause
for concern. There have also been suggestions that chronic giardiasis can result
in long-term growth retardation [93]. Thankfully, there are several
pharmaceuticals that are commonly used to treat giardiasis, including
metronidazole, tinidazole, nitatazoxanide, and less commonly paramomycin,
furazolidone, quinacrine, albendazole and mebendazole. Currently however,
treatment of giardiasis is largely by metronidazole (also called Flagyl™).
Metronidazole is believed to act against anaerobic bacteria and susceptible
protozoa by reductionofits nitro group by pyruvate ferredoxin oxidoreductase
(PFOR) (the homologue of aerobic pyruvate dehydrogenase enzymes), the
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terminal part of the glycolytic pathway. This generates reactive toxic nitro
radicals that cause damageto the cell. The drug is generally well tolerated,
although some patients suffer with unpleasant side effects and incidences of
resistance are occasionally reported. In laboratory derived resistant isolates of
G. lamblia, PFOR is often downregulated several fold and complementary
enzymesare believed to take its place. Nitazoxanide also possesses a nitro
group onits thiazole ring, raising the possibility that a mechanism of action
similar to that of metronidazole could be responsible for its anti-G. lamblia
activity [94]. Research however showed that no such metabolism of NTZ
could be observed [24]. Parallels were also drawn between the cofactor of
PFOR, thiamine pyrophosphate (TPP — Figure 3.1), which shares some
structural similarity to the thiazolides. It was postulated that NTZ might
compete with TPP for a binding site on PFOR,thus inactivating or modifying
its activity. However, NTZ appears to hijack a TPP intermediate and cause the
reversal of pyruvate binding [24]. This mechanism is thought to have a high
barrier to resistance since mutations in PFOR would notaffect the interaction
of TPP and NTZ without affecting the interaction between PFOR and TPP,
and could have lethal effects.
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Figure 3.1. Structures of nitazoxanide and thiamine pyrophosphate.
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Application ofproteomics to the discovery ofmechanismsofaction
The discovery of the mechanism ofaction of a drug can often be expedited by
the judicious use of proteomic or transcriptomic techniques and protein
expression profiling can reveal important changes in the abundance ofproteins
or metabolic pathways involved in conferring resistance to a drug. Studies of
the Leishmania proteomeusing 2D gel electrophoresis (2D-GE) have revealed
over-expression of known drug resistance factors and have also postulated
post-translational modification of drug targets that had not been previously
considered [95]. The use of 2D-GE has since been improved greatly and
techniques such as difference gel electrophoresis (DIGE) have gained
popularity in investigating resistance and virulence in many different
organisms. Recent examples include chemoresistance in cancercell lines [96],
drug resistance in Candida albicans [97] and Acinetobacter baumannii [98]
and virulence factors in Entamoeba histolytica [99] and examples for many
other pathogensexist.
The speed with which custom high resolution oligonucleotide arrays can now
be generated for organisms with sequenced genomes, has meant that
comparative array techniques have now beenused to discover mutations that
are associated with drug resistance [100]. High throughput sequencing
methods are also now beginning to provide an accurate and rapid utility for
profiling changes in transcript expression and for discovering mutations [101,
102].
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Suitibility ofG. lambliafor proteomic andtranscriptomic study
Aside from its interesting phylogenetic positioning that indicates that it is a
very early branching eukaryote, one key factor that makes G. /amblia an ideal
candidate for study is the ability of some isolates to be grown either
axenically, or in co-culture with a host cell. This provides scope for
experimental approaches that ensure that observed protein changes can be
directly attributed to the perturbation of the system under consideration, and
are not indirect effects mediated through the host system for example, as might
be the case with other parasites such as Toxoplasma gondii. The requirements
of a media for axenic growth mimic the favourable conditions of the host [103]
including low O, content, high cysteine content and the addition ofbile salts.
Modified TYI-S-33 is the most commonly used growth mediain the culture of
G.lamblia. There are however several other factors and_ technological
developments that make G.lamblia increasingly appealing for a model for
study.
G. lamblia Genomics
A major technological advance that has enabled more effective research into the
G. lamblia proteomeis the availability of a fully sequenced genome(available at
www.giardiadb.org [104]). Whilst at the start of this project, the G. lamblia
genomedatabase wasat a fairly early stage of development, considerableefforts
of researchers in this area has meant that the genome is now fully sequenced
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with good coverage and furthermoreit is provided alongside a rangeoftools for
querying the data. The data has also been integrated with anothercross species
database of related organisms, EuPathDB (www.eupathdb.org), which provides
several tools for cross species comparisons. Perhaps most importantly, the
availability of this database facilitates the use of other techniques that rely on
these data, i.e. transcriptomics and proteomics.
G. lamblia Transcriptomics
The availability of comprehensive genomic sequence data makes the use of
microarray technologies for the study of G. /Jamblia now feasible. The Pathogen
Functional Genomics Resource Centre (PFGRC) (http://pfgrc.jcvi.org/) has free
arrays available but approximately 50 % ofthe oligomers on these arrays belong
to now depreciated gene sequences. Thus far, the use of these and other arrays
appearsto be largely limited to attempts to correctly diagnose G. lamblia as the
causative agent in gastrointestinal disease where it is present. They have also
bee used to investigate unresolved questions about G. /amblia’s phylogenetic
classification [105]. One notable exception was as study performed by
researchers at the University of Berne, Switzerland [106]. In their study,
microarrays were used to investigate laboratory derived resistance to NTZ.
Anothertranscriptomic study worthy of note has looked at host cell changesin
response to infection with G. lamblia [107]. The results of this study suggest
that G. lamblia causes many changesin expression in host cells and in particular
G. lamblia appears to induce chemokine responses different to other enteric
pathogensthat cause intestinal inflammation, providing a possible insight as to
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how G. lamblia establishes chronic infection, often without causing significant
inflammation in humans.
G. lamblia Proteomics
In G. lamblia the level of refinement and annotation of the genomic data is
improving rapidly and a recent release of the database (version 1.2) eliminated
nearly half of the predicted genes on the basis that they were unlikely to
represent true proteins. However, current gene annotation is heavily reliant on
homologousproteins from other organisms and the multiple and sometimes
unexpected functionalities of some proteins, means that species specific
functional studies are needed for accurate interpretation of results.
Improvements in G. /amblia specific data would also create a better foundation
for the creation of in silico models. Currently only a relatively small proportion
of genes have functional annotations associated with them, and G. lamblia-
specific proteins such as the giardins might never be described fully without
direct experimentation.
There are relatively few existing studies that have investigated protein
expression in G. lamblia, and certainly none that investigate how protein
expression might be modified in response to NTZ resistance. The majority of
studies are focused towards laying more complete foundations of our
understanding of the biology of the parasite or understanding the way the
parasite interacts with its hosts. A recent review [108] gives an excellent
overview ofthis area, and also highlights ways in which the developmentofthis
area could be improved. It praises the integration of the mature genomes of
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parasites such as Toxoplasma gondii with thorough proteomic profiling studies
that have used multiple techniques to identify up to 30 % of the predicted
proteome [109].
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Aimsofstudy
Wewish to improve the understanding of the mode ofaction of nitazoxanide
against G.lamblia parasites. G. lamblia can be grown axenically and its
genome has been fully sequenced and partially annotated. Furthermore, a
laboratory derived, NTZ resistant strain (also cross resistant to MET) and a
METresistant strain are available for comparison with the wild type one
(NTZr/METr, NTZs/METr, and WT respectively). The study will primarily
focus on the problem from a proteomic perspective, but will also be followed
up using both quantitative transcriptomic data, and also with the re-analysis of
an existing microarray dataset. Together these approaches will be used to
investigate how gene expression is modulated in parasites that have acquired
resistance to NTZ and MET,andtheresults used to infer possible mechanisms
of resistances.
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Methodsand Materials
Description ofpreparation ofresistant strains
Samples of G. /amblia were kindly provided by Prof. Andrew Hemphill at the
Institute fiir Parasitologie at the University of Bern and were grownasfollows:
Trophozoites from G. /amblia WB clone C6 were grown under anaerobic
conditions in 10 mL culture tubes (Nunc, Roskilde, Denmark) containing
modified TYI-S-33 medium [110]. To initiate subcultures, cultures with
confluent trophozoite lawns were incubated on ice for 15 min. Suspended
living (adherent) trophozoites were counted (Neubauer chamber, 200x).
Subcultures were initiated by adding 10* trophozoites to a new culture tube.
The METr clone was cultivated in the presence of concentrations of
metronidazole increasing to 60 uM, whereas double-resistant clone
NTZr/METrwascultivated in the presence of up to 40 uM nitazoxanide [106].
Cells were passaged in the absence of drug for several generations before
being snap frozen in nitrogen ready for transport.
2-Dimensionaldifference gel electrophoresis (DIGE)
A 2D-DIGEexperiment was performed using the common methods outlined
in Chapter 2 and the experiment specific manner below.
Cell Lysis and Sample Preparationfor Proteomic Analyses
For each of the cell lines four biological replicates were obtained and each
frozen pellet was solubilised in cell lysis buffer (20 mM Tris, 7 M urea, 2M
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thiourea, 2 % (w/v) CHAPS, 2 % (w/v) ASB-14, complete mini protease
inhibitor, DNase, pH 8.5 (onice)) using 1 mlper 1.1 x 10° cells.
Total protein concentration was determined using the 2D-Quant kit (GE
Healthcare) in which proteins are precipitated to leave potential interfering
contaminants in solution followed by resuspension in a copper containing
solution and a quantitative measurement of the level of unbound copperthat
remains after binding to protein has occurred. The 2D Quant Kit is compatible
with all of the reagents in the lysis buffer except ASB-14 which had not been
tested. The results of the assay proved to be unreliable possibly as a result of
the ASB-14. To overcome this, samples were precipitated to removesalts,
contaminants and otherinterfering substances using the 2D Clean-Up kit (GE
Healthcare) using the most recent concentration values obtained for the assay
and resuspended in 8 M urea, 30 mM Tris, 4 % (w/v) CHAPS,pH8.5 so as to
be compatible with the BSA-coomassie assay (Bio-Rad). After determination
of protein concentration, all samples were adjusted to the same concentration
(equal to the lowest measured concentration obtained) and stored frozen.
CyDye™Minimal Labelling
The following nomenclature was used for each sample, WT, C4 and C5 refer
to the Wildtype, NTZr/METr and NTZs/METrstrains respectively and
subsequent numbering refers to the biological replicate. Labelling was
performed as outlined in table 3.1 and 3.2 using the method described in
Chapter2.
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 Gel Id Cy3 Cys Cy2
1 W3 C41 STD
2 Ww2 C44 STD
3 C42 C52 STD
4 C51 Wi STD
5 C53 C54 STD
6 C43 Ww4 STD
 
Table 3.1. Labelling and “Gel Id”allocation of samples. W, C4 and C5refer to
the WT, NTZr/METr and NTZs/METrstrains respectively and subsequent
numberingrefers to the biological replicate. The internal standard (STD) was
created from equal amounts ofall samples. An unlabelled preparative load was
 
added to Gel3.
Gel Id Cy3 Cy5 Cy2 Sypro
1 W3 C43 STD -
2 Ww2 C44 STD -
3 C42 Ww4 STD -
4 C41 Wi! STD -
5 - - - Prep
 
Table 3.2. Labelling and “Gel Id” allocation of samples. W and C4 refer to the
WT and NTZr/METrstrains respectively and subsequent numberingrefers to
the biological replicate. The internal standard (STD) was created from equal
amounts of all samples. An unlabelled preparative load run on a separate gel
(Gel5).
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qRT-PCR
To provide accurate and useful information about the underlying cellular
processes controlling protein expression we measured levels of mRNA
transcripts of 22 genes encoding the proteins differentially expressed (as
determined by 2D-DIGE) between wildtype and NTZr/METrstrains of G.
lamblia.
Sample preparation
cDNA and RNA samples were prepared at the Institute fiir Parasitologie by
Carolin Maier, University of Bern using the Qiagen RNeasy™ kit and DNase 1
for the RNA isolation and the Quiagen Omniscript™ RT kit for reverse
transcription to cDNA,according to manufacturers’ instructions in both cases. A
polyT-ANCprimer was used for subsequentreal-time PCR.
qRT-PCR procedure
Quantitative real-time PCR was performed with 4 wL of 1:100 diluted cDNA
using the Quanti TectTM SYBR Green PCR Kit (Qiagen) in a 10 wL standard
reaction containing a 0.5 mM concentration of forward and reverse primers
(completelist in Table 3.3)(MWGBiotech, Ebersberg, Germany). Furthermore,
a control PCR included RNA equivalents from samples that had not been
reverse transcribed into cDNA (data not shown) to confirm that no DNA was
amplified from any residual genomic DNA that might have resisted DNase I
digestion. PCR wasstarted by initiating the ‘Hot-Start? Taq DNA-polymerase
reaction at 95°C (15 min). Subsequent DNA amplification was performed in 40
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cycles including denaturation (94°C for 15 s), annealing (60°C for 30 s) and
extension (72°C for 30s); temperature transition rates in all cycle steps were
20°C/s. Fluorescence was measured at 82°C during the temperature shift after
each annealing phase. For each gene, three replicate experiments were
performed. Expression levels of the genes summarized in were given as values
in arbitrary units relative to the amount of constitutively expressed housekeeping
gene ACT[106].
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 Gene Target ORF Forward/ Primer Sequence
number Reverse
Primer
Hypotheticalprotein 4259 F TGACATGTTCGGTTTTGGGG
R AGCAGCAGGCTGCTGGGT
Beta-giardin 4812 F AGGTTCCACGACAAGATGGA
R GATGGCGATCTGGTTCTGG
Calmodulin 5333 F CCTATAAACCTGCCCCAGG
R CATTGACGTACCCGTCACC
Hypothetical protein 8038 F TTTGGACTCGGCAATACCCA
R TCTTCGAAAGGCTGGTTTCC
Protein disulfide isomerise 5 8064 F TGCATCTCAACACGTCATATG
R CCTCCTGGCAGACCTCAC
Nucleoside diphosphate kinase 11301 F TGAACGCACCTTTCTCATGG
R CCCCATCATGGTGCGGGA
20S proteasome alpha subunit2 11434 F AGGAAGGCTCTCAATAGGGA
R ACGAGCTAACATATTAACGGG
Hypothetical protein 11497 F CCCCCTGAATTTCAACCAGA
R TGAGAGACGTGATGGTGGG
Carbamate kinase 16453 F CTTAGCGAGATTCTCGCCC
R ACGAAGGTAGAGCAGCTGG
Hypothetical protein 16588 F AGCACCTTGCGGCGTACC
R TCTTGGCTGCTGCAGGGG
Protein 21.1 17060 F CCCCTGCAGCAGCCAAGA
R CCGTTAGGGCTGCTTGGG
Giardia trophozoite antigen 1 17090 F ACTCCTGTTGCAAAGATATGG
R TATCTCCCCGGAGTTCTCC
PPI-B precursor 17163 F AAGGTCTTCTTTGACATCACC
R GCCCAGCATTCGCCATGG
Gammagiardin 17230 F GTCATCGTTCTCGACCGTC
R GTAGACTCCAGCTCGCGG
Xaa-Pro dipeptidase 17327 F CCTCTACGTCACGGGCTG
R CCCCGCCGTCTGCTCCA
Elongation factor 2 17570 F GGTTGTGATGGAGGAAGCC
R GTCTGGACGCAAACACCCT
Spindle pole protein, putative 24537 F CTTAAGGTTGTGGCTCCCC
R TGCCTGCAGTGAAGCGCC
Protein 21.1 27925 F GAGTGTGTGAAGATCCTGGA
R AGGCAATCAGTTGAAAAGGGA
Delta giardin 86676 F GCGCGCCTTCTGCCCTC
R TTGTCAAGGTGCTCAATCCC
Triosephosphate isomerase 93938 F TGCCTGCTCGTCGCCCC
R CCCCGTTCCCCTCTAGGT
Alpha-7.3 giardin 114787 -F GCTGCAGCGAAGGCTACC
R GATCAGCCTGCAGCGGAC
Protein 21.1 14872 F AACAGGCACCTACAACCCC
R TTAGAATAGTTTCCCCCACCA
 
Table 3.3. Primers used for (RT-PCR experiments. Open reading frame (ORF)
numbers correspond to ID’s for species GL50803(WB C6) in GiardiaDB
(www.giardiadb.org)
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Microarray Method
Transcriptomic analysis ofresistance to NTZ in Giardia lamblia
To gain further insight into gene expression changes that are associated with
resistance to NTZ, a microarray dataset originally created at the University of
Bern was re-analysed. This two colour microarray dataset using the
NTZr/METrcell type from the same source has thus far only had relatively
crude and arbitrary criteria of >-4, <4 fold change applied to it to determine
potentially altered gene expression in the drug resistant cell type. We have
applied more accurate andstatistically robust methods to the analysis of these
data including normalisation that accounts for inherent systematic spatial
effects (i.e. print tip group effects) as well as investigating the use of other
more broad methods such as_ over-representation analysis, using
hypergeometric distibution of Gene Ontology terms.
The experimental work for the microarray experiments is entirely the work
ofresearchers at The University ofBerne, Switzerland. Detailed descriptions
regarding the preparation of RNA samples, microarrays, hybridisation and
data acquisition can befoundin the originalpaper [106].
A brief description of the microarray method is reproduced here, with
permission,for convenience.
Aminoallyl cDNA was prepared using a combination of random primers
(Promega) and Omniscript reverse transcriptase and was subsequently purified
using a Roche PCRpurification kit to remove contaminating amino groups
that would interefere with subsequent labelling. Samples were then lyophilised
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until required. Lyophilised samples were rehydrated and labeled with either
Cy3 or Cy5 cyanine flourescent dyes. Dye-labelled cDNA wasthen purified
by Roche PCRpurification kit according to the protocol. Purified cDNA was
again lyophilized and stored in the dark until microarray hybridization.
Microarrays from the Pathogen Functional Genomics Research Center (J.
Craig Venter Institute, Rockville, MD, USA) containing 19230 elements
consisting of duplicates of 70-mer oligomers derived from 9115 predicted
open-reading frames (ORFs) including the clearly identified 6470 ORFsofthe
genome of G. lamblia WB Cé6as described in the G. lamblia database and of
500 Arabidopsis thaliana control oligomers were prepared for hybridisation.
Slides were hybridised with samples, pooled from equal amounts of the
labelled cDNA, washed and subsequently scanned using a GenePix Personal
4000B scanner (Molecular Devices, Sunnyvale, CA, USA). Data files
including annotation and evaluation of the hybridized slides was performed
using the GenePix Pro. Twotechnical replicates were performedintotal.
Re-analysis ofWT vs. NTZr/METr microarray data
Aspart of this study, to gain further insights into the transcriptomic data from
the microarray data, it was re-analysed using the statistical computing tool R
[111] (www.r-project.org). The analysis also used the following package
libraries which provided the meansto execute specific functions of the analysis:
limma, limmaGUI, statmod, RZHTML,tcltk, marray and sma [112-115]. The
data used in this analysis is available online at the following location:
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http://www.ipa.vetsuisse.unibe.ch/index.php?option=com_content&task=view&
id=56&Itemid=134&lang=EN.
The data available is a Excel spreadsheet (Microsoft Corporation) copy of the
output from the microarray analysis software Genepix Pro (Molecular Devices),
and essentially contained the same information as a .gprfile (the format used by
Genepix) without the header information that described some of the scanner
settings etc. In order to make the data contained in the .xls file compatible with
the .gpr format, the raw tab delimited data was edited in Notepad++ and the
header information was added to the file. Once raw median foreground and
background expression levels for each colour channel (Cy3 (532 nm) and Cy5
(635 nm)) were loaded into limma by LimmaGUI, the data was background
subtracted using the normexp + offset method (offset =50) rather than local
median feature background subtraction which often results in a high number of
negative expression values whichlater results in missing data due to theinability
to calculate the log, ratio from a negative value.
Within each array, the data was normalised using a print-tip group loess
normalisation algorithm and the data did not require normalisation between
arrays. Within array duplicates were averaged before applying a linear fit model
and genes were ranked in order of the significance of their evidence for
differential expression using the eBayes method (empirical Bayes) to compute
moderated t-statistics, moderated F-statistic, and log-odds of differential
expression and sorted by their log odds with the topTable function. P-values
were adjusted using the “Holm” method, a less stringent step-down modification
of the Bonferroni method, howeversince current available methods cannot take
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into accountthe likely positive correlation both within array and between array
technical replicates and the sample size (i.e. two technical replicate arrays) is
very small, this was merely used forindicative andillustrative purposes.
Data were exported back to Excel and spots with low expression levels (<800)
or logy fold-change less than +1 (actual +2 fold change) were excluded. Product
descriptions were also updated using the latest release of G. lamblia DB (which
saw large proportion of the 9115 original set of G. lamblia genes included in
the microarray experiment depreciated leaving only 4692 genes). Available gene
ontology terms (GO terms) were also extracted from the database and used for
overrepresentation analysis.
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Bioinformatic Analyses
Informatic analysis ofDIGE experiments
To try and deconvolute protein expression changes due to NTZ resistance, from
generic stress responses, or changes that confer resistance to MET,the results
from the WT vs. NTZr/METr analysis were combined with the WT vs.
NTZr/METr+NTZs/METr combined experiment. Both of the datasets have the
potential to answer different biological questions, i.e. the comparison between
the WT and NTZr/METrstrain, should detect modulated proteins that result in
resistance to either NTZ or METor both but mayalso contain information that
relates to a stress response. The WT vs NTZr/METr+NTZs/METr comparison
however should mainly detect modulated proteins that result in resistance to
METsince both a NTZs and NTZrstrain are included in the analysis. A stress
response may also be detected. Thus by using the latter data set to infer which
proteins from the first data set might be modulated due to METrora stress
response it is hoped the powerto identify proteins specific to NTZ resistance
will be improved. Furthermore, by describing the data in a more generic way
using Gene Ontology (GO) terms, it was hoped that broader areas for
investigation might be identified.
Proteomic Analyses
GO Terms
Proteins found to be differentially expressed by DIGE were interrogated for
function using GO term annotations. Gene and GO term data were downloaded
from G. lambliaDB and from this an annotation file compatible with
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Ontologizer was created. Ontologizer’s integrated GraphViz connection was
used to generate a graph of the full lineage of all GO terms found in the
proteomic datasets using the default graph rendering tool ‘Dot’.
Transcriptomic Analyses
GO-Term Hypergeometric Distribution Testing
Gene and GO term data were downloaded from G. lambliaDB and from this an
annotation file compatible with Ontologizer 2.0 was created. When provided
with a population and its respective annotations, Ontologizer was used to
determine overrepresentation using hypergeometric distribution analysis,
initially using the parent-child setting in order to account for the hierarchical
nature of GO terms but also using term-for-term and topology-weighted
methods. Ontologizer’s integrated GraphViz connection was used to generate a
graph of the significant GO terms using the default graph rendering tool ‘Dot’.
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Results
A direct proteomic comparison between the WB C6 wildtype strain of G.
lamblia (WT) and a laboratory derived NTZ resistant (NTZr) cell line [28] was
initially conceived. A challenge in interpreting this approach is the inherent
difficulty in determining which changes in protein abundance are the direct
effects of the characteristic under study (i.e. drug resistance in this case). For
example, a recent proteomic investigation of encystation in G. lamblia [116],
indicated the involvement of HSPs 70 and 90, however due to the acidic bile
conditions required to induce encystation, it is difficult to determine if these
proteins are essential to encystation, or if they simply facilitate survival. To
resolve this dilemma,in this study two protein data sets were created. Thefirst
compared the WT to the NTZr/METr strain, and a second dataset was
generated that included both the NTZr/METr strain and a metronidazole
resistant (NTZs/MET?r)strain. It was hoped that by comparing these datasets
we might be able to deconvolute, the effects of drug stress, and also detect
proteins whose modulation might be more relevant to MET resistance than
NTZresistance in the cross resistant strain.
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Proteomic analyses
2D-DIGE of Wildtype vs NTZr/METr Giardia lamblia.
To investigate potential protein changes that might have occurred during the
acquisition of resistance to NTZ,cell lysate from wildtype and NTZr/METrG.
lamblia were compared using 2D-DIGE.
Typical 2D gels
Small scale tests of the lysis conditions using a mini SDS PAGEgel and both
pH 3-10 NL and 4-7 IEFstrips were successful (not shown), so 3-10 NLstrips
were used for large scale gels to maximise proteome coverage. A typical
separation is shown in Figure 3.2, including an overlay of the three CyDye
wavelengths illustrating how protein levels can been seen to differ between
samples.
Spot matching and DeCyder analysis examples
Whilst spot detection in DeCyder was comprehensive and generally satisfactory,
spot matching between gels usually required significant manual intervention
(landmarking) to achieve an acceptable level of accuracy.
Protein identifications
The majority of protein identities in the following lists are assigned on the
basis of being the ‘top hit’ presented by the results of the Mascot scoring
algorithm (that is, possessing the strongest statistical evidence for a correct
identification), however in two cases, ambiguity in the assignments resulted
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from Mascot’s scoring system automatically switching its proprietary scoring
system to an alternative one upon submission of a query where;
“the ratio of the number of queries to the numberof entries in the database,
(after any taxonomyfilter), exceeds 0.001 [91]
This scoring algorithm is intended for use with MudPIT data however, andis
intended to account for protein hits that have arisen as a result of a high
numberof low scoring peptides. A low intensity threshold during LC/MSto
maximise sensitivity and the small size of the G. Jamblia genome meansin
manycasesthe scoring algorithm was changed automatically. To ascertain the
extent to which the scoring algorithm affected the assignmentofa top hit, the
results were re-scored using the standard scoring algorithm with an ion score
cut-off of 20. Ambiguity in the assignmentof ‘top hit’ was only a factor in the
two aforementioned cases and the result pertaining to Elongation factor 1 was
discounted in favour of the default result due to the apparent mismatch
between the proteins predicted mass and the observed migration distance. The
results and analysis take this into account.
Thirty one differentially expressed protein spots could be matched to a
corresponding spot on the preparative gel. Of the thirty-one spots,
identifications were made for twenty-five. In each case, the highest scoring
protein as determined by Mascot, matching the specified criteria was used for
the identification. In total, eighteen unique proteins were detected as being
differentially expressed due to the same protein being identified in multiple
spots in four instances. Whilst both alpha-7.3 and beta giardin hits were
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modulated in the same direction, spots corresponding to protein 21.1
(GL50803_17060) and peptidyl-prolyl cis-trans isomerase B were modulated
in both directions. These results might be evidence of an isoform shift or post
translational modifications (PTM). In All twenty-seven identifications are
shownin Table 3.4.
Simple validation ofprotein identification results
As another measure of the accuracy of the Mascot hits the predicted protein
masses from G. lambliaDB wereplotted against the observed migration distance
on the gel. The majority of protein identifications aligned well along a single
straight line. Proteins that did not align well were identified as Protein
21.1(GL50803_17060 / GL50803_27925) and Elongation factor 2
(GL50803_17570) as indicated by black arrowsin Figure 3.3.
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 ORF Average RatioProtein Name Number ttest (WT: NTZr/METr)
Beta-giardin 4812 0.015 -1.32
Beta-giardin 4812 0.034 -1.25
Calmodulin 5333 0.002 2.09
Hypothetical (putative nucleoporin) 8038 0.038 1.63
Protein disulfide isomerase PDIS / Dyenin light chain 8064/9848 0.043 -1.36
20S proteasomealpha subunit 2 11434 0.00069 1.57
20S proteasomealpha subunit 3 14497 0.0043 ~—- 1.83
Hypothetical (Bacterial type SMC domain) 15499 0.036 1.84
Carbamate Kinase 16453 0.045 -1.48
hypothetical (ribosomalprotein p2) 16588 0.034 -1.32
Protein 21.1 17060 0.0013 2.62
Protein 21.1 17060 0.0036 2.77
Protein 21.1 17060 0.031 -2.97
Giardia trophozoite antigen GTA-1 17090 0.047 1.35
Peptidyl-prolyl cis-trans isomerase B precursor 17163 0.012 -1.44
Peptidyl-proly] cis-trans isomerase B precursor 17163 0.014 1.64
Peptidyl-prolyl cis-trans isomerase B precursor 17163 0.032 2.48
Peptidyl-prolyl cis-trans isomerase B precursor 17163 0.048 1.66
Xaa-Pro dipeptidase 17327 0.035 1.88
Elongation Factor 2 17570 0.026 -1.57
Spindle pole protein 24537 0.033 2.35
domi (Ankrepeats / Bacterial type SMC 27925 0.047 “1.37
Triosephosphate isomerase, cytosolic 93938/112304 0.0079 1.57
Alpha-7.3 giardin 114787 0.038 1.51
Alpha-7.3 giardin 114787 0.044 1.77
 
Table 3.4. Identities and average ratio change for proteins differentially
expressed in the NTZr/METrstrain of G. lamblia. Cell lysates of WT and
NTZr/METr G. Lamblia were compared using DIGE. Protein spots with
significantly different (t-test = <0.05) relative abundance were picked from the
gel and identified using mass spectrometry. Duplicate identities in the table arise
from the sameprotein being identified in independent spots.
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Figure 3.2. A typical 2D separation of Giardia lamblia proteins. Panel a) Cy2,
b) Cy3, c) Cy5, d) False colour composite of all channels
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Figure 3.3. Plot of the predicted massofeach protein from release 1.2 of
GiardiaDB against observed migration distance on a logarithmic scale. Arrows
indicate points corresponding to protein spots identified as Protein 21.1
(i.d.:GL50803_17060 / 27925) and elongation factor 2 (GL50803_17570)that
do not appear to correspondto the rest of the data, possiblyas a result of either
incorrect assignmentof identity, alternative splicing or protein degradation.
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2D-DIGE of WT vs. NTZr/METr + NTZs/METr Giardia lamblia
Protein identifications
Aspreviously mentioned, the NTZr/METrstrain of G. /amblia is also cross
resistant to metronidazole, however a NTZs/METrstrain of G. lamblia has
also been generated by passaging growingcells in sub-lethel concentrations of
MET. In order to attempt to understand the similarities and differences
between the resistance mechanisms that occur in each ofthe strains, a second
DIGE experiment was designed to compare the NTZr/METr + NTZs/METr
strains together and the WT. Using this dataset, it should be possible to
identify the proteins that have changed as a result of being grown under drug
pressure, albeit at sub-lethal levels. Moreover, if the mechanismsthat provided
resistance to the METrstrain are similar, or the same as those conveying
resistance in the NTZr stain, we might expect to see very similar proteins and
processes modulated as in the WT vs. NTZr/METrdataset.
After matching the gel images there were over 200 protein spots that were
significantly modulated at the 5 % level, so in order to make the analysis more
practical, the protein spots with significant differences (t-test < 0.01) were
picked for analysis. The results are shown in Table 3.5.
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 Protein Name DB t-test Average Ratio (WT:
Identifier NTZr/METr+NTZs/METr)
Hypothetical protein 4259 0.004 5.56
Hypothetical protein (general stress/FMN-binding
split barrel superfamily) 5810 0.0093 3.11
Wos2protein 10429 0.003 4.41
Wos?protein 10429 0.0035 -1.78
Hypothetical protein (bacterial type SMC domain) 13584 0.0049 1.8
Peroxiredoxin 1 14521 0.0021 -1.93
Peroxiredoxin 1 14521 0.0073 2.6
Alpha-6 giardin 14551 0.0064 1.67
Protein 21.1 14859 0.0041 -1.43
Protein 21.1 14859 0.0056 1.52
Peroxiredoxin 1 15383 0.0061 2.33
Protein 21.1 17060 0.0028 -1.38
Protein 21.1 17060 0.0071 2.28
Alpha-11 giardin 17153 0.0086 -1.27
Peptidyl-prolyl cis-trans isomerase B precursor 17163 0.006 -1.26
Peptidyl-prolyl cis-trans isomerase B precursor 17163 0.0076 -1.42
Gammagiardin 17230 0.002 1.75
Gammagiardin 17230 0.0078 2.05
Elongation factor 2 17570 0.0017 -1.84
Protein 21.1 27925 0.0037 2.52
NADHoxidaselateral transfer candidate 33769 0.0033 -1.75
Alcohol dehydrogenase 93358 0.0095 2.13
SKD1protein 101906 0.00015 6.28
Arginine deiminase 112103 0.0015 -1.58
Arginine deiminase 112103 0.0036 -1.74
VSP with INR (TSA417) 113797 0.0045 -5.22
Alpha-7.3 giardin 114787 0.0028 1.82
Alpha-7.3 giardin 114787 0.0051 1.73
Alpha-7.3 giardin 114787 0.0079 1.53
 
Table 3.5. Identities and average ratio change for proteins differentially
expressed in both the NTZr/METr and NTZs/METrstrain of G. lamblia. Cell
lysates of WT and NTZr/METr + NTZs/METrG. lamblia were compared using
DIGE. Protein spots with significantly different (t-test = <0.05) relative
abundance were picked from the gel and identified using mass spectrometry.
Duplicate identities in the table arise from the same protein being identified in
independentspots.
86
Combinedanalysis ofDIGE datasets
Proteins differentially expressed in both DIGE experiments
To identify proteins more likely to be generic responsesto the sub-lethal doses
of either NTZ or MET in the growth media the proteins that are shared
between both analyses were identified and are given in Table 3.6.
Proteins differentially expressed in only WT vs. NTZr/METr DIGE
Protein lists for both DIGE experiments were also compared to determine which
proteins were modulated uniquely in the WT vs. NTZr/METr DIGEin orderto
enrich for proteins that are related to resistance to NTZ. The results of this are
given in Table 3.7.
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 Protein Name ORF Number
Protein 21.1 17060
Peptidyl-proly] cis-trans isomerase 17163
Elongation factor 2 17570
Protein 21.1 (Ank repeats/ Bacterial type SMC domain 27925
Alpha 7.3 giardin 114787
Table 3.6. G. lamblia proteins differentially expressed in both WT vs.
NTZr/METrand WT vs NTZr/METr + NTZs/METr DIGEexperiments.
 
Protein Name ORF Number
Beta-giardin 4812
Calmodulin 5333
Hypothetical (putative nucleoporin) 8038
Protein disulfide isomerase PDI5 / Dyenin light chain 8064/9848
20S proteasomealpha subunit 2 11434
20S proteasomealpha subunit 3 14497
Hypothetical (Bacterial type SMC domain) 15499
Carbamate Kinase 16453
hypothetical (ribosomalprotein p2) 16588
Giardia trophozoite antigen GTA-1 17090
Xaa-Pro dipeptidase 17327
Spindle pole protein 24537
Triosephosphate isomerase, cytosolic 93938/112304 
Table 3.7. G. lamblia proteins differentially expressed in only the WT vs
NTZr/METrDIGEexperiment.
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qRT-PCRanalyses
To further investigate the detected protein changes identified by 2D-DIGE,
levels of mRNAtranscripts of the corresponding genes were measured by qRT-
PCR relative to the actin (ACT) gene which has been shown to remain
unchanged between the wildtype and NTZr/METrclone [28]. The results of
these measurements are shownindividually for clarity in Figure 3.4 and together
to moreclearly illustrate relative levels oftranscript abundance in Figure 3.5.
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(Previous page) Figure 3.4. Differences between mRNAlevels of genes
correspondingto proteinsdifferentially modulated in 2D DIGE experiments for
WTand NTZr/METrG. /amblia. Transcript levels were measured byRT-PCR
and are shownin arbitrary units relative to beta actin (y-axis scale varies).
Students t-test was applied to the data and graphs highlighted in red denote
significant results (p = <0.05). See figure 3.5 for alternative presentation ofdata.
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Figure 3.5. Alternative presentation of differences between mRNAlevels of
genes corresponding to proteins differentially modulated in 2D DIGE
experiments for WT and NTZr/METrG. lamblia. Otherdetails as perfigure 3.4.
mRNA levels displayed on consistent axis to illustrate relative abundace
between genes.
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Microarray re-analysis of WT vs NTZR/METR microarray data.
Two microarray screensofthe transcriptome of WT vs. NTZr/METrG. lamblia
were analysed using limma and limmaGUI. From the raw red/green background
subtracted expression intensities M (intensity ratio) and A (average intensity)
were calculated, equations for which are shownbelow.
M = log, R — log, G
1A= 7% (log, R + log, G)
An MA plot (Figure 3.6) revealed no abnormally scattered groups of spots that
might indicate problems in hybridization or damageto the array and only very
slight intensity dependent effects in the data as characterised by an asymmetric
“fan-tail” distribution. However the asymmetric distribution appeared to be an
effect only on the empty array spots and was corrected by subsequent
normalisation. However, plotting the same data according to their ‘print-tip
group’ i.e. the printer tip with which each tip was printed, revealed considerable
systematic biases in the data (Figure 3.7 (top panel)). The data were therefore
normalised within arrays using the print-tip LOWESS (locally weighted
scatterplot smoothing) method the results of this are illustrated in Figure 3.7
panel a (top - before) and b (bottom - after). Data did not appear to require
normalisation between arrays (Figure 3.8) and had a very high correlation
coefficient of >0.99. After averaging within array replicate spots, and
application of a linear regression model, data were assessed using empirical
Bayesianstatistics, and ranked by the topTable function in order of significance
93
of their evidence for differential expression as measured bytheir ‘log odds’, or
‘B statistic’. The resulting dataset for all genes was filtered using several
methods. Empty, reserved and control spots and those
94
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Figure 3.6. Print-tip group lowess normalization of microarray data.
M plots are shownforslide | (A) before and (B) after within array
lowess normalization. Black spots = Giardia genes, Blue =
Arabidopsis control spots, Red = Blank
 M BoxPlot for slide 1 with no normalizationA 
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Figure 3.7. Print-tip group lowess normalization of microarray data.
M box plots are shown for each print-tip group before (A) and after
(B) lowess normalization.
M BoxPlot forall slides with normalization within arrays only
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with very low average expression (less than 500 on a linear scale) were
excluded, as were genes with a log. fold change between 1 and -1
(corresponding to a 2-fold change). Genes with Holm adjusted p-values <0.05 (a
multiple testing correction) were also eliminated. Dueto the relative age of the
release of the gene model that was used to construct the microarray, the
remaining data were cross-referenced with G. lambliaDB and depreciated genes
were also eliminated. This resulted in a final subset of 278 genes including 37
that had appearedin the previously published analysis of this data . These do not
include hypothetical proteins, which were not specified in the publication (see
Table 3.8 and appendix forfull list) and includes several large families or groups
of proteins, the largest ofwhich are summarised in Figure 3.9.
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Figure 3.9 Distribution of categories of genes differentially expressed in
NTZr/METr Giardia lamblia as determined by two colour microarray
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 Database ID Product Description Log, FC
13864 Heat shock protein HSP 90-alpha 2.313765
98054 Heat shock protein HSP 90-alpha 2.240585
21942 NADP-specific glutamate dehydrogenase -1.62711
103676 Alpha-tubulin 1.494247
5435 Cyst wall protein 2 -1.45207
17249 Coiled-coil protein 1.48684
10429 Wos2protein 2.277021
27310 Stress-induced-phosphoprotein 1 1.419363
115066 High cysteine membraneprotein VSP-like 1.378404
7260 Aldose reductase 1.116979
7031 Spindle pole protein, putative 1.793511
4812 Beta-giardin 2.118459
12139 Protein 21.1 2.238835
8722 Myb1-like protein -1.13812
137672 High cysteine membraneprotein VSP-like -1.22458
27925 Protein 21.1 2.448497
112103 Arginine deiminase 1.654431
10193 WD-repeat membraneprotein, putative -1.27463
15411 Kinase, NEK-frag 1.121846
17043 Glyceraldehyde 3-phosphate dehydrogenase -1.01292
15953 Kinase, NEK 1.060772
16745 Axoneme-associated protein GASP-180 1.253151
8174 Protein 21.1 1.412708
5188 Protein 21.1 1.673959
16967 Kinase, NEK 1.200261
15026 Src-associated protein-like protein 1.159118
17327 Xaa-Pro dipeptidase 1.075094
24590 Protein 21.1 1.09809
6140 Kinase, NEK -1.26339
8173 Glycerol kinase -1.45102
16125 Glycerol-3-phosphate dehydrogenase -1.23923
8726 Actin related protein 1.61917
16906 Phosphatidate cytidylyltransferase 1.084544
5638 Cyst wall protein 1 -1.10152
16124 TCP-1 chaperonin subunit eta 1.267606
15228 Ribosomalprotein SISA -1.18637
17551 Protein 21.1 2.238335
101291 Beta tubulin 1.32733
17570 Elongation factor 2 1.097469
4410 SALP-1 1.30995
16283 Aminoacid transporter family -1.4905
11992 TCP-1 chaperonin subunit epsilon 1.751945
21444 Spindle pole protein, putative 1.679051
15455 E04F6.2 like protein 1.067718
16532 Protein 21.1 2.38583
137726 ABCtransporter ABCA.1, putative -1.13739
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 9270
17053
88369
10255
16412
113622
8803
16867
9515
10219
88765
7103
96460
10570
135231
5489
100955
9046
23492
1695
16453
8445
3762
93011
17097
17587
9720
16235
14628
16272
8044
17046
14225
98126
7439
10370
15410
14568
16839
16376
3643
103807
17060
17558
9062
14859
17585
Dualspecificity protein phosphatase CDC14A
Protein 21.1
Protein 21.1
Translation initiation factor elF-4A, putative
Heat-shockprotein, putative
Protein 21.1
Protein 21.1
AAAfamily ATPase
Coiled-coil protein
Protein 21.1
Cytosolic HSP70
Kinase, NEK
Alanyl-tRNA synthetase
FKBP-typepeptidyl-prolyl cis-trans isomerase
Histone H3
Kinase, NEK-frag
Mitotic spindle checkpoint protein MAD2
Sugar transport family protein
Protein 21.1
Rabl1
Carbamate kinase
Kinase, NEK
Protein 21.1
Protein 21.1
Protein 21.1
CTP synthase
Protein 21.1
Kinase, CAMK CAMKL
Phosphatidylinositol-4-phosphate 5-kinase, putative
Kinase, NEK
Seven transmembraneprotein |
Protein 21.1
CXC-richprotein
Highcysteine protein
Ser/Thr phosphatase 2A, 65kDa reg sub A
ATP/GTPbindingprotein, putative
Ser/Thrprotein kinase
Ser/Thr protein phosphatase PP1-alpha2 catalytic subunit
Kinase, NEK-frag
ATP-dependent RNAhelicase p47, putative
70 kDapeptidylprolyl isomerase, putative
Protein 21.1
Protein 21.1
Kinase, CMGC DYRK
Long chain fatty acid CoA ligase 5
Protein 21.1
Protein 21.1
1.528975
1.884784
1.295851
1.107429
1.087815
1.759351
-1.09839
1.466503
1.35918
1.080224
2.587132
-1.11853
1.629698
1.508949
1.035544
1.001745
1.686949
-1.15105
1.365797
1.022995
1.999925
1.288165
1.146573
1.326728
1.032724
1.455262
1.168541
1.320865
1.002283
1.010616
1.168636
2.050509
-1.00507
-1.40177
1.694196
1.074461
1.222071
1.290058
1.017439
1.047976
1.625197
1.049963
1.837992
1.458509
1.056904
2.074651
1.316811
 
101
 9548
40390
15048
86676
17571
11309
11165
6199
8855
7268
1657
6242
15823
14553
41288
11204
40376
33689
14578
8364
16205
17230
17120
4355
11247
2661
16001
102051
16569
17578
113021
10361
15344
7648
13464
23496
14821
6602
12164
13964
103164
17188
10666
33083
11953)
114773
112866
Cathepsin L precursor
Protein 21.1
ATP-dependent RNAhelicase-like protein
Delta giardin
Trichohyalin
High cysteine membraneprotein Group |
Protein 21.1
Kinase, STE Dicty2
P115, putative
Protein 21.1
Translationinitiation factor
Translationally controlled tumorprotein-like protein
1,4-alpha-glucan branching enzyme
CCAAT-bindingtranscription factor subunit C
Mucin-like protein
Plant adhesion molecule 1
Highcysteine non-variant cyst protein
Dipeptidyl-peptidase III
Kinase
Thymidine kinase
Kinase, NEK
Gammagiardin
CEGP!I protein
Nif3-related protein
Ribosomalprotein L13a
Cyclin-dependent kinases regulatory subunit
Glutamate-cysteineligase
Aminoacid transporter family
Transcriptional regulator, Sir2 family
Kinase, NEK-frag
Acetyl-CoA carboxylase/pyruvate carboxylase fusion protein,
putative
P60 katanin
MCM2
SMC6protein
Splicesome-associated protein
RNApolymeraseAIlarge subunit
HesB domain-containing protein
Protein 21.1
Small nuclear ribonucleoprotein Sm D3, putative
Kinase, NEK
H-SHIPPO 1
Kinase, NEK
Histoneacetyltransferase GCNS5
Mlh2-like protein
Coatomeralpha subunit
Cysteine protease
Reverse transcriptase/endonuclease, putative
-1.51624
1.096409
1.560042
1.228856
1.33616
1.665564
1.053181
-1.08261
1.024114
1.413642
-1.10527
1.191121
1.220688
-1.24779
1.001736
-1.41588
-1.02141
1.009179
-1.22841
2.183257
-1.00998
2.238187
-1.16244
-1.16136
1.033089
-2.4402
-1.57894
-2.09489
-1.75134
1.330388
-1.12655
-1.43448
-1.07227
-1.09617
-1.48997
1.255903
-1.27966
-1.54236
-1.06471
-1.12532
1.536103
-1.96401
-1.20642
-1.1201
-1.9776
1.15101
1.190626
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 8152 Kinase, NEK - 1.68594
17495 RADSO DNArepairprotein, putative -2.01367
16841 DinFprotein -1.10705
1894 U3 small nucleolar RNA-associated protein 11, putative 1.06382
113610 GlcNAc-PIsynthesis protein -1.55766
15248 Spindle protein, putative -1.27922
5013 Endothelin-converting enzyme 2 -1.6208
14872 Protein 21.1 -2.62251
35428 Valine-tRNAligase -1.09424
6404 Kinesin-9 -2.80198
 
Table 3.8. List from “topTable” of most differentially expressed genes
excluding genes correcsponding to hypothetical proteins and VSPs. Geneslisted
exhibited Log, ratio >1.0 or <-1, Holm adjusted p-value < 0.01, and b-statistic
corresponding to a>99 % chanceofdifferential expression. The order of the
genesin thetable is based on the significance of the evidence fortheir
differential expression (B-statistic). A full list is available in the appendix.
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Bioinformatic analyses
Bioinformatic analysis ofproteomic data
To describe the proteomic data in a more systematic manner, and to enable the
comparison of broaderareas of the biology of G. /Jamblia without reference to
specific proteins and genes, GO termswerealso used to describe the data from
the DIGE experiments. Hypergeometric distribution analysis is commonly
applied to this type of hierarchical data, howeverproperstatistical tests cannot
be applied to these data due to differences between proteomic and genomic
‘background populations’. Unlike genomic experiments, the pool from which
proteins are picked maydiffer significantly from the theoretical pool required
to makestatistical calculations. This can be the result of things such as cell
differentiation or life-cycle stage. Furthermore, the sample size is
insufficiently large for hypergeometric analysis. The GO termsarestill useful
in describing in a simple and logical manner the types of proteins in each
group however
GO annotations occurring in both DIGE experiments
To identify GO terms that might be present due to sub-lethal doses of drug in
their growth media, Lists of individual GO terms from both the WT vs.
NTZr/METr and WT vs. NTZr/METr + NTZs/METrDIGEexperiments were
compared and terms appearing in both DIGE experiments were compiled.
Since assigning the most specific GO term possible also implicates every term
precedingit in the hierarchy by default, the very small numberofproteins used
creates a relatively large network of GO termsthat are bestillustrated in their
104
native hierarchal layout (Figure 3.10). The small number of proteins in this
group however meansthatlittle information outside of that known about the
individual proteins can be gleaned from this data.
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GO annotations only in WT vs. NTZR/METR DIGE
Lists of individual GO terms from both the WT vs. NTZr/METr and WTvs.
NTZr/METr+NTZs/METr DIGE experiments were compared and terms
appearing uniquely in the WT vs. NTZr/METrexperiment were compiled. The
larger number of proteins in this group suggests that there are potentially
significant differences between the specific responses of the NTZr/METr
parasites and a generic drug orstress response. The greater numberofproteins
also means that a greater number of GO terms are implicated. The terms and
full lineages are shown in their hierarchal layout in figures 11 (biological
process),12 (molecular function) and 13 (cellular component). In summary, the
biological processes of translation, protein synthesis and proteolysis were
heavily present. The nuclear pore and ribosomes were highlighted as being
important cellular components. The molecular functions implicated are more
difficult to summarise due to a smaller number of available annotations,
although catalytic functions, particularly peptidase and isomerise activity were
implicated, as were (metal) ion binding, and the activity of structural molecules.
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Bioinformatic analysis ofmicroarray data
Hypergeometric distribution analysis ofGO terms
Usingthe filtered topTable list of differentially expressed genes given in Table
2.9, Ontologizer was used to ascertain which (if any) GO terms were
overrepresented using hypergeometric distribution and the Parent-child method
(Figure 3.14). Significantly (p<0.05) overrepresented terms are highlighted in
colour with greater intensity of the colour denoting greater significance. The
most significant GO terms were unfolded protein binding and protein folding.
The other significant termsare also given in tabular form in Table 3.9.
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Table 3.9. Hypergeometric distribution analysis of differentially expressed
genes using the Parent-child union method. GO Aspect describes the type of
term, M = Molecular function, B = Biological process, C = Cellular component.
113
Discussion
2D-DIGE was used to determine which proteins are modulated in a strain of
G. lamblia resistant to NTZ (NTZr/METr)relative to a wildtype strain (WT).
Using qRT-PCR, we also quantified the levels of mRNA of the genes
encoding the differentially expressed proteins to gain further insight into the
underlying biology of their expression. By using the results of a second DIGE
experimentthat also included a NTZs/METrstrain of G. lamblia it was hoped
that proteins modulated due to METresistance, or the stress of being grown
under drug treatment conditions could be identified. An existing microarray
dataset comparing WT and NTZr/METrG. /amblia was also re-analysed to
gain further insight into the transcriptomic changes occurring in this strain
during the acquisition of resistance.
There are five proteins that were identified in both the WT vs. NTZr/METr
experiment and the WT vs. NTZr/METr + NTZs/METr DIGE experiment.
This could suggest that their presence could be due to a generic responseto the
sub-lethal growth conditions (Table 3.6). The proteins were identified as
Protein 21.1 (P21.1) (GL50803_17060), P21.1 — containing a putative
bacterial type SMC domain (GL50803_27925), Peptidyl-prolyl cis-trans
isomerase, Elongation factor 2 and Alpha 7.3 giardin. Of these proteins, the
level of transcript corresponding to the two P21.1s and Alpha 7.3 giardin
differed significantly between the WT and NTZr/METrstrain. The measured
increase in abundance of Alpha 7.3 giardin protein corresponded well to the
observed increase in transcription, however the regulation of the two P21.1s,
appears to be more complex. For P21.1 (GL50803_17060), proteins spots that
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were both up- and downregulated were detected in both DIGE experiments.
Plotting their observed migration distance against their hypothetical mass
(from G. lambliaDB) (Figure 3.3) showsthat although oneof the spots for this
protein appears in its expected location (GL50803_17060), the two other
instances appear at a much lower mass of approximately 20-25 kDa. Using
“Compute pI/Mw”tool at ExPASy [117] to predict just the portion of the
predicted protein that contains peptide hits, yields a Mw of ~22,032 Da. This
portion corresponds with a predicted ankyrin repeat domain andis consistent
with the hypothesis that this is the result of either proteolysis or alternative
splicing. Little information about this P21.1 (GL50803_17060) is currently
available.
Although the other P21.1 (GL50803_27925) was also present in both DIGE
experiments, closer inspection of the results reveals that this protein was
downregulated in one experiment and upregulated in the other (unlike the
other proteins that were all modulated in the same direction) and thus maystill
be important in NTZ resistance. The increase in transcript levels between WT
and NTZr/METrstrains for the corresponding gene, as measured by qRT-
PCR, is one of the largest measured here and was also detected in the re-
analysis of the microarray data with a similar fold increase. Both P21.1
(GL50803_27925) and a Hypothetical protein (GL50803_15499 — protein
upregulated, transcript not measured) are predicted to possess bacterial-type
SMC(structural maintenance of chromosomes) domains. SMC containing
proteins are part of the condensin complex that plays a central role in
chromosome assembly and segregation. Chromatin condensation, spindle
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microtubule nucleation and the alignment of the nuclei along the dorsal—
ventral axis, all occur during early mitosis in G. lamblia (a binucleate
organism). The opposite directions of modulation of this P21.1(27925) in the
two DIGE experiments, alongside the identification of a hypothetical protein
containing a similar SMC domain and Spindle pole protein being modulated in
NTZr G. lamblia, suggests that cell cycle events and mitosis may be
significant events in NTZ resistance.
Other proteins with cell cycle and mitosis related functions were also found
solely in the WT vs. NTZr/METr DIGE; Calmodulin (upregulated),
Hypothetical nucleoporin autopeptidase (upregulated), and Beta giardin
(protein downregulated, increased mRNA) and a possible Dyenin light chain
(downregulated). Beta-giardin localizes to the ventral adhesive disk of G.
lamblia and appears to be homologous with SF-assemblin. It has been
proposed that SF-assemblin is involved in reconstructing the microtubular
structures in the cell after mitosis [118, 119]. Structural observations of G.
lamblia cells undergoing mitosis have pointed to the ventral disk being an
important novel component of nuclear division [120, 121] supporting the
hypothesis that beta giardin is involved in this process. The decreased level of
beta giardin in the NTZ resistant strain is also consistent with the findings of
Muller et al [106] who also observed significant down regulation of several
genes involved in cell division in a comparison of the same cell types. Also
included in this group is a hitherto hypothetical protein that appears to be a
nucleoporin autopeptidase, part of the nucleoporin complex. Regulation of the
nucleoporins is believed to contribute to the control of the cycle [122] and
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different components of the nuclear pore complex (NPC) regulate differential
gene expression dependent on the current phase in the cell cycle. We have
observed modulation of this protein but with no significant change in
transcription. This is similar to that observed in HeLa cells by other markers,
where levels of Nup96 (also a nucleoporin) are controlled by ubiquitin
mediated proteasomal degradation rather than new transcription [122].
Modulation of 2 components of the 20s proteosome that are believed to be
involved in this process were modulated. In the case of Nup96, increased
degradation leads to an increased cell cycle speed and vice versa [122]. The
closest homologue appears to be Nup98 however, a protein often implicated in
several types of cancer [123], which has functionsin transport, viral infections
and mitosis [122].
Changes in proteins involved in cell cycle events and chromosome
organisation could be indicative of a cell that is preparing to undergo mitosis
[124], or perhaps enter another life cycle stage. i.e. encyst. This may be a
possible explanation for the observed cell cycle protein changes and changes
in proteins related to organisation of the chromosome. If resistance does
involve proteins involved cell cycle progression we might also expect to see
differences in growth rates between NTZr/METr, NTZs/METr, and WTcell
lines, and indeed the NTZs/METr strain grows more slowly than the
NTZr/METrclone which in turn grows more slowly than the wildtypestrain,
potentially indicating that the resistant strains have alterations in their growth
mechanisms[28].
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In further support of cell cycle events being important factors in NTZ
resistance, the microarray data reveals that a great many VSPs are
differentially expressed in the NTZr/METrstrain. Svard et al [125] previously
noted widespread changes in VSPs upon encystation, particularly
downregulation and internalisation of the main surface protein, TSA417, and
upregulation of other VSPs, which is presumed to be a host immune evasion
response. However, TSA417, which was ranked highest in the microarray
‘topTable’, with levels of transcript downregulated approximately 10 fold (-3.4
logo2FC) in the NTZr/METrstrain, was also observed as being over 5 fold
downregulated in the WT vs. NTZr/METr+NTZs/METr DIGE experiment,
suggesting that part of this process could be a commonresponse to NTZ and
MET.
Another notable group of proteins modulated solely in the NTZr/METrstrain
are those of protein degradation:- 20s proteasome alpha subunit 2
(upregulated), 20s proteasome alpha subunit 3 (downregulated) and Xaa-Pro
dipeptidase (upregulated). Changes in the levels of proteins responsible for
wider scale protein degradation might indicate a need for the cell to
breakdownproteins that have either been misfolded or are unfolded. The 20s
core of the proteasome is responsible for a number of protein degradation
functions including the degradation of aggregated oxidised proteins [126, 127].
The increase in chaperone proteins (particularly HSP90) in the microarray
experiments also supports the notion that NTZ might cause an increase in
misfolded proteins. In this scenario, NTZ resistance could be brought about by
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an increase in protective enzymesthat repair proteins that would otherwise be
lethal to the cell.
In addition to the increases in chaperone type proteins, the microarray data
showed significant changes in the expression of several large groups of genes
(Figure 3.9 and Table 3.8). The VSPs and P21.1s are particularly prominent
examples of this. These VSP changes might be indicative of epigenetic
changes occurring in response to drug treatment that are normally deployed in
G. lamblia to counter host immune defences [128]. Epigenetic changes in gene
expression are not regulated by changes in the underlying genomic sequence
but by other mechanisms such as DNA methylation or histone acetylation
which can ‘activate’ whole regions of DNA. Widespread constitutive changes
in expression of this type might also mask a change in a protein(s) that could
be directly responsible for resistance to NTZ however. The fact that resistance
to NTZ and METis maintained in the absence of NTZ during trophozoite
growth but easily lost after a round of en- and excystation [106] further
supports the notion that it is an epigenetic change in gene/protein expression,
rather than a genetic mutation that is leading to resistance.
Since biochemical pathway analysis is still a field in its infancy, and
interaction information for proteins in G. /amblia is virtually non-existent, a
more abstracted approach to identifying areas of biological significance was
also taken. GO terms were used to describe the data in broader terms, and has
highlighted someareas for investigation that might not have been observed by
considering proteins in isolation. There are some difficulties applying this
technique to G. /amblia, since annotation of the genome with GOtermsisstill
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largely limited to electronic annotation from homologous proteins and
structural motifs. This will develop over time and, with further G. lamblia
specific annotation, may yet still reveal more interesting biology other than
what will be discussed here. Furthermore, whilst the information was freely
available, this task required the manual extraction and compilation of data into
formats readable by the software used.
From the proteomic data, there were several GO term lineages that appear
solely in the NTZr/METr strain that warrant further study. In terms of
biological processes it appears that the synthesis of amino acids, the
metabolism of proteins and translational elongation appear to be important
(Figures 11, 12), as do the ribosome and nucleus (nuclear pore) in terms
cellular locations (Figure 3.13). This suggests that changes in protein synthesis
are potentially very important in NTZ resistance. Extending this type of
analysis to the microarray data which is better suited to this type of analysis,
allows us to look for statistically overrepresented terms using hypergeometric
distribution. Table 3.9 and Figure 3.14 show thethat analysis of the ‘topTable’
genes from the microarray experiment indicates that the most significantly
overrepresented terms are Protein folding and Unfolded protein binding and
also cytoskeletal components may be important. The latter result changes
depending on the method used for analysis however the “parent-child”
analysis method used was chosenasa result of its more conservative approach
compared to the other two common methods. The identification of Protein
folding, Unfolded protein binding and cytoskeletal components as important,
appears to support the results from the proteomic data and although, there are
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not very large overlaps in the actual genes from the proteomic and
transcriptomic data, by considering the results using GO terms, we cansee that
highly related processes appear to be occurring.
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Summary
Using data from both proteomic and transcriptomic sources and using multiple
drug resistant strains of Giardia lamblia, information about possible genes,
proteins and biological mechanisms involved in resistance to NTZ have been
investigated. Cross resistance of the NTZr stain used presented a particular
problem. This was addressed with the inclusion of a NTZs/METrstrain in the
analysis. This approach has highlighted someinteresting proteins and biological
processes that warrant further study. Control of cell cycle events appears to be
particularly important, with many of the differentially expressed proteins
possesing functions relating the cell cycle, mitosis, and chromosomal
organisation. The proteomics experiments also indicated that protein
degradation might also be important, and this was further implied by the
bioinformatic analysis of the microarray data which, by using gene ontologies
(GO terms) to describe the data, has specifically implicated the areas of amino
acid synthesis, metabolism ofproteins, translational elongation, protein folding,
unfolded protein binding and components of the cytoskeleton as being of
importance. None of the changes observed in these experiments suggested that
modulation of the expression or function of PFORis of particular significance to
these NTZrstrains however.
Using a global approach to study resistance to NTZ in an organism with
immature genomeannotation has imposed somelimitations in interpreting the
results (many uncharacterised hypothetical proteins for example). Revisiting the
data in time, mightstill reveal useful information regarding the mechanism of
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resistance to NTZ in G. lamblia. Meanwhile, proteomic experiments in human
hepatocellular carcinoma cells expressing hepatitis C virus proteins have been
performed (Chapter 4). Human proteins and their interactions are better
characterised and the results should result in fewer functional annotation
limitations.
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Chapter 4
Modulation of Hepatic Replicon (RP7) Cell Proteome in Response to
Treatment with NTZ
Introduction
Knowledgeofthe anti-viral properties of the thiazolides is increasingly widely
publicised and thiazolides are believed to be a viable option for improving the
treatment of hepatitis C virus (HCV) [9-11, 13, 14, 16-18, 129]. Used as a
monotherapy, data on the efficacy of NTZ suggests it is of limited use for the
treatment ofHCV. NTZ is currently in advancedstagesofclinical trials for the
treatment of HCV when used in combination with other existing standard of
care (SOC) therapies such as pegylated interferon and ribavirin however, since
in combination with these existing treatments, sustained virologic responses
(SVR)are observed [130].
The anti-viral properties of the thiazolides raise new questions regarding the
mode of action of NTZ that cannot be satisfactorily addressed by previous
research from non-viral targets. One of the main appeals of the thiazolides as a
treatment for Giardiasis and anaerobic bacterial infections was the widely held
belief that it elicited its efficacy via targeting of PFORvia its cofactor; as such
it would be both specific to organisms that relied on anaerobic energy
metabolism to survive, and difficult for resistance to be acquired. Viruses do
not possess PFORin their genomes and hence the mode of action against them
mustlie elsewhere. Recent developmentsin eliciting the mode ofaction of the
thiazolides against HCV hasled researchersto believe that they act by directly
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increasing protein kinase R (PKR) auto-phosphorylation and activation [131,
132]. This response normally occurs in the presence of double stranded RNA
(dsRNA)[133], but the mechanism by which NTZ augmentsthis processis yet
to be described. Activation of PKR, is an important host anti-viral response
which leads to phosphorylation of elongation initiation factor 2a (eIF2a) and
subsequently reduced protein synthesis and reduced levels of unfolded protein
and several other downstream effects. When effected by PKR this process is
termed the integrated stress response (ISR). However,it can also be induced as
part of the unfolded protein response (UPR) where protein kinase-like
endoplasmic reticulum kinase (PERK) takes on the role of PKR in response to
high levels of unfolded protein in the lumen of the endoplasmic reticulum
(ER) [134-136]. In metazoans, two other proteins also act in concert with
PERK ineliciting the UPR, these are inositol-requiring protein 1 (IRE1) and
activating transcription factor 6 (ATF6). IRE1 activation results in auto-
phosphorylation and the ability to cleave a short intron sequence from X-box
binding protein-1 (XBP1) mRNA. The remaining mRNAis ligated by an
unknownagent, changing its translated protein form from a repressor to an
activator of transcription of UPR genes. There are also other additional
mechanisms proposed for ways in which IRE1 mayrelieve cellular stress via
interactions with tumour necrosis factor receptor (TNFR)-associated factor-2
(TRAF2) [137]. ATF6 meanwhile is transported from the ER to the Golgi
apparatus. Here ATF6 is cleaved by twoproteases, in the luminal domain and
the intra-membrane domain, releasing the cytoplasmic domain to be
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transported to the nucleus to activate UPR genes with the ER stress response
element (ERSE) [138-141].
PERK, IRE1, and ATF6all appear to be ‘activated’ and controlled by similar
mechanisms via a highly abundant ER chaperone protein, binding
immunoglobulin protein (BiP — syn: GRP78, HSPAS5), a memberofthe HSP70
family. Under normal conditions, this ‘master control protein’ binds the
luminal domains of PERK, IRE1 and ATF6 and prevents them from
homodimerisation or transport to the Golgi. However under high levels of
unfolded protein in the ER, BiP dissociates and allows PERK, IRE1 and ATF6
to undergo the relevant transformations that cause them to initiate the UPR.
Several components of HCV have been shownto initiate the UPR including
NS4B [142], envelope [143], and core [144] proteins and furthermore,
suppression of either PERK, ATF6 or IRElcan lead to suppression ofviral
replication [145] indicating that the UPRis a positive factor in HCV infection.
Whilst induction of the UPR, which normally leads to reduced protein
synthesis, initially appears at odds with the requirement for HCVto replicate,
it has been shown that HCV acts to modulate certain aspects of the UPR to
ensure that viral proteins are still rapidly produced. HCV E2 and NSSA
proteins have been shownto bind to and repress the kinase activity of PKR
[146, 147], and the activity of the spliced isoform of XBP1 is also repressed
through as yet unknown mechanisms [148] preventing downstream
mechanisms that promote protein degradation. These examples of
simultaneous induction and repression of highly connected pathways are
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fascinating examples of the delicate control HCV exerts over cellular
processes.
Since HCV is ultimately lethal to cells, much of the work to elucidate the
biology of HCV infections has been done using hepatocellular carcinomacell
lines that express a sub-genomicreplicon of HCV. This replicon is lacking in
key components ofHCV (usually the envelope protein) that prevents assembly
of the complete virus particle, but still allows viral replication to occur without
causing the cells to die. This also allows for much greater safety than working
with viable virus particles. The proteomic studies in this chapter use Bart 791,
a highly efficient HCV replicon that has had the core, El, E2, P7 and NS2
genes deleted [149] (Figure 4.1) and whilst the absence ofthese viral proteins
means the modelis not perfect, replicons currently represent one of the best
model systems currently available for investigating new drugs to combat HCV
infection.
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Figure 4.1. Schematic of (a) the Bart-79I replicon, and (b) the full length HCV
genome. Key: HCV structural proteins: C = core, El = envelope 1, E2 =
envelope 2. HCV Non-structural (NS) proteins: NS2, NS3, 4A = NS4A, 4B =
NS4B, 5A = NSSA, 5B = NSSB. Other features: NTR = nontranslated region,
neo = neomycin resistance gene, E-IRES = encephalomyocarditis internal
ribosomeentry site, IRES = internal ribosome entry site. Details adapted from
Elazaret al. (2003) [149] and Tanet al. (2002) [150]
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Aims
The aim of this chapter is to investigate the mode of action of the thiazolides
against HCV. To achieve this Huh7 cells expressing a sub-genomic replicon of
HCVweretreated with NTZ and TIZ. By using DIGEto profile the proteomic
response of these cells it was hoped that proteins and/or pathways involved in
effecting the efficacy of the thiazolides might be revealed. Human genes and
proteins are amongst the best characterised and annotated and we therefore
used this data to apply three bioinformatic approaches to the investigation of
possible groups of functional and biological relationships in the identified
proteins.
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Methodsand Materials
Preparation ofHCVrepliconcells
RP7 cells (details below) were kindly grown, treated and lysed by Dr. Jeffrey
Glenn and Dr Ping Liu, Stanford University. Huh7 cells were transformed with
the Bart-79I sub-genomic replicon of HCV and grown in Dulbecco's modified
Eagle's medium and 1x minimal essential medium nonessential amino acids
(100x) (Invitrogen), to which 1 mg/ml of G418 was added. A G418-resistant
colony colonies was isolated, expanded, passaged in 700 pg/ml G418, and
termed RP7 [149]. RP7 cells were subsequently passaged in the above media
with the inclusion of dimethyl sulphoxide and either 10 or 20 uM NTZ or TIZ
during growth as outlined in Table 4.1.
Cell Lysis and Sample Preparation
RP7 Cell pellets were in lysed in lysis buffer consisting of 30 mM Tris/HCl, 8
M urea and 4 % (w/v) CHAPS(pH 8.5). Cell contaminants were then removed
from the samples using the 2D-Quant Kit (GE Healthcare), a precipitation
based method and resuspended in the same sample lysis buffer as above.
Protein concentration was measured using the BSA-coomassie assay and the
concentration of the samples was adjusted to 5 — 10 mg.mI'. The pH ofeach
sample was checked, and if required, carefully adjusted to pH 8 — 9 using 50
mM sodium hydroxide.
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2D-DIGE method
For full details of the 2D-DIGE methodusedplease refer to the relevant portion
ofthe Materials and Methodssection in Chapter 3
CyDye Minimal Labelling
Labelling was performed as outlined in Chapter 3. Samples were randomly
allocated to a gel and either Cy3 or CyS labelling (Table 4.1)
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 Gel No. Cy2 Cy3 Cy5 Sypro
Gel1 STD RP7.1 NTZI10 -
Gel 2 STD RP7.2 TIZ10 -
Gel 3 STD NTZ20 RP73_ -
Gel 4 STD TIZ20 RP74_ -
Gel 5 - - - Prep
 
Table 4.1. CyDye labelling and allocation of protein samples to DIGE gels.
Samples were labelled according to the table above. RP7.x denotes biological
replicates of untreated HCV replicon expressing cells; NTZ10, RP7 cells
passaged in 10 hM NTZ; NTZ20, RP7 cells passaged in 20 uM NTZ; TIZ10,
RP7cells passaged in 10 uM TIZ; TIZ20, RP7 cells passaged in 20 uM TIZ.
The internal standard, STD was created from equal amounts ofall samples. An
unlabelled preparative load (Prep) for picking and identification purposes was
made from all samples and run on fifth gel.
 Parameter Setting
Database: MSDB
Taxonomy: Homosapiens
Fixed modifications:
Variable modifications:
Enzyme
Maximum missed cleavages
Peptide charge
Peptide tolerance
MS/MStolerance
Carbamidomethylation (C)
Oxidation (M)
Trypsin
1
1+, 2+ and 3+
+2.0 Da
+ 0.8 Da
 
Table 4.2. MASCOT parameters used to ascertain the identity of proteins
modulated in DIGE experiments.
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Identification ofproteins by tandem mass spectrometry
MS operating procedures were identical to those outlined in Chapter 3.
Database searches were performed using a dedicated in-house Mascotserver,
either individually using the standard ms/ms webbrowserbased interface or
using the Mascot Daemon to automate the search.In either case the parameters
used are given in Table 4.2. An overall Mascot score of at least 50, and at least
70 % presence of b or y ion series in any peptide was required for a positive
match. Further details including scores and peptide coverage are given in the
appendix. Identifications from MSDB were mappedto several other identifiers
including Entrez GeneIDs and Uniprot accessions for compatibility with other
databases.
PantherDB categorisation
Proteins were grouped according to the direction of their modulation and
categorised using the highest level of PantherDB classification system
(www.pantherDB.org) [151] which is arranged in a directed acyclic graph
(DAG)structure using increasingly more specific terms to describe a gene or
protein. PantherDB possesses 31 biological processes and 29 molecular
functionsat its primary level of classification and is a useful tool for describing
changesin experiments with large datasets. The results of the DIGE experiment
were categorised using both biological process and molecular function
ontologies.
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DAVID genefunctionalclassification and analysis
The Database for Annotation, Visualization and Integrated Discovery (DAVID)
[152, 153] (http://david.abcc.ncifcrf.gov/) was developed for the analysis of
genomic data, where there is one to one representation of genes to results;
howeverits ability to extract large amounts of data relating to the proteins or
genes of interest and perform several types of meta-analysis such as the
clustering of related termsto find functional groups of proteins, makes it useful
for identifying features, functions, processes, and pathwaysin the protein data.
DAVID uses kappastatistics to measure the degree of agreement between the
terms annotated to pairs of genes. Pairs above specified thresholds are used to
seed clusters which are then iteratively merged to form larger groups based on
other rules such as the degree of overlap for members of the group. This process
is repeated until clusters stabilise.
Entrez Gene IDs for up- and down-regulated proteins were uploaded to DAVID
as a ‘genelist’ via the web submission form. The up- and down-regulatedlists
were also combined to create a further list of all differentially expressed
proteins. For the purposes of clustering, duplicate results were ignored. DAVID
annotates the submitted list with data from several selectable sources. Protein
information was investigated using several different information sources
howeverfor the results outlined below, the following data sources were used to
analyse this dataset: GO terms (biological process, molecular function and
cellular component), protein domain information from InterPro, PIR and
SMART, functional categories from SwissProt and UniProt and disease
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annotations from OMIM.Highstringency settings were used for the generation
ofclusters.
Visualisation ofprotein interactions using STRING
The web tool STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins) [154] (http://string.embl.de/) was used to visualise possible
connections between the proteins identified as being modulated upon RP7cell
treatment with the thiazolides. The network was visualised using both medium
and high confidence interactions based on all available prediction methods
(genomic context, high-throughput experiments, conserved co-expression and
previous knowledge)
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Results
Protein identifications andstatistics
To learn more about the modeofaction of the thiazolides against HCV, human
liver carcinomacells expressing a sub-genomic replicon of HCV were grown
and passagedin the presence of either NTZ or TIZ at both 10 and 20 uM andthe
subsequent proteomic changes profiled using 2D-DIGE. Four biological
replicates of each treatment condition and of untreated cells were requested,
however only a single biological replicate of each treatment condition was
received from our collaborators. As a result, thiazolide treated cells were
groupedtogether to ensure analysis wasofsufficient statistical power.
DeCyder analysis revealed 85 gel spots that were differentially expressed (p <
0.05) upon treatment with thiazolide. These protein spots were excised from the
gel, and tryptically digested. Peptides were analysed by LC MS/MSand using
Mascot, the ion masses were searched against the MSDB database with the
Homo sapiens taxonomy filter applied. Of the 85 spots analysed, 70 spots
contained proteins that matched confidently to a protein (or proteins) that
matched the selection criteria outlined in the methods. The identifications
correspondedto 40 unique proteins. Thefull list of protein hits is given in Table
4.3.
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 Av.
cure Protein Name t-test (Ivested/
Control)
71 actin, gamma | 0.024 -2.34
71 actin, gamma | 0.044 -1.42
351 amyloid beta (A4) precursorprotein 0.026 2.27
301 annexin Al 0.0018 3.82
51382 ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D 0.00043 -1.97
51382 ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D 0.012 -1.7
51382 ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D 0.028 1.71
810 calmodulin-like 3 0.0012 3.02
1192 chloride intracellular channel 1 0.0044 1.82
1152 creatine kinase, brain 0.027 2.64
51726 DnaJ (Hsp40) homolog, subfamily B, member 11 0.012 1.71
10961 endoplasmic reticulum protein 29 0.013 1.95
2023 enolase 1, (alpha) 0.037 -2.05
1936 eukaryotic translation elongation factor 1 delta 0.029 1.99
1975 eukaryotic translation initiation factor 4B 0.04 1.86
1975 eukaryotic translation initiation factor 4B 0.04 1.54
1975 eukaryotic translation initiation factor 4B 0.0066 1.65
1975 eukaryotic translation initiation factor 4B 0.023 1.92
1975 eukaryotic translation initiation factor 4B 0.0031 2.71
2950 glutathione S-transferase pi | 0.015 1.89
2950 glutathione S-transferase pi 1 0.031 1.75
2937 glutathione synthetase 0.015 1.66
3329 heat shock 60kDaprotein 1 (chaperonin) 0.0096 -3.07
3329 heat shock 60kDaprotein 1 (chaperonin) 0.037 1.26
3329 heat shock 60kDaprotein | (chaperonin) 0.017 2.36
3329 heat shock 60kDaprotein | (chaperonin) 0.046 2.38
3329 heat shock 60kDaprotein | (chaperonin) 0.0082 2.57
3303 heat shock 70kDaprotein 1A 0.0084 3.55
3303 heat shock 70kDaprotein 1A 0.014 3.88
3309 heat shock 70kDaprotein 5 (glucose-regulated protein, 78kDa) 0.017 2.47
3309 heat shock 70kDaprotein 5 (glucose-regulated protein, 78kDa) 0.015 3.36
3309 heat shock 70kDaprotein 5 (glucose-regulated protein, 78kDa) 0.0024 3.44
3309 heat shock 70kDaprotein 5 (glucose-regulated protein, 78kDa) 0.0021 3.54
3309 heat shock 70kDaprotein 5 (glucose-regulated protein, 78kDa) 0.0071 3.91
3312 heat shock 70kDaprotein 8 0.038 2.25
3312 heat shock 70kDaprotein 8 0.0014 3.46
3312 heat shock 70kDaprotein 8 0.041 3.82
3312 heat shock 70kDaprotein 8 0.0069 4.31
3313 heat shock 70kDaprotein 9 (mortalin) 0.028 2.11
3313 heat shock 70kDaprotein 9 (mortalin) 0.006 2.17
3313 heat shock 70kDaprotein 9 (mortalin) 0.046 2.21
3313 heat shock 70kDaprotein 9 (mortalin) 0.03 2.73
3313 heat shock 70kDaprotein 9 (mortalin) 0.018 3.12
3313 heat shock 70kDaprotein 9 (mortalin) 0.01 1.89
3313 heat shock 70kDaprotein 9 (mortalin) 0.025 3.24
3190 heterogeneous nuclear ribonucleoprotein K 0.038 -3.25
3190 heterogeneousnuclear ribonucleoprotein K 0.0085 -1.41
4001 lamin B1 0.0079 3.05
9782 matrin 3 0.015 2.47
10763 nestin 0.021 -1.78
4691 nucleolin 0.031 2.14
5184 peptidase D 0.0095 2.51
5478 peptidylprolyl isomerase A (cyclophilin A) 0.043 1.46
10935 peroxiredoxin 3 0.0063 1.63
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5691
5902
5928
6238
6238
6711
10992
7086
7086
7086
7167
7167
84790
10383
proteasome (prosome, macropain) subunit, beta type, 3
RANbinding protein 1
retinoblastomabinding protein 4
ribosomebinding protein 1 homolog 180kDa (dog)
ribosomebinding protein 1 homolog 180kDa (dog)
serum albumin precursor
spectrin, beta, non-erythrocytic 1
splicing factor 3b, subunit 2, 145kDa
transketolase
transketolase
transketolase
triosephosphate isomerase 1
triosephosphate isomerase |
tubulin, alpha Ic
tubulin, beta 2C
0.026
0.0083
0.012
0.037
0.0066
0.012
0.0087
0.038
0.02
0.043
0.0057
0.013
0.04
0.024
0.015
-2.69
2.00
1.91
1.86
2.21
-2.22
2.48
1.38
1.93
2.18
2.07
-1.82
1.68
1.55
-1.8
Table 4.3. Identities and expression changes of RP7 cell proteins modulated in
response to thiazolide treatment. Huh7cells expressing the Bart79I HCV,sub-
genomic replicon termed RP7 weretreated by the addition of either 10 uM or
20, NTZ or TIZ to their growth media (see Table 4.1) but are considered
‘thiazolide treated’ for statistical purposes.
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PantherDB categorisation
To provide a high level overview of the protein data, the PANTHER
classification system was used. There are several similar classification systems
designed for this purpose, such as Gene Ontologies (GO) or the MIPS
Functional Catalogue (FunCat), however where PANTHER differs is the
method by whichclassification occurs. PANTHERborrowsterminology from
GOterms, but rather than attempt to be comprehensive and classify each item
individually, the PANTHERsystem developsits classifications by using a blast-
based similarity scoring to create groups of proteins and to develop hidden
Markov models (HMMs)for that group. Functional diversity of those high level
groups is represented by HMMsdeveloped from further subgroups of the
original set. The advantage of this method is that new protein sequences can be
quickly scored against the HMMsto assign the most likely appropriate
functional category.
Figures 4.2 and 4.3 show the distribution of classifications for all proteins
modulated by the presence of NTZ, as well as individual distributions for up-
regulated and down-regulated groups. Overall, changes in the expression of
‘cytoskeletal’, ‘chaperone’ and ‘nucleic acid binding’ proteins represented the
largest categories of molecular functional changes. The largest changes in
biological processes were ‘protein metabolism and modification’, ‘cell structure
and motility’, intracellular protein traffic’ and ‘immunity and defence’.
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Figure 4.2. PantherDB molecular function classifications for RP7 cell proteins (A) modulated in
any direction, (B) upregulated and (C) downregulated, upontreatment with the thiazolides
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Figure 4.3. PantherDBbiological process classifications for RP7 cell proteins (A) modulated in
any direction, (B) upregulated and (C) downregulated, upon treatmentwith the thiazolides
DAVID genefunctionalclassification and analysis
Whereas PANTHERwasusedto provide a simplified top-down overview ofthe
RP7 proteins modulated in response to thaizolide treatment, the Database for
Annotation, Visualization and Integrated Discovery (DAVID) [152, 153],
approaches the problem from an alternative perspective. DAVID integratesall
of the information from several large databases (e.g. GO, KEGG,InterPro,
Entrez etc.) and uses fuzzy clustering algorithmsto cluster terms associated with
a set of genes based ontheir relatedness. This allows the user to see what groups
of related functions, domains or pathways (and others) may be present in the
data that may not be visible by observing protein names alone. Up-regulated,
down-regulated and all modulated proteins were annotated and functionally
clustered and approximations describing the most prominent resulting clusters
are shown in tables 4.4, 4.5 and 4.6. The full results of the clustering analyses
are included in the appendix.
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 Cluster Summaries for All Proteins
Protein chaperone
Anti-apoptosis
Cytoskeletal
Cell death and development
Cellular localisation and transport
Nucleotide binding (ribonucleotides)
Nucleoside metabolism
RNAbinding
Establishmentof localisation
Protein localisation
Mitochondrialtransit peptide
Regulation of gene expression
Regulation oftranscription
Max. Numberin cluster
5
5
11
9
7
10
5
W
O
W
R
e
WwW
Table 4.4. Summary offunctional clusters resulting from analysisofall proteins
identified as modulated by treatment ofRP7 cells with NTZ or TIZ using
DAVID.Althoughstatistical significance cannotcurrently be reliably counted,
data is presented with higher ‘enrichmentscores’ (i.e. enriched term with respect
to that predicted by the genome,rather than proteome) at the top ofthelist.
 Cluster Summaries for Upregulated Proteins
Protein chaperone
Anti-apoptosis
Protein metabolism
Apoptosis
Cellular localisation and transport
Nucleotide binding (ribonucleotides)
Establishmentoflocalisation
RNAbinding
Nucleoside metabolism
Protein localisation
Mitochondrialtransit peptide
Ion binding
Regulation of gene expression
Regulation oftranscription
Max. Numberin cluster
5
—-
OV
Nn
Oo
BAO
HON
eS
9
ates
RI
GS
,
EG
O!
Gy
sa
Table 4.5. Summary of functional RP7 protein clusters up-regulated after
treatment with NTZ or TIZ identified by DAVID.Althoughstatistical
significance cannotcurrently be reliably estimated, data is presented with higher
‘enrichmentscores’ (i.e. enriched term with respect to that predicted by the
genome,rather than proteome) at the top ofthelist.
 Cluster Summaries for Downregulated Proteins Max. Numberin cluster
Organelle lumen 3
Structural molecule 3
Nucleotide binding 3
Table 4.6. . Summaryoffunctional clusters resulting from the analysis of
proteins that were down-regulated proteins after treatment ofRP7 cells with
NTZ or TIZ identified by DAVID. Althoughstatistical significance cannot
currently be reliably counted, data is presented with higher ‘enrichmentscores’
(i.e. enriched term with respect to that predicted by the genome, rather than
proteome) at the top ofthelist.
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Visualisation ofprotein interactions using STRING
STRING (http://string.embl.de/) is a multispecies tool for examining known
and predicted protein interactions using information derived from a numberof
sources varying in reliability from text-mining to expertly curated databases.
The interactions returned to the user may not only be physical interactions but
also associations implied by other methods such as their genomic context, or
conserved co-expression. STRINGis interactive and allowsfiltering of certain
types of interactions and the various levels of interactions can be investigated
in further detail and can also assign a combined probability of the interaction
being real based on the numberand confidences of the individual predictions.
For the 41 unique identifications made, 38 could be assigned a Uniprot ID
compatible with STRING. The resulting interaction network from these
proteins is shown in Figure 4.4. This network consists of nodes (proteins) and
edges (the interaction) and is shown in “confidence view” (Figure 4.4, top
panel), where the intensity and thickness of the edges represents the combined
confidence in the interaction (thicker and darker = more confident) and
“interaction view” (Figure 4.4, bottom panel), with individual predictions
colour coded accordingto their type.
The predicted STRING network is highly interconnected; indicating that the
RP7cell response detected by DIGE may well be a coordinated one rather than
several disparate responses, however manyofthe interactions are predicted by
text mining which can be unreliable. Filtration of the interaction network to
only interactions with high combined confidence score (> 0.7) resulted in the
network in Figure 4.5. This network appears to centre around several heat
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shock and stress response proteins. GRP78 (HSPAS5in Figure 4.5) appears
particularly well connected to the network. Using k-means clustering to
separate the network results in three groups of proteins belonging to areas
which can be approximately summarised as; ER chaperones, glycolytic
enzymesandribonucleotide binding proteins.
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Figure 4.4. STRING protein interaction network (>medium confidence) for RP7
cell proteins modulated in response to thiazolide treatment. Network is shown in
both confidence view (top) and interaction type view (bottom).
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Figure 4.5. STRINGprotein interaction network (=high confidence) for RP7 cell
proteins modulated in response to thiazolide treatment. Network is shown in
both confidence view with darker, thicker lines corresponding to higher
confidencescores.
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Discussion
In earlier chapters, proteomic and transcriptomic techniques were used to
investigate resistance to the thiazolides in Giardia lamblia parasites. Some
interesting avenuesfor further investigation were revealed, however describing
the underlying biology of the system proved challenging due to therelative
lack of characterisation of the G. /amblia genome and hence the lack of a
meansto integrate the transcriptomic and proteomic data in a meaningful way.
Using a Huh7cell line that had been transformed with a sub-genomicreplicon
of HCV (RP7cells) with clinical relevance to HCV infection, proteomic
changes in response to treatment with the thiazolides were investigated.
Humancell lines are well characterised and as such the annotation of the
protein data should be highly beneficial in interpreting the results. Furthermore
there is already someresearch into the proteomic response of the Huh7 cell
line to the HCVreplicon. In addition to looking at the individual results, three
differing bioinformatics approaches were used to help describe and
functionally categorise the response to the thiazolides and predict their
interactions.
When RP7cells were treated with the thiazolides and the protein separated by
2-DE the abundance of 70 identifiable protein spots corresponding to 40
unique proteins wassignificantly altered. After identification of these proteins,
some trends were immediately apparent from the data with 24 of the 70
identifications being heat shock proteins (HSPs), and with only a single
exception, all HSP spots were upregulated. This result is reflected in both the
PantherDB categorisation where “chaperone” proteins are the largest
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molecular function category for up-regulated proteins and joint largest in the
“all regulated” protein group. Termsrelating to chaperones and unfolded
protein binding were also present in the DAVID cluster assignments and
although applying the DAVID cluster enrichment score (designed for array
type experiments) to a DIGE dataset violates some assumptions used in
calculating this score, this functional cluster appeared to be the most enriched
relative to the rest of the genome as the background set. Amongst the up-
regulated HSPs (and someof the biggest fold changes overall) is BiP. The
importance of BiP and the UPR to HCV infection has already been discussed
in this chapter's introduction, and its up-regulation could provide an
explanation for the up-regulation of the other HSPs. During either HCV or
HCVreplicon expression ATF6is activated, cleaved and is transported to the
nucleus via the Golgi to transcribe genes with ER stress response elements
(ERSE) in their promoters [155]; many of these genes have chaperone
functions. XBP1 is also amongstthe transcriptional targets of targets of ATF6
and the up-regulation of DnaJ (Hsp40) homolog, subfamily B, member 11
(syn: HEDJ), which appears to be transcriptional target of XBP1 [156],
provides further evidence for this process. One study has also shownthat BiP
is transcriptionally up-regulated during HCV replicon expression, although the
total BiP protein is reduced [155]. The seemingly large up-regulation of BiP
upon thiazolide treatment of the RP7 cells suggests that the HCV replicon
might be suppressing the translation of BiP and that the thiazolides are
somehow interfering with this suppression. In fact, several of the detected
changes are synonymouswith the reversal of the response of Huh7 cells to
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HCV or an HCV replicon. This hypothesis is somewhat supported by
comparing the types of changes observed in Huh7cells expressing an HCV
replicon compared to untransformed cells [157] to the types of changes seen in
the DIGE dataset. Using panther classifications, there are some similarities
between proteins modulated upon introduction of the HCV replicon [157]
upon treatment with the thiazolides, for example chaperones and nucleic acid
binding proteins and processes such as protein metabolism and modification,
howeverthe comparisonis limited by the differences in cell types between the
studies. There are howeverseveral differences between these data particularly
the prominence of cytoskeletal and structural proteins in this study. Both up
and down-regulated cytoskeletal proteins were identified and several of these
are types of actins and tubulins. Actins and tubulins have been shownto be
essential to the membrane bound replication complexes (RC) of HCV [158,
159]. Furthermore we detected modulations in both peptidylprolyl isomerase
A (cyclophilin A) [160] and creatine kinase [161] which havecritical roles in
HCVreplication complexes. These results suggest that the thiazolides might
act, in part, by disrupting the HCV RC.Interestingly, transketolase (TKT)
which was detected as being up-regulated uses thiamine pyrophosphate (TPP)
as a cofactor. As discussed in Chapter 3, PFOR is inhibited via the hijack of
activated TPP by NTZ. PFORis important to anaerobic glycolysis whilst TKT
is essential to the pentose phosphate pathwaythat feeds into glycolysis. Triose
phosphate isomerase (TPI1) and enolase (ENO1) which were both modulated
upon treatment with the thiazolides are both also key components of the
glycolytic pathway. Thus a modeofaction that involves glycolysis should not
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be ruled out; however there does not appear to be any strong direct link
between glycolysis and HCV pathogenesis.
STRING wasusedto investigate interactions between the identified proteins.
Uploading the protein IDs to the STRING webservice returned a highly
interconnected network with only 7 proteins not possessing a connection to the
rest of the group. The interconnectedness of the group is also evident in the
number of DAVID function clusters that overlapped. This is likely due to the
fact that proteins such as the HSPs andstructural proteins inherently interact
with a great many proteins. Many of the STRING connections were however
based only on evidence from text-mining and closer inspection of the network
revealed that some of these connections may be unjustified. The STRING
network was therefore filtered to only high confidence interactions. The
resulting network appears to indicate that BiP (HSPASin figures 4.4 and 4.5)
is well connected to a core group of proteins. However, separating the network
by k-means seems to indicate three main areas exist, ER chaperones,
glycolytic enzymes and ribonucleotide binding proteins. Although promising,
analysis using STRING has not provided any significantly different or
additional information that has not been alluded to with the other types of
analysis. The potential of the technique was well demonstrated, by being the
only one of the three bioinformatic techniques to isolate a group of proteins
with glycolytic associations. However, with the most confident interactions
belonging to well characterised diseases and processes the powerto reveal
novel interactions is limited. Furthermore, the parts of the resulting networks
that are not supported by experimentally proven interactions may be error-
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prone due to the inherent difficulties in using text-mining to predict
interactions. With increased reliability of prediction algorithms, and
experimental discovery of other interactions, this type of analysis may well
become much more powerful and useful in reconstructing cellular processes in
a systems biology manner.
The currently held hypothesis that thiazolides activate PKR through the
inhibition of HCV dephosphorylation of the ER stress response enzyme can
neither be fully confirmed or refuted using the data from this study but the
modulation of several proteins heavily involved or related to ER stress
pathways appears to lend weight to this hypothesis. The modulation of
proteins required for the functioning of replication complexes of HCV could
indicate another area that may bea target of the thiazolides. In Chapter 3,
attempts are made to separate potential non-specific stress responses from
other changes that might have relevance to the thiazolide’s primary mode of
action. Since it is known that HCV interacts with and controls several aspects
of stress response it seems likely that attempting to distinguish between
different levels of stress response would bea futile exercise.
Proteomics, transcriptomics and several bioinformatic approaches have been
applied to investigate the modesofaction of the thiazolides. These differential
approaches can provide a great deal of information about the way some
organisms respondto the thiazolides, but this information alone is unlikely to
reveal the targets of the thiazolides or to prove interactions. In Chapter 4, drug
targets are sought by affinity chromatography, using an untransformed (non-
replicon) Huh7cellline.
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Chapter 5
Identification of Proteins with Binding Interactions to the Thiazolides
Introduction
Like many type of chromatography, affinity chromatography exploits the
differences in the inherent attractive forces between interacting molecules
relative to other molecules in a solution. Specifically, the user selects a molecule
and immobilises it to a stationary support as ‘bait’ and in theory, by doingthis,it
should be possible to purify only those molecules that have specific affinity for
the bait. Where the identification of directly interacting targets is desired, it is
important to attempt to create conditions that minimise spurious interactions
whilst maximising the affinity between the immobilised molecule and its true
targets. In some instances, it is the ability of affinity chromatography to be
performed under non-denaturing and/or native conditions that allows the
‘interfering’ interactions to be exploited to discover the secondary, tertiary,
quaternary etc. interactions, and hence derive information regarding complexes
that might be present in vivo. To this end there are several techniques that have
sought to enhancethe basic affinity technique to include very strong and/or very
specific molecular interactions. Two notable and successful examples ofthis are
tandem affinity purification (TAP tagging) which uses a custom n-terminal
sequence “tagged” onto the protein of interest [162] and the use of biotin-
streptavidin interactions [163, 164] where an avidin binding biotin label is
conjugated to the molecule of interest. The main advantages of these methods
are their very low level of contamination (especially for TAP tagging), non-
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denaturing conditions and the ability to purify intact complexes. Since we
neither have a knownprotein target to tag, nor any method for biotinylation of
TIZ or NTZ, TAP tagging and biotinylation are not currently possible. Given
sufficient time, it would be possible to derivatise the thiazolides to enable
biotinylation and other tagging protocols. However, this was not possible in the
timeframe of this project. An investigation of commercially available products
that might be useful to immobilise the thiazolides revealed that the existing
hydroxyl group of TIZ could be covalently attached using an epoxy activated
agarose/sepharose.
There have already been several published investigations into the mode of
action of the thiazolides in parasites and anaerobic bacteria including a study
by Muller e¢ al. [165] who used affinity chromatography to identify a novel
Giardia lamblia nitroreductase, that can bind to and can be inhibited by NTZ.
There have, however, been relatively few studies that have studied the effects
of the thiazolides in the host, with one notable exception; Muller ef al. [166]
have shown that in human colon cancer cells glutathione-s-transferase pi
(GSTP1) binds to and is inhibited by certain thiazolides [166]. Clinical trials
are underway to test thiazolides for the treatment of HCV. It has been
hypothesised that anti-HCV properties are elicited through the host cells. Since
HCVaffects the liver, the hepatocellular carcinomacell line Huh7 was chosen
for the investigation into potential host targets of the thiazolides. Moreover,
the replicon transformed cells (RP7) used for the DIGE experiments in
Chapter 4 were derived from thiscellline.
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Aims
The aim of this chapter was to discover which (if any) proteins are targets of
the thiazolides in host cells. To acheive these aims, tizoxanide (TIZ) and two
derivatives were conjugated to an epoxy activated agarose resin (EAA) and
used in affinity chromatography experiments against Huh 7 cell lysates.
Stearic effects that might influence the binding of putative targets to
thiazolides were addressed by repeating experiments using two other
thiazolides that have the samestructural core as TIZ and RM4832, but benefit
from the addition of an hydoxyl group on the benzenering. It was hoped that
using the alternative compounds might also give furhter insight into the way
different functional groupsaffect the binding putative targets.
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Methodsand Materials
Cells and reagents
Huh7 cells grown in Dulbecco's modified Eagle's medium and 1x minimal
essential medium nonessential amino acids (100x) (Invitrogen) were kindly
donated by Dr. Jeffrey S. Glenn and Dr. Ping Liu (Stanford University).
Frozen cells were shipped to Liverpool and lysed in approximately 1 ml of
lysis buffer containing 50 mM Tris/HCI pH 8.0, 1 % (v/v) Triton-X-100, 0.1
mg.ml' DNase and 2x Complete Mini protease inhibitor cocktail (Roche
Diagnostics, UK) per 10° cells. All other reagents were purchased from VWR
International (Leicestershire, UK) unless specified.
Synthesis ofThiazolides
TIZ was supplied by Romark Laboratories, L.C. (Tampa, Florida, USA). Other
thiazolides were synthesized by the Chemical Synthesis Group, Department of
Chemistry, University of Liverpool. A typical synthesis of RM4832 was
performed as follows: To a stirred solution of acetylsalicylic acid (1.44 g, 8
mmol) in 80 mL of dry Et2O at 0 °C was added pyridine (0.77 mL, 9.6 mmol)
followed by dropwise addition of thionyl chloride (0.7 ml, 9.6 mmol).Stirring
was continued at 0° C for 4 hrs, then the white precipitate was filtered off and
the filtrate was concentrated under vacuum to give the acid chloride which was
used without further purification. 2-Amino-5-bromothiazole, HBrsalt (2.08 g,
8 mmol) followed by a solution of the above acid chloride in EtOAc (15 mL)
were sequentially added to a biphasic mixture of NaHCO; (2.68 g, 32 mmol)
in H2O (25 mL) and EtOAc (25 mL) with vigorousstirring at 20°C and the
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reaction was continued for 12 h. The layers were separated and the aqueous
layer was extracted once with EtOAc (20 mL). The combined organic extracts
were washed with 0.5 N HCI (2x 10 mL), followed by brine (20 mL). The
organic layer was dried over MgSO,and concentrated under vacuum to give a
pale yellow solid which wastriturated with EtzO (2x 10 mL) andfiltered. The
resulting solid was dried under vacuum to give the O-acetate of RM4832
(1.76g, 63%); a portion (116 mg, 0.36 mmol) was heated in conc. HCI (1mL)
at 50° C for 24 hrs. The reaction mixture was cooled to ambient temperature,
filtered and the solid washed with H2O (dist.) until the washings were at
neutral pH. The solid was dried under vacuum to give RM4832 (75 mg, 66%),
mp 196-197°C. Found: C, 40.1; H, 2.35; N, 9.35; m/z, 298.9489;
CioH7BrN202S requires C40.15; H, 2.3; N, 9.3%; CioHgBrN202S (MH" for
™Br) requires m/z, 298.9490; 'H NMR [400MHz, (CD3)2SO] 7.00 (1 H,t, J =
7.9 Hz, ArH), 7.05 (1 H, d, J = 8.2 Hz, ArH), 7.49 (1 H, t, J = 8.2 Hz, ArH),
7.65 (1H,s, thiazole 4’-H ) and 7.96 (1 H, d, J = 7.9 Hz, ArH); '°C NMR[100
MHz, (CD3)2SO] 102.1, 116.3, 117.1, 119.7, 130.3, 134.5, 138.4, 157.4, 158.2
and 164.6; MS (CI) m/z 299 and 301 (M*for ”’Br, *'Br respectively).
Affinity chromatography
Preparation ofAffinity Chromatography Resin
TIZ, DHTIZ and DHRM4832 (see Table 5.1) were covalently attached to an
epoxy activated sepharose (GE Healthcare, UK) with a 1,4-bis(2,3-
epoxypropoxy-)butane (12 atom) spacer arm via either the 2- or 4- hydroxyl
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residues as indicated in Table 5.1, according to the manufacturer’s
instructions. The procedure wasas follows.
Between each of the following steps, each solution was removed by gentle
centrifugation at 1000 x g and careful decanting of the resulting supernatant.
Epoxy activated sepharose was washed with four rounds ofdistilled water to
removethe storage media andto re-swell the resin, before being incubated in a
volumeof coupling buffer (100 mM NaCO3, pH 9.5, 5 % (v/v) DMSO) equal
to the volume of the swollen resin containing 200 uM ofthiazolide per ml of
buffer, with gentle inversion at 37 °C overnight (minimum 16 hours). The resin
was then washed several times with 10 column volumes (CV) of coupling
buffer to remove residual thiazolide before the medium was blocked with 1 M
ethanolamine (pH 8.0) for at least 4 hours at 45°C. The blocked resin was then
extensively washed with alternating rounds of high (pH 9.5) and low (pH 3)
pH buffer and subsequently equilibrated with binding buffer (100 mM
Tris/HCl! pH 8.0, | % (v/v) DMSO). Control, ‘drug-free’ sepharose resin was
obtained by following the same procedure, omitting the addition of a
thiazolide.
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 Core Structure Name Chemical groups
4'
0 7 \ Nitazoxanidea Ds Tizoxanide3 N s
H ]'
4 6 DHTIZ
5 RM4832
DHRM4832
2 -O(COCHs) / 5’ -NO,
2 -OH* / 5’ -NO>
2 -OH / 4-OH* / 5-NO;
2 -OH / 5’ -Br
2 —OH / 4 -OH* / 5’ —-Br
 
*Hydroxyl groups used for conjugation with epoxy activated agaroseresin in
affinity chromatography experiments.
Table 5.1. Namesandstructures ofthiazolides used orreferred to in this
chapter
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Column Packing
Although not directly used for any particular method, the GE Healthcare
Guide “Affinity Chromatography: Principles and Methods” [167] was used
for guidance. Resin was suspended in a slurry containing approximately 10
column volumes (CV) of equilibration buffer (i.e. 1 ml resin = 10 ml buffer)
and packed undergravity in a 1 cm dia. x 10 cm glass Econo-column(Bio-rad
laboratories Ltd., Hemel Hempstead, UK)
Chromatographyprocedures
DH shift elution
The column waspacked and equilibrated with 10-20 CVs binding buffer (100
mM Tris/HCl, pH 8.0). This was followed by the addition of 1 mL of Huh 7.5
cell lysate (approx 1 x 10° cells) clarified of particulate matter by
centrifugation for 5 minutes at ~10’000 x g at 4°C before stopping the flow of
the column for approximately 10 minutes to allow potentially slower binding
interactions to take place. The column was then thoroughly washed with at
least 10 CV of binding buffer and then 5 CV of elution buffer (100 mM
glycine, pH 2.5). The column was then re-equilibrated with binding buffer
before regeneration using three alternating rounds of low and high pH buffers
as before. One mL fractions were continuously collected from just before
addition of cell lysate to the column until at least one round of column
washing was completed. Protein contained in fractions was precipitated with
10 % (w/v) trichloroacetic (TCA) acid at -20 °C overnight. Precipitated
protein was recovered at ~16’000 g for 25 min at 4°C. Protein pellets were
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resuspended in 30 mM Tris, 1 % (w/v) CHAPS,6 M urea before assaying for
protein concentration using Bio-Rad’s BSA Coomassie assay to determine
correct amounts for loading onto SDS-PAGEgels.
Competitive elution
The column was packed and equilibrated with binding buffer containing
DMSOto ensure thiazolide solubility (100 mM Tris/HCl, pH 8.0, 5 % (v/v)
DMSO)(10-20 CV). This was followed by the addition of 1 mL of Huh 7.5
cell lysate before stopping the flow of the column for approximately 10
minutes to allow potentially slower binding interactions to take place. The
columnwasthen thoroughly washed with 20 CV ofbinding buffer. Five CV of
competitive elution buffer (100 mM Tris/HCl pH 8.0, 25 % (v/v) DMSO,1
mM TIZ) was added to the column and 1 ml fractions collected in 1.5 ml
microcentrifuge tubes from just before addition of cell lysate to the column
until the start of column washing steps commenced. This was followed by a
re-equilibration with a low pH elution buffer (100 mM glycine pH 3.0, 1 %
(v/v) DMSO)before regenerating the column using alternating rounds of high
and low pH buffer. Fractions were collected and protein was concentrated by
TCAprecipitation for separation and further analysis on 12 % (w/v) 1D-SDS
PAGEgels.
Pre-incubation with TIZ
Prior to chromatography, approximately 1 ml ofcell lysate (0.25 x 10° cells)
wastreated with 1 mM TIZ for 4 hours at room temperature (~=21 °C), before
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chromatography was performed using the competitive elution method
described above.
Protein recovery and concentration
RP trap column
In initial experiments unsuccessful attempts were made to concentrate the
relatively dilute eluate using a small reversed phase column. Eluted fractions
were removed of particulate matter using a 45 um pore syringe filter
(Millipore). A C4 reversed phase micro trap column (Michrom Bioresources,
Inc., California) was equilibrated with 2 % (v/v) acetonitrile (ACN), 97.9 %
(v/v) H20, 0.1 % (v/v)trifluoroacetic acid (TFA). Fractions were brought to
the same ACN/TFA composition before being injected over the column. A
second buffer of 70 % (v/v) ACN, 29.9 % (v/v) H20, 0.1% (v/v) TFA was
used to elute proteins from the column.
TCA precipitation
To concentrate protein from the dilute eluate for visualization on SDS-PAGE
gels, 100 % (w/v) TCA wasprepared and to each | mlfraction, 111 pl was
added to give a final concentration of 10 %. Tubes were mixed by inversion
and centrifuged for 30 minutes at 16,000 x g at 4 °C to sediment the protein.
The supernatant was carefully removed and discarded whilst the protein pellet
was resuspended in 15 yl of 30 mM Tris/HCl, 4 % CHAPS,8 M urea and the
pH wascarefully adjusted to pH 8.0 with the addition of 2 M.
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1D SDS-PAGE
Samples in a modified Laemmli sample buffer [168] (120 mM Tris/HCl, 20 %
(v/v) glycerol, 4 % (w/v) SDS, 200 mM DTT,trace Pyronin Y), were heated
at 95 °C for 5 minutes before being loaded onto a 12 % (v/v) acrylamide gel
with a 4 % (v/v) acrylamide stacker. Electrophoresis was performed at a
constant 200 V for approximately 45 minutes. Benchmark Protein Ladder
(Invitrogen) was used as the molecular weight marker throughout. Gels were
post-stained with Sypro Ruby (Invitrogen) and visualised using the Ettan
DIGE Imager (GE Healthcare) followed by staining with colloidal coomassie
for manual excision of bands for MSidentifications. The ‘quick’ Sypro Ruby
staining method was usedas outlined in the manufacturer’s instructions. Gels
were washed with gentle agitation in a fixing solution of 50 % (v/v) methanol,
7 % (v/v) acetic acid for 30 minutes at room temperature with fresh buffer
added after 15 minutes. The fixing solution was subsequently replaced with
Sypro Ruby stain and the gel was heated in a microwave to just below the
boiling point of the solution, this heating was repeated after leaving gel to cool
for 30 seconds and again after 5 minutes with gentle agitation between heating
steps. This was then agitated for a further 23 minutes. The gels were then
washed for 30 minutes at room temperature with a mixture of 10 % (v/v)
methanol and 7 % (v/v)acetic acid.
In order to facilitate the excision of protein bands, the gels were post-stained
with colloidal coomassie after brief washing with distilled water for 5 minutes
before immersing the gels in a solution of 20 % (v/v) methanol, 0.08 % (w/v)
coomassie brilliant blue (G250), 0.01 % (v/v) phosphoric acid, 10 % (w/v)
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ammonium sulphate for 1 — 7 days until protein was sufficiently stained. The
gels were then washed with distilled water to reduce backgroundstaining of
the gels and stored in 1 % (v/v) acetic acid solution.
Protein identification by mass spectrometry
Tryptic digestion ofproteins
Gel bands containing proteins identified as being of interest were excised and
destained with repeating rounds of 25 mM ammonium bicarbonate, 50 % (v/v)
acetonitrile (ACN) for 10 min at 37 °C, then 100 % (v/v) ACN for 10 min at
37°C until completely colourless. Solvent was removedandthe plug allowed
to air dry for 10 min. 10 ul of Trypsin solution (25 yg Trypsin diluted with
250 wl 50 mM Acetic acid then diluted 1 in 10 with 25 mM ammonium
bicarbonate) was added and incubated at 37 °C for 1 hr followed by the
addition of a further 10 pl 25 mM ammonium bicarbonate and incubation at
37°C overnight. Digestion was stopped with 2 pl of 2.6 M formic acid.
Mass Spectrometry
LC-MS/MSdata oftryptic peptides was acquired using a LTQ ion-trap mass
spectrometer (Thermo-Electron, Hemel Hempstead, UK) coupled on-line to a
Dionex Ultimate 3000 (Dionex Company, Amsterdam, The Netherlands)
HPLC system equipped with a nano pepMap100 C18 reversed phase column
(75 um; 3 um, 100 Angstroms) as described in the General Materials and
Methodschapter.
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Results
Conjugation ofthiazolides to epoxy activated sepharose
The manufacturer’s instructions state that | ml of swollen resin contains 25-40
umolesof active ligand, thus the concentration of 200 umoles of TIZ per ml of
coupling solution was expected to be in excess. There is currently no simple,
validated method for assaying the amount of TIZ that had bound to the
agarose, however, at the pH ranges used during this procedure, TIZ, DHTIZ
and DHRM4832 are bright yellow/orange in solution and since this colour
remained after extensive washing with buffers containing high concentrations
of DMSO(to ensure complete solubilisation of compounds), it was assumed
that adequate binding to the epoxy activated agarose had occurred.
Concentration ofcolumn eluate using a reversedphase trap
The eluate from the affinity columns was too dilute to be analysed by 1D SDS-
PAGE without prior concentration. By using a reversed phase protein trap
column it was hoped that protein could be efficiently recovered and
concentrated without resorting to protein precipitation which can result in
protein that is difficult to resolubilise. Unfortunately, this method repeatedly
resulted in total loss of protein as determined by visualisation with 1D SDS-
PAGE(data not shown). This procedure method was abandoned in favour of a
TCA precipitation method.
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Elution ofboundproteins by decreasingpH
The chromatography procedure resulted in a large number of fractions that
were too dilute for futher analysis. To determine which fractions contained
eluted proteins (if any), the elution profile of the chromatography procedure
was determined. Fractions were TCA precipitated and protein concentration
quantified; a representative elution profile from a low pH elution experiment
can be seen in Figure 5.1. In all five experiments of this kind, the elution
profiles showed similar peaks at flowthrough (fractions Fl — F4) and for
elution (E2). These peak fractions were visualised using 1D-SDS PAGE
Althoughaninitial trial-run lacking proper controls appeared promising, with
several bands that appeared enriched in the eluate compared to the raw lysate
and flowthrough fractions, subsequent analysis with the inclusion of proper
controls (Figure 5.2) consisting of ethanolamine blocked EAA without
tizoxanide using different quantities of cell lysate, highlighted a particular
problem with the specificity of the resin and effectively excluded several of
the previous “candidates” for TIZ binding. The high level of interfering
interactions in this system made it very difficult to distinguish true interactions
with TIZ from interactions with the agarose resin or spacer arm. It further
highlighted the requirement for a more stringent or thorough washing and a
more specific method of elution. One band of approximately 24-25 kDa does
however appear to be consistently eluted from TIZ-agarose but not control-
agarose resins. MSanalysis of total eluate indicates this band is likely to be
GSTP1,a previously identified thiazolide binding protein [166].
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Figure 5.1. Typical elution profile of Huh7 cell extract using TIZ-agarose.
Chromatography was performed in two main steps; a binding and washingstep,
followed by a high pH elution step. Fractions were collected and TCA
precipitated before assaying them for protein concentration using Bio-Rad BSA
Coomassie assay.
168
Control-agarose TIZ-agarose TIlZ-agarose
0.25x10° Huh7 0.25x10° Huh7 ~—-0.5x10® Huh7AL
 
 
Figure 5.2. SDS PAGEanalysis of Huh7cell proteins eluted from TIZ-agarose
and unbound agarose columns. Separations of Huh7 cell lysate were
performed using both control-agarose and TIZ —agarose columns using glycine
elution buffer (pH 3.0) to remove bound proteins. Lanes: M = Mw (kDa)
marker, C = cell lysate, FT = Flowthrough after washing steps, E = protein
eluted at pH 3.0.
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Competetive elution with NTZ
To try and improvespecificity of elution, more extensive washes of ‘unbound’
cell lysate were introduced to remove as many non-specific interactions from
the column as possible. Increased washing appeared to have had positive
effect on the level of background binding and was maintained throughout
subsequent experiments. A 1 mM TIZ wash wasalso used to selectively
release thiazoldie bound proteins from the column, further enhancing
specificity of the results.
In addition to these changes, it was decided that a more comprehensive
overview of the elution might provide useful information, and so all fractions
were TCA precipitated and visualised using 1D SDS-PAGE (Figure 5.3).
Background subtracted lane profiles were also generated using TotalLab
(NonLinear Dynamics Ltd.). One main band correspondingto a protein of ~31
kDa wasconsistently eluted by 1 mM TIZ elution buffer when using the TIZ
agarose (Figure 5.3, lane 18, and close-up detail Figure 5.4, panels A and B).
This protein band was not seen with blocked control agarose resin which
lacked conjugated TIZ (Figure 5.4, panel C), indicating that the interaction
was not a result of non-specific binding. This band was excised from the
analysis of two separate separations and digested with trypsin before analysis
by LC MS/MS.In both cases, there were several proteins identified in the gel
slice, however in both cases the highest scoring protein was identified as
NAD(P)H quinone oxidoreductase (NQO1) with highly significant Mascot
scores and good sequence coverage (see Figure 5.5 and appedices). The
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monomer of NQO1 has a mass of 30774 Da which corresponds well to the
massofthe band observedonthe gels.
A second band of approximately 38 kDa also appears to follow a similar
elution profile over the first four elution fractions (Figure 5.4, fractions 18-22),
however this behaviour was also observed in control experiments and was
therefore an identification was not sought.
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Figure 5.3. Visualisation of protein fractions eluted from TIZ-agarose column
using competitive elution. Fraction 17 — flowthrough. Fractions 18 - 24
fractions eluted with 1 mM TIZ. Approximate molecular weights (MW)in
kDa. Arrowsindicate band excised for identification by MS. A) Original gel
image B) Background subtracted and gel distortion corrected lane profiles
analysed using TotalLab.
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Figure 5.4. Close-up detail of SDS-PAGE visualisation of competitive elution
using TIZ containing buffer. A and B) using TIZ-EAA resin and C) using
ethanolamine blocked control resin EAA. The bands at approximately 31 kDa in
panels A and as indicated with arrows, were unambiguously identified by LC-
MS/MSas NAD(P)H Quinone oxidoreductase 1.
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 Match (ID): MASCOTScore: Sequence coverage (%):
NQO!|HUMAN 343 / 357 58 / 48 (Combined: 60)
Sequence andpeptide coverage
1 VGRRALIVLA HSERTSFNYA MKEAAAAALK KKGWEVVESD LYAMNFNPII
RRR KE KEKE KKEKKK KKKKKKKEKEEK KEKEKEKKKK KRKKKKKEKEE
wk KKK KK KKK KKK KEK KEK KKK EK K KKKKKK KK KK KK KK
Da SRKDITGKLK DPANFQYPAE SVLAYKEGHL SPDIVAEQKK LEAADLVIFQ
** ** Kak kaka KKK aK KKK KKKK KRERKKREKKRAK KKEEKKKKRK
KKK KK KK KKK KK KKK KK KKK KEKK
101 FPLQWFGVPA ILKGWFERVF IGEFAYTYAA MYDKGPFRSK KAVLSITTGG
KEMCERKEERER kek EK KKEKKEEKEEK KKKEKEERE
151 SGSMYSLQOGI HGDMNVILWP IQSGILHFCG FQVLEPOLTY SIGHTPADAR
Ka KKK KKK
201 IQILEGWKKR LENIWDETPL YFAPSSLFDL NFQAGFLMKK EVQDEEKNKK
KK KK CKKEK Kk KK KEK
KEKEKKEKKKK KKEAEKKKEKKEKEK
251 FGLSVGHHLG KSIPTDNQIK ARK
KKEKKKKKKK KKK KKK KKK
Figure 5.5. Identification ofNQOI by mass spectrometry. Asterisks below and
above the amino acid sequence indicate hits in the first and second
identifications respectively
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Alternative conjugates
The stoichiometry and stereochemistry of binding are likely to be important
factors in any potential interactions with proteins, particularly as the ligand has
been immobilised using a spacer arm which will undoubtedly affect any active
site interactions to some extent by imposing spatial constraints. To investigate
this, working with Mazhar Iqbal in the Dept of Chemistry, two compounds
were synthesised that possessed alternative binding sites for conjugation to the
epoxy activated agarose (Figure 5.6). Competitive elution chromatography
was conducted in the manner described previously and the SDS-PAGEresults
of the final flowthrough fraction andfirst elution fractions are shown in Figure
5.6 (bottom panel). With these conjugates there do not appear to be any bands
specifically eluted by TIZ, and the lack of a band that corresponds to the
elution of NQOI1 as in previous experiments was also noted. A similar
experiment by our collaborators revealed that NQO1 also binds to another
thiazolide that is structurally similar to DHRM4832 with a methyl group in
place of the secondary hydroxyl group (Figure 5.7) where binding occurs in
the same orientation as TIZ.
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Figure 5.6. Structures of TIZ and alternative conjugates DHTIZ, DHRM4832
and SDS-PAGEanalysis of affinity chromatography using these conjugates.
Red boxes indicate most probable point of conjugation to epoxy activated
agarose. Gel lanes (from left to right) Marker, final wash,first eluate fraction,
second eluate fraction, third etc.
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' H,C
Figure 5.7. The structure of the NQOI1 binding thiazolide. The above
thiazolide was conjugated to an EAA resin via the hydroxyl group.
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Pre-Incubation with TIZ
Although a novelputative target of TIZ had been identified (NQO1) by elution
with TIZ, the identification ultimately relies on interactions with a conjugated
thiazolide that is unlike that which would be encountered in vivo. To address
this and to circumventany issues of non-specific binding, Huh7cell lysate was
preincubated with TIZ so that binding sites could be occupied by the drug and
therefore prevent binding to TIZ-agarose. This was compared to an untreated
cell lysate subjected to the same procedure. Figure 5.8 shows proteins
competitively eluted from TIZ-agarose for both treated and untreated cell
lysates. There were no observable differences between the two conditions,
even in the region corresponding to the expected location ofNQO1, for which
binding has already been demonstrated. Whilst there may be several factors
that have prevented the observation of differential binding between the two
conditions, the lack a band corresponding to NQOI mayindicate that non-
specific proteolytic degradation has occurred. Despite the inclusion of a
protease inhibitor cocktail in the lysis buffer, this is still possible since some
commonly usedprotease inhibitors (e.g. PMSF) posses half lives in the order
of an hour at room temperatures.
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 Figure 5. 8. Comparison of competitively eluted proteins bound to TIZ-
agarose after with (+) and without (-) pre-treatment of Huh7 cell lysates with
TIZ. Lanes: M = Mw Marker, FT = final flowthrough after washing step, E1, 2
and 3 = 1 mM TIZelutedfractions.
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Discussion
Identification of cellular targets of new drugs is an essential part of
understanding their mode of action and important in improving their efficacy
and safety. The application of affinity chromatographyto this area of research
has both advantages and disadvantages, but when working effectively provides
a targeted approach to answering complex biological questions (e.g. [169]). In
combination with other experimentation (e.g. transcriptomics, proteomics, or
classical biochemical studies), the relevance of an interaction can be assessed.
Conceptually, the method is simple; the inherent and specific affinity between
an immobilised drug andits targets are used to capture binding partners from a
homogeneoussolution of biological sample (cell lysate). There are however a
number of areas where contamination of the results with interfering data such
as non-specific binding and ‘piggybacking’ interactions makes interpretation
of the results difficult and the analysis problematic. Non-specific binding with
the chromatography bed is probably most problematic in this study however.
As can beclearly seen in Figures 5.2, and 5.4, panel C, even with blocked
agarose containing no boundligand,there is a remarkably high level of protein
binding to the chromatography bed, eliminating several strongly staining
bands that would otherwise appear to be clear candidates for targets of TIZ.
Since contamination waspresent in both control and TIZ-agarose resins, the
background binding must be a product of methodological and technical
factors, most probably interactions with the porous agarose and long spacer
arm (a 12 carbon 1,4-bis(2,3-epoxypropoxy-)butane) [170, 171]. Similar
problems with background binding can be seen in a 2007 study of Giardia
180
lamblia, using the same type of chromatography bed conjugated to the
thiazolides [165].
Nevertheless, with improvements that enable deconvolution ofinterfering data
from the sought after biological result, affinity chromatography has proven
itself to be a valuable tool for identifying possible cellular targets of the
thiazolides, reliably identifying NQO1 as a binding partner to TIZ, howeverif
further information is to be gleaned or more research is to be conducted using
other conjugates, improvements in the specificity of the separation muststill
undoubtedly be made. Improvements in removing the background
contamination would likely be gained by moving away from a gravity flow
method and using either a column packed under pressure with fully
controllable linear flow rates and real-time absorbance measurements or by
using a non-column method such as batch chromatography or even a hybrid
method such as expanded-bed chromatography [172] that would allow
complete suspension of the resin in the washing buffers. Developments should
also be made in the method for concentration of the column elute for
visualisation by SDS-PAGE.Initially, a reversed phase protein trap column
wasalso investigated, this column was used within recommended parameters
and manufacturer’s instructions were followed precisely. However this method
repeatedly resulted in the total loss of protein. The exact cause of this failure is
currently unknown; howeverthe low pH ofthe elution buffer and the small
amounts of TFA in the concentrated protein may have rendered samples
incompatible with SDS-PAGE.It is also possible that a fault in the trap holder
which might have caused sample to leak to waste, or that no protein was eluted
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from the TIZ-agarose column during these experiments. Since manual
operation of the trap column wasalso proving to be time consuming, the RP
trap was abandoned in favour of a more straightforward TCA precipitation
with the appropriate pH adjustments. However,particularly if used in-line with
mass spectrometry, the RP trap column method could still prove useful. Other
methods such as lyophilisation [173], dialysis and centrifugal concentration
[174-176] could also be tested for suitability for this application.
Other methods of investigation were also concieved; working with Mazhar
Iqbal (Dept of Chemistry) plans to derivatise the thiazolides and enable the use
of click chemistry [177] were made. This would have enabled the use of a
range of covalent tags such asbiotin. It was also hoped that thiazolides bearing
an azido group could also be synthesised. This photoreactive bond would have
enabled the thiazolides to be covalently linked to their in vivo targets and
allowed for some interesting MS mass tagging applications using heavy and
light isotopes, and allowed for experiments to determinethe site of binding in
any elucidated interactions.
Ultimately affinity chromatography has the powerto identify possible targets
of a drug, however to determineif this interaction is biologically meaningful,
direct investigation of this putative interaction must be performed. In Chapter
6, the interaction between NQO] andthethiazolides is further investigated by
classical enzymekinetic techniques.
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Chapter 6
EnzymeKinetics of NQO1 andthe Thiazolides
Introduction
In Chapter 5, affinity chromatography of Huh cell lysate using three different
immobilized thiazolides, demonstrated that there was an interaction between
the immobilised form of Tizoxanide (TIZ) and human NAD(P)H Quinone
oxidoreductase 1 (NQO1). Furthermore, this interaction was not apparent with
the two other thiazolide conjugates that were used for chromatography. These
thiazolide derivatives were synthesized with an additional hydroxyl group on
position 4 of the benzene ring moiety in order to provide an alternative
orientation for conjugation with the agaroseresin.
NQO1, a homodimeric FAD-binding protein, catalyses the two electron
reduction of quinonesto their less toxic hydroquinone form, bypassing radical
formation that might otherwise damage the cell. Undergoing what has been
termed a ‘ping-pong-type’ reaction NADHbindsthe active site and reduces
FAD, a cofactor situated close-by. NAD* then leaves the active site
whereupon quinone can bind and subsequently be reduced to its hydroquinone
form before release. Access to the active site is carefully controlled by
tyrosine-128 and residues 232-236, which form a loop, that act as a lid and
restrict access to the binding after either the substrate or cofactor has departed
[178]. NQO1 is an important cytoprotective enzyme, whose response is
mediated by the antioxidant response element (ARE) and is also involved
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more generally in xenobiotic metabolism, for example the detoxification of the
phenolic metabolites of benzene [179]. NQO1 also interacts with and stabilises
p53, an anti-apoptotic protein [180]. Mutations in p53 are often associated
with certain types of cancers. Altered expression of NQO1has been observed
in several aberrant tissues [181], including several tumourcells, making it an
interesting target for pro-drug type treatments for cancer whereby the drugs
undergo what has been termed ‘bioreductive alkylation’ by NQO1 to become
‘activated’ and as a consequence causing toxicity to the cell [182, 183]. NQO1
expression is typically induced by oxidative stress, via the induction of Nrf2
and subsequent binding to genes possessing ARE in their upstream sequences
[184].
To determine if the interaction between the thiazolides and NQO1 maybe of
physiological significance, the interaction between the thiazolides and NQO1
was further studied. The binding interactions of TIZ and five other thiazolides
were investigated using in solution kinetics and in silico modelling
approaches.
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 Core Structure Name Chemical groups
3 3 _Nitazoxanide 2 -O(COCH3) / 5’ -NO»
: LY s3 7 @ Tizoxanide 2 -OH* / 5’ -NO>
H l'
4 6 DHTIZ 2 -OH / 4-OH* / 5’ -NO2
5
RM4819 2 -OH /3 -CH3/5’ —Br
RM4832 2 -OH / 5’ -Br
DHRM4832 2 -OH / 4 -OH* /5’ -Br
RM4850 2 -OH/5 -CH;/5’ -Cl
RM4857 2 -OH/ 5’ -H
RM4863 2 -OH/ 5’ -SO,CH3
 
*Hydroxyl groups used for conjugation with epoxy activated agaroseresin in
affinity chromatography experiments.
Figure 6.1. Namesandstructures of thiazolides used orcited in this chapter.
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Aims
The experiments of Chapter 5 demonstrated that TIZ binds to NQO1andthat
it is eluted under low millimolar concentrations. The aim of this chapter wasto
examine in greater detail the binding interactions between NQO1and several
thiazolides, including TIZ, using in solution kinetics and in silico modelling
approaches to determine its possible physiological significance. To achieve
this, an assay measuring the enzymatic activity of NQO1 wasestablished and
the effects of thiazolides on the activity were assessed. Computational
modelling experiments were also undertaken to predict how interactions might
be mediated.
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Methodsand Materials
Cells and reagents
Huh 7.5 cells, which were kindly donated by Jeffrey S. Glenn (Stanford
University), were lysed in buffer containing 50 mM Tris pH 8.0, 1 % (v/v)
Triton-X-100, 0.1 mg.ml'! DNase and 2x Complete Mini protease inhibitor
cocktail (Roche Diagnostics, UK). All other reagents were purchased from
VWRInternational (Leicestershire, UK) unless specified.
Sources ofthiazolides
TIZ was supplied by Romark Laboratories, L.C. (Tampa, Florida, USA). Other
thiazolides were synthesized by the Chemical Synthesis Group, Dept of
Chemistry, University of Liverpool, under the supervision of Dr A. Stachulski.
Initial assay conditionsfor monitoring quinone reduction.
The initial conditions were based on Ernster [185]. The final reaction mixture
contained 50 mM Tris/HCl pH 7.4, 5% DMSO(for drug solubility), 200 uM
NADH, 65 uM menadione sodium bisulphite (MBS), 1 unit of recombinant
NQO1in a final reaction volume of 1 mL. The reaction wasstarted by adding
the reaction buffer to MBS and NQO1and subsequent mixing by inversion. A
positive reaction was shownbythe conversion ofNADH to NAD+ detected at
340 nm using an Ultrospec 4100 (GE Healthcare) at 21 °C. Concentrations of
NADHwere calculated using an extinction coefficient of 6220 M’!.cm"
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Troubleshooting ofAssay Conditions
During steps taken to troubleshoot the assay, the reaction buffer, based on the
work of Lind et al. [186], contained the following: 50 mM Tris/HCl (pH 7.4),
5 % (v/v) DMSO, 200 nM NADHandstarting amounts of NQOland MBS
were varied as specified in the results. The reaction was monitored by the
removalof an aliquot of reaction mixture and measurement of the conversion
ofNADH to NAD+ at 340 nm using an Ultrospec 4100 (GE Healthcare) at 21
°C. Concentrations of NADH werecalculated using an extinction coefficient
of 6220 M!.cm’!
Monitoring ofreaction via reduction ofcytochrome C.
Since the previous efforts to use NADHat 340 nm to monitor the reduction of
menadione bisulphite to its hydroquinone form had been unsuccessful, a new
assay was adapted from Lindet al. [186]. The reaction was assayed in 50 mM
Tris/HCI pH 7.4, 500 1M NADH,0.08 % (v/v) Triton-X-100 (an activator of
NQOl1), 0.07 % (w/v) bovine serum albumin (also an activator of NQO1)
(Sigma Aldrich, UK), 77 uM cytochrome C (Sigma Aldrich, UK) in final
reaction volume of 1 mL. Menadione (MEN) and NQO1 were addedto the
reaction as specified in the results section. The reaction was started by the
addition of NQO1 (Sigma Aldrich, UK). Reaction rates at 21 °C were
determined using menadiol-mediated reduction of cytochrome C, which was
monitored by an ultrospec 4100 (GE Healthcare, UK) at 550 nM. An
1extinction coefficient (¢) of 29.5 mM!.cm’ was used to determine
concentration of reduced cytochromeC.
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Final NQO1 Kymenadione and IC50 determinations
The NQOI enzyme assay was adapted from Lind et al. [186]. The reaction
was assayed in 50 mM Tris/HCl pH 7.4, 500 nM NADH,0.08 % (v/v) Triton-
X-100, 0.07 % (w/v) bovine serum albumin (Sigma Aldrich, UK), 77 uM
cytochrome C (Sigma Aldrich, UK) and menadione over a range of
concentrations (0.125, 0.25, 0.5, 1, 2, 4, 8, 10 uM) in a final reaction volume
of | mL. The reaction wasstarted via the addition of 50 ng (0.0246 U) human
recombinant NQO1 (Sigma Aldrich, UK). The menadiol mediated reduction of
cytochrome C was monitored at 550 nM using an ultrospec 4100 (GE
Healthcare, UK). An extinction coefficient of 29.5 mM™'.cm™ was used for
cytochrome C. Ky was calculated by non-linear regression using Graphpad’s
Prism software. For IC50 determinations, reaction conditions were as above
but the menadione concentration was fixed at 2 wM and varying
concentrations of thiazolide (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30 uM) were used.
IC50 values were calculated using nonlinear regression using PRISM
(GraphpadSoftware).
Computational modelling
Computational modelling was performed in collaboration with Dr Neil Berry
and Dr Prabha Jayapal at the Dept of Chemistry. A brief description of their
methodsis given below.
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The structural coordinates of NQO1 were retrieved from PDB (1D4A), and
modeler 9v was used to generate the model to be used in docking simulations.
The quality of the model was assessed using Procheck [187] and Verify3D
[188]. Minimization of the model and generation of force fields was performed
using GROMACS[189]. Models for the structures of the thiazolides were
generated and optimized using Spartan (Wavefunction Inc) (HF/6-31G*). The
resulting models were used for docking simulations using Autodock4.0 [190],
a program (14) which is based on a molecular mechanics force field, to model
the substrate-enzymeinteractions using a genetic algorithm for searching. The
simulations were carried out in two stages - “blind docking” and “refined
docking”. The grid maps representing the protein were calculated with the aid
of autogrid, a utility of the autodock software. Two different grid maps with
different dimensions (“blind docking” covering the enzyme surface and
“refined docking” for the active site) were calculated for the protein. Both in
the blind and refined docking, the simulations were carried out using
Lamarckian Genetic Algorithm with the initial population of 300 individuals
and with the crossover rate, mutation rate and elitism set at the default values
of 0.8, 0.2 and 1 respectively. Resulting orientations lying within 2.0 A in the
RMSDwere clustered together and represented by the orientation with the
most favourable free energy of binding.
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Results
To establish and validate the assay, the Kmmenadione Was Sought, for comparison
to existing values. In order to do this, a working assay wasrequired
Initial assay conditions
Theinitial assay conditions, which were based on those suggested by Ernster
[185], resulted in an upwards sloping curve (Figure 6.2) that is not
characteristic of the expected Michaelis Menten kinetics [191]. Furthermore
the duration of the assay was unacceptably long since both NADH and
menadione sodium bisulphite are relatively unstable; breakdown of the
substrates is likely to be a concern.
Troubleshooting ofAssay Conditions
The paragraphs below describe some of the steps that were taken to
troubleshoot the unusually slow but accelerating reaction curves.
Initial experiments exhibited low but accelerating rates of reaction (Figure
6.2). Therefore the assay was carried out using various concentrations of
enzyme (Figure 6.3) and substrate (Figure 6.4). Alterations in enzyme
concentration did not correct the accelerating reaction rate. Furthermore,
reactions proceeded in an unexpected order suggesting sources of uncontrolled
variation, althoughinitial velocities rose with increasing enzyme concentration
(Figure 6.3). Increasing the concentration of MBSresulted in reaction curves
in their expected order, with higher substrate concentrations leading to faster
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overall rates of reaction although the curvesstill did not reflect typical enzyme
kinetics and saturation of the active site was not achieved. This suggested that
MBSconcentration might be limiting the reaction rate and it was decided to
use both very high concentrations of menadione, but to also to vary the
concentration of enzymeoverseveral orders of magnitude. (Figure 6.5). At 1
mMthe curve appeared to follow relatively normal enzyme kinetics albeit with
a slow overall rate and an initial lag phase. At 50 mM therate of reaction was
unexpectedly slow. This may be dueto substrate inhibition which can occur at
very high concentrations of menadione. Changing the concentration of enzyme
appeared to have no discernable effects on the reaction, which further suggests
menadione wastherate limiting factor and that concentrations of enzyme were
in excess. To confirm this, the concentration of menadione was added at
starting concentrations of 0.1, 1 and 10 mM. 1 U of NQOI was used.
Reactions were performed in duplicate. Figure 6.6 reveals that whilst at 100
uM menadione the unusual upward sloping curve wasstill present, at 1 mM
the reaction appeared more as expected. At 10 mM,unlike in the previous
experiment where 50 mM appeared to suppress the reaction, 10 mM
menadioneresulted in a much quicker reaction rate, consuming over 170 nMol
ofNADHwithin the first 5 minutes. Notably, saturation wasstill not achieved.
In a final attempt to resolve the issues with the assay, the concentration of
NADHwasincreased to 300 uM but NQOI wasreduced to 0.005 U since
several previous experiments had indicated that the enzyme maybein excess,
and concentrations of menadione were 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50,
and 60 uM (Figure 6.7). Reactions were performed in duplicates. At 35 uM
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menadione, the reaction plateaus after >280 nmoles NADH have been
depleted, corresponding to the total amount added to the starting
concentration, however curves possess the accelerating form as seen
previously were again observed and werealso in an unusual order with 25, 35
and 60 uM menadioneresulting in the highest reaction rates. Saturation of the
enzymeactive site wasstill not achieved.
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Figure 6.2. Conversion ofNADH to NAD+using 1 unit of recombinant NQO1
in ImL 50 mM Tris/HCl] pH 7.4, 5% DMSO, 200 uM NADH, 65 uM MSB.
Reaction was monitored by observing the MSB-mediated conversion ofNADH
to NAD+at 340 nm
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Figure 6.3. Effects of NQO1 concentration on the conversion of NADH to
NAD+ by NQO1. Reaction buffer contained 50 mM Tris/HCI (pH 7.4), 5 %
(v/v) DMSO, 200 uM NADH,65 uM MSBand 0.5, 1, 2 or 4 units ofNQOI per
mL. A: Conversion over time of NADH to NAD+; B: Initial reaction
velocities.
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Figure 6.4 Effects of MSB concentration on conversion ofNADH to NAD+ by
NQO1. Reaction mixture contained 50 mM Tris/HCl (pH 7.4), 5 % (v/v)
DMSO,200 pM NADH,| unit of NQOI/ mL and MSB(25, 50 100, 200, 400
uM). Conversion ofNADH to NAD+ was measured at 340 nm. Reactions were
performedin singlicate.
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Figure 6.5. Effects of various enzyme concentrations on conversion of NADHto
NAD+ by NQO1at 2 concentrations ofMSB. Reaction mixture contained 50
mMTris/HCl (pH 7.4), 5 % (v/v) DMSO,200 uM NADH,MSB(1 and 50
mM), and NQOI(10, 1 and 0.01 units per ml). Reactions were performed in
singlicate.
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Figure 6.6 Effects of various concentrations of substrate MSB on the conversion
ofNADH to NAD+ by NQOI. Reaction mixture contained 50 mM Tris/HCl
(pH 7.4), 5 % (v/v) DMSO,200 uM NADH,MSB(0.1, 1 and 10 mM)and 1
U/mL ofNQO1. Despite low concentrations of enzyme, saturation ofthe active
site could not be achieved. Reactions were performed in duplicate.
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Figure 6.7 Effects of concentration ofMSB (0 — 60 1M) on conversion of
NADHto NAD+ by NQOI. Reaction mixtures contained 50 mM Tris/HCl (pH
7.4), 5 % (v/v) DMSO, 300 uM NADH, NQO! (0.005 U/mL) and MSB(0,5,
10, 15, 20, 25, 30, 35, 40, 45, 50, and 60 uM).
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Monitoring ofmenadione reduction via reduction ofcytochrome C
Asearlier attempts to monitor the reduction of menadione using the reduction
of NADH at 340 nm had been unsuccessful, a new assay method for
measuring the rate of reduction was adapted from Lind et al. [186]. After
lengthy investigations into what might be causing the problems with the assay,
several factors were identified as being potentially problematic and were
addressed with a different assay design. The new assay used the menadione
mediated reduction of cytochromeC to determine the reaction rate to avoid the
problem of overlap of the absorbances of NADH and MBS. Menadione
(MEN) was used in place of MBS which should be more heat, light and
humidity stable; and several technical improvements were also made to the
method to minimise variation between and within experiments. These included
starting the reaction by the addition of enzyme and mixing carefully with a
clean plastic sparging stick; BSA and Triton-X-100 were also added as
activators ofNQO1 but DMSO wasomitted.
Using 100 ng (0.05 U) and 10 ng (0.005 U) of recombinant human NQO1,
reaction kinetics appeared normal (Figure 6.8), with 100 ng proceeding more
quickly than with 10 ng and reaching a plateau as would be expected
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Figure 6.8 Reaction kinetics of MEN-mediated reduction of cytochrome C at
550 nm at 2 concentrations of NQO1 (0.001 and 0.01 units/mL). Reaction
mixture contained 10 1M MEN, 50 mMTris/HCl (pH 7.4), 500 uM NADH,
0.08 % (v/v) Triton-X-, 0.07 % (w/v) bovine serum albumin and 77 uM
cytochromeC in final reaction volume of 1 mL.
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Kn,menadione Determination
With the parameters of the assay apparently within normal limits, the
suitability of the assay system for probing the interaction with the thiazolides
was determined by measuring the Kymenadione. The value was calculated in
Prism (Graphpad) using non-linear regression, fitting a classical Michaelis
Menten kinetic model, yielding a value of 2.45 uM (SE + 0.34). Later whilst
inhibition type was being determined, the non-linear regression was used again
to fit new data to an uncompetitive model of inhibition, yielding a new value
of 2.15 uM (SE + 0.32)
TIZ andfive other thiazolides inhibit NOO].
The interaction between NQOI1 and thiazolides was investigated further by
assaying the reduction of menadione to menadiol, in the presence of
thiazolides. All of the compounds tested exhibited an inhibitory effect on
NQOI under the conditions used (Figure 6.9). TIZ, RM4819 and RM4863
showed IC50 values in the low micromolar range (~3 uM) whilst RM4832 and
RM4857 had higher IC50 values of 13.92 uM and 12.04 uM,respectively.
However, some low-level inhibition ofNQO1 was observed with RM4850,the
relative insolubility of the thiazolides meant that an IC50 value could not be
accurately reported in this case.
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     —@ RM4819—“m RM4832~k~ RM4850~-™ RM4857+ RM4863-~@ TIZ2 J 0 I 2
Log[Thiazolide]
Compound _IC50 (uM) 95 % CI Goodnessoffit - R”
TIZ 2.00 1.73 - 2.31 1.00
RM4819 1.59 0.99 - 2.55 0.97
RM4832 13.92 10.18 - 19.03 0.94
RM4850 >30 - .
RM4857 12.04 6.85 - 21.17 0.89
RM4863 1.35 1.09 - 1.68 0.96
 
Figure 6.9. Concentrations of 7 thiazolides causing 50 % inhibition (IC50) of
NQOl1 activity. Using a range of concentrationsof the thiazolides, ICSO values
for the inhibition ofNQO1 were determined. Curves werefitted to the data
points using non-linear regression, with PRISM (GraphPad).
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Determination ofinhibition type
To further investigate the interaction of TIZ with NQO1 and to elucidate
further information regarding the type of inhibition, different concentrations of
MEN(1, 2, 4, 6, 10 uM) were varied over different [TIZ] (0, 0.5, 1, 2, 10 uM).
Initial reaction velocities were recorded and plotted on a double reciprocal
(lineweaver-burke) plot of 1/[menadione] vs. 1/initial velocity (Figure 6.10).
With the exception of measurements taken at 0 4M concentration of TIZ,
which deviated slightly, lines of best fit to the data lie parallel to each other, a
characteristic seen only in uncompetitive inhibition[191]. This was confirmed
using GraphPad Prism to fit the data to uncompetitive (inhibitor binds
substrate-enzyme complex), non-competitive (inhibitor acts without affecting
substrate binding) and competitive (substrate and inhibitor compete for
binding) inhibition models. Examination of the R?values andresidual plots for
the fitted models confirmed that uncompetitive inhibition best described the
data (not shown).
In silico modelling ofthe interaction ofthe thiazolides andNQO1.
In parallel to the in vitro data, to investigate how and where the thiazolides
under consideration may bind to NQO1, a molecular modelling docking
experiment was performed in collaboration with Prabha Jayapal of Dept. of
Chemistry. An in silico model of NQO1 was built based on the previously
derived X-ray crystal structure (PDB: 1D4A) [178]. Docking simulations were
performed using Autodock 4.0 to identify a likely binding site, and binding
modesofthe thiazolides. “Blind docking” experiments revealed that the most
204
favourable binding energy was observed for nitazoxanide in the pocket close
to the FAD co-factor. Refined docking experiments were performed in this
region using all the molecules. The best calculated free energy of binding
(AG,) for each thiazolide is shown in Table 6.1. An example of a conformer
from the lowest energy cluster of each docking simulation is shown in Figure
6.11. Comparison with the crystal structure of NQOlin complex with the
uncompetitive inhibitor dicoumarol (Figure 6.12) indicated that the location
for TIZ binding is the same. The accuracy of the model is supported by the
experimental results suggesting that TIZ is also an uncompetitive inhibitor of
NQO1.
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Table 6.1. Jn silico determinations of free energy binding (AG») of TIZ andits
analogues.
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Discussion
Using affinity chromatography, a binding interaction between human NQO1
and an immobilized conjugate of TIZ was identified. To determine the
physiological significance of this interaction, enzyme kinetic studies were
performed using TIZ andrelated thiazolides.
Initial kinetic experiments using NADHasan indicator of quinone reduction
failed to yield useful results, regularly producing reaction rate curves that were
problematically slow, which suggested that there were also issues affecting
reproducibility. Whilst the latter was easily addressed with methodological
changes, any single cause of the slow yet accelerating reaction rates remains
somewhatelusive, but several possible explanations for the accelerating rates
are proposed. With respect to MBS,three areas for concern were identified.
Firstly, at high concentrations, MBS is absorbed at 340 nm. Secondly, high
menadione concentrations can also inhibit the enzymatic activity of NQOI.
Finally, menadione sodium bisulphite, chosen for its water solubility, has
limited stability to heat, light and humidity. Therefore, over time, the
breakdown of MBS,therelief of substrate inhibition and concomitant decrease
in OD as MBSwas reduced by NQOI1, could have all contributed to the
apparent accelerating rate of the reaction curves. Breakdown of NADH may
have also exacerbated this. Breakdown of MBS and NADH would not be a
problem over a short assay time; however the very slow rates of reaction
meant that the assay times were extended to obtain a meaningful change in
OD.Atthis point it is worth noting that the concentrations of MBS that were
used in several of the troubleshooting experiments were far in excess of the km
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and should have been at saturating concentrations, this suggests that the
enzymeconcentration wasin great excess.
Looking retrospectively at the troubleshooting experiments where the enzyme
concentration was varied, a plot of enzyme concentration against initial
velocity (Figure 6.3, lower panel) reveals downward curving dependency of
initial velocity on enzyme concentration. Tipton [191] describes one of the
common causes for this can be contamination of the enzyme solution with
dissociable inhibitor. Without rigorous testing we cannot be certain if the
enzymesolution was contaminated with inhibitor. However, according to the
manufacturer’s specifications, the specific activity of the first vial (263 U/mg)
was nearly half of that of the new batch (492 U/mg). Considering everything
that is now known abouttheinitial attempts to establish a working assay,it is
still difficult to determine the precise cause of the problems although several
factors indicate that the problem was probably associated with the enzyme.
The initial reaction conditions were based upon a method widely used in
studies of NQOI1 [185] and several publications have used the method
successfully [192].
Using the new assay, the Kmmenadione. WaS Measured to be 2.5 (£0.4) UM . This
is in good agreement with previously published values of between ~ 2 and 4
uM [193, 194]. Initial single point experiments (not shown) indicated TIZ may
be an inhibitor of NQO1 so IC50 values for the various thiazolide compounds
were obtained. All of the compoundstested exhibited some inhibitory activity
against NQO1, although for some of the compounds an IC50 value could not
be accurately determined dueto the limits of solubility in this particular assay
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system. The experimental data yielded low uM (<3 uM) ICS5O values for TIZ,
RM4819 and RM4863 that would be easily physiologically achievable (21),
whilst slightly higher IC50 values were obtained for RM4832, and RM4857
(14 and 12 uM respectively). RM4850 had a much lower, but still significant
inhibitory effect on NQO1 (+30 uM). The results suggest that TIZ is a
uncompetitive inhibitor relative to menadione. An uncompetitive inhibitor
binds the enzyme-substrate complex, however in ping pong kinetic enzymes
this result can arise if the inhibitor is competitive with respect to the first
substrate, in this case NADH. The docking simulations indicate that TIZ and
the other thiazolides bind in the same way as dicoumarol, and inhibitor of
NQO1. Dicoumarol competes with NADH for access to the active site of
NQOI, but is uncompetitive with respect to its quinone substrates, supporting
the accuracy of the dockingresult.
The calculated AG, values from the docking simulations all show similar,
relatively strong binding of all thiazolides studied but no significant
differences in the predicted binding energies between the molecules studied
were found. The in silico calculations indicate that the thiazolides bind to the
active site and may share many of the same interactions, but there were
discrepancies between the AGyin silico data and the IC50 in vitro data. Certain
assumptions about the state and flexibility of the active site must be made
before docking calculations can proceed, which is an inherent limitation of
computational modelling. However, the modelling has relevance to affinity
chromatography, and an examination of the docking simulations reveals
several commonfeatures that could account for the observed bindingaffinities.
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The importance of the phenyl ring in affecting thiazolides binding to NQO1, as
implicated by the affinity chromatography, is further emphasized by the
docking simulations. For all molecules there was predicted to be a co-planar z-
stacking interaction (~3 A separation) between the phenolic portion of the
compounds with the ring structure of FAD. All molecules also display an
edge-to-face m-stack with TRP105. The binding pocket around the head group
of FAD is aromatic rich, thus the possibility for m-stacking and hydrophobic
contacts seemsa likely driving force for binding. The additional methyl group
on the phenyl ring of RM4819 may also contribute an additional favourable
hydrophobic interaction compared with the other molecules under
investigation. Many of the docking simulations revealed the potential for the
formation of hydrogen bonds with either TYR126 or TYR128(as indicated by
dashed blacklines in Figure 6.12) although the exact position of these residues
in vivo is uncertain because the residues are mobile to some extent, forming a
‘lid’ to the active site. The high degree of similarity between these interactions
and those between NQO1 andits natural substrates indicates further that this is
a highly viable possibility for the location of binding between TIZ and the
active site ofNQO1
TIZ, RM4832, RM4850 and RM4863 have been tested for their potency
against HCV and HBVreplication [13] and the IC50 results for these
compoundscorrelate very well with the data acquired for the potency of the
thiazolides against HCVreplication, and share the same orderof potency.It is
unclear at this point if this correlation is merely coincidental or if there is some
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other connection between NQO1 and HCVinfection, although one candidate
for the link is the tumor suppressor protein p53 whichis stabilized by NQO1
[180], and inactivated by the non-structural protein 5 A (NS5A) ofHCV [195].
It is possible that the interaction of thiazolide and NQO1 causes a favourable
change in conformation that promotes stabilization and accumulation of p53,
or that a transient increase in oxidative stress due to NQOI inhibition,
stimulates a new round ofanti-oxidant response element controlled genes such
as nqgol, which could also lead to p53 stabilisation. Stabilisation of p53 could
also be a candidate for the cell cycle-dependent, anti-proliferative effects of
the thiazolides observed by Mulleret al. [196]. Furthermore, p53 has also been
shown to mediate apoptosis upon chronic activation of the unfolded protein
response (UPR) [197] an integral process to the pathogenesis of HCV [198].
The UPRis triggered by an accumulation of unfolded protein (i.e. during viral
infection) in the lumen of the endoplasmic reticulum causing BiP, which acts
as a master control switch of the UPR,to dissociate from proteins ATF6, [RE1
and PERK which subsequently become active and lead to protein folding,
protein degradation and translational attenuation. In particular, translational
attenuation results from the phosphorylation of eIF2a. Some proteins of HCV
have been shownto inhibit PERK, thus increasing the overall levels of protein
synthesis.
Based soley on the observation that thiazolides inhibit NQO1, it is difficult, if
not impossible, to conclude that NQO1represents a host-based mode-of-action
that would explain NTZs wide-spectrum of effects. However, as the latest in
an increasingly long list of putative targets, the possibility of multiple modes
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of action becomesa probability, and the likelihood that, in vivo, the possibility
that NTZ targets or interacts with only a single enzyme seemslesslikely. In a
study to determine possible HCV resistance to thiazolides, Korba ef al. [12]
hypothesize that these compounds can mediate their anti-viral effects through
the host cell. The results of the present study appear to support this hypothesis
and demonstrated direct interactions between the thiazolides and hostcells.
Having identified another putative target of the thiazolides and also
investigated proteomic and transcriptomic changes modulated by thiazolides in
two differing cellular systems, the question of whether the results of these
experiments relate to one another remains. Thefinal chapter of this thesis will
discuss the findings of the present study and the research of others and see if
any further light can be shed on the modeofaction of the thiazolides.
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Chapter 7
General Discussion
Nitazoxanide seemingly provides potential therapeutic solutions to several
problems of global clinical significance to humans. The range of maladies
against which NTZ has a demonstrated potential is remarkable and includes, but
is not limited to, diseases caused by anaerobic bacteria, parasites such as
Giardia lamblia [199] and Cryptosporidium parvum [200], several viruses
including HCV, HBV [13], Rotavirus [20, 21] and Influenza A virus [201] and
even the proliferation Caco2 colon carcinomacells [166]. This wide range of
activity suggests that NTZ may have multiple modesofaction; the discovery of
multiple putative host and pathogen targets supports this, as do the accounts of
both its activity against axenic G. lamblia cultures and host mediated resistance
mechanismsinviral replicon cells.
The primary aim of the present study was to investigate the mechanisms of
action of NTZ against a parasite and a virus. In Chapter 3, the differences in
protein expression between a NTZ resistant strain of the intestinal parasite
Giardia lamblia and a wild-type strain were investigated using DIGE. The
protein changes observed in this experiment were also quantified on a
transcriptional level using RT-qPCR and in addition to this, a microarray
comparison of a resistant strain was reanalysed to gain new perspectives on
global transcriptomic changes. A DIGE analysis of a NTZs/METrstrain of G.
lamblia was also analysed to address the issue of cross resistance of the NTZr
strain to MET. The implications of these results were considered on the basis of
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both individual proteins, by grouping the types of proteins involved and also,
where possible, using bioinformatic techniques to describe the changes in
functions and processes that were unique to the NTZrstrain. The data indicated
that a group of annexin repeat proteins named ‘protein 21.1’ with various
predicted functions were associated with NTZ resistance in G. Jamblia.
Unfortunately virtually nothing is known about these proteins and therefore
without further study, little can be concluded regarding their functions and role
in resistance. The large number of differentially expressed VSP genes and
modulations in proteins related to cell mitosis suggested that cell cycle events
may be affected by NTZ. Comparison of molecular functions and biological
processes using GO terms indicated that amino acid synthesis, translational
elongation, protein folding and unfolded protein binding mayalso be important
processes modulated by NTZ. The bioinformatic interpretation of the results in
Chapter 3 is likely to improve with further refinements to the gene models and
more comprehensive annotation ofthe genome.
In Chapter 4, the DIGE technique was used to study the effects of NTZ on
HCV, by using an Huh7cell line expressing a sub-genomic replicon of HCV
treated with thiazolide. The replicon lacks the envelope and core proteins of the
full virus and thus cannot form infectious viral particles, but is still able to
replicate the other viral proteins and is a good model for HCV replication
overall. Large changes in heat shock proteins, including BiP, a protein that is
critical in regulating the UPR [136], and host elements with importance to HCV
replication complexes [159] were evident and were confirmed by bioinformatic
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analysis. Several nucleotide binding proteins and proteins with glycolytic
functions were also differentially expressed. The high quality functional
annotation data for humanproteins (in contrast to that for G. lamblia) was used
with three bioinformatic techniques to investigate the data. The greatest amount
of information was gained from PantherDB [151] and DAVID [152, 153, 202]
which use various gene annotations to describe the data and quickly confirmed
similar areas of significance as described above. Interactions between the
thiazolide modulated proteins were also investigated using STRING [154]. The
potential of this tool for discovering groups of proteins within datasets that
might be functionally related wasillustrated by its being the only technique to
isolate the group of proteins with glycolytic associations, but the reliability of
the interactions was somewhat underminedbythe possible presenceof errors in
the network due to automatically text-mined interactions.
After looking at changes in the global expression in systems of importance to
host and pathogen interactions, affinity chromatography was used to establish
interactions between host proteins and thiazolides. Non-specific binding of
proteins to the resin and spacer arm initially proved problematic. However by
using a TIZ-agarose conjugate, a protein of approximately 31 kDa was
repeatedly eluted with 1 mM TIZ buffer. This protein was not eluted when
thiazolide derivatives were conjugated to the agarose resin in an alternative
orientation. The protein eluted with TIZ was identified as NAD(P)H Quinone
Oxidoreductase 1, a FAD bindingprotein that catalyses the 2 electron reduction
of quinonesto their less toxic hydroquinone form via mechanismsthat do not
generate toxic radical species [182]. In Chapter 5, a detailed study on the
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interaction between NQOI and thiazolides showed that NQOI1 could be
inhibited by TIZ and several other thiazolides. The inhibition type was also
determined to be uncompetitive with respect to menadione, binding the enzyme
substrate complex. The results of the docking studies indicate that TIZ binds the
same location and interacts with the active site in the same manner as other
inhibitors, such as Dicoumarol [203] which is also uncompetitive with respect to
menadione, supporting the accuracy of the model; however the AG» values did
not correspond to the measured ICS0 values.
The most definitive finding of this study was the inhibitory activity of the
thiazolides against NQO1. It is unclear howthis fits into the wider picture, and
the question of whether the inhibition of NQO1 could cause someorall of the
proteomic changes that have been observed in RP7 cell lines requires further
study before this question can be conclusively answered. The effects of
dicoumarol, which is an inhibitor of NQO1, on the proteome of Huh7cells and
on HCV’sability to replicate, should provide answers to this question. Both the
experimental and modelling data support the notion that thiazolide binding to
NQOI occurs in a manner analogous to other inhibitors such as dicoumarol.
NQO1has been shown to be up-regulated in certain types of tumourcell lines
and has been targeted using ‘pro-drugs’ which becometoxic to the cell upon
activation by NQO1 [204]. TIZ has also been shownto inhibit proliferation of
rapidly proliferating Caco2 cells, a colorectal adenocarcenoma cell line,
although in the same study it was hypothesised that this activity was mediated
through GSTP1 [166]. Nonetheless, the inhibition of NQO1 could be an
important mechanism for the survival ofcells in which NQO1is over-expressed.
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NQOI1also has role in stabilising the tumour suppressor protein p53, which
controls cell cycle progression and DNA repair [180, 192]. Simultaneous
interference with this interaction, as occurs with dicoumarol, in combination
with the inhibition of NQO1, which is an important detoxifying enzyme, could
leave cells vulnerable to the deleterious effects of oxidative stress arising from
defects in protein folding.
Based onthe results of the DIGE experiments, it has not been possible to draw a
single definitive conclusion about the mechanism of action of thiazolides. Most
proteomic techniques are probably best considered to be hypothesis generating
however, since their results alone cannot often provide direct evidence for a
particular interaction, The DIGE experiments have, however, suggested that
there may be several biological areas which are of particular importance to the
mechanism of action of thiazolides. Despite fundamental differences between
the proposed mechanismsofaction of thiazolides against G. Jamblia and HCV,
the results of the two DIGE experiments share some functional themes. These
functional overlaps are primarily protein folding and unfolded protein binding
and the data suggests that HSPs may havesignificant roles in both systems.
Whetherthis is the result of commonsystemic effects of the drug that do not
represent the primary modeofaction i.e. drug stress, or represents a previously
undiscovered common contribution towards the mechanism of action in both
systems is unclear. Whatis clear is that this result warrants further study in both
systems and maybeofparticular relevance to the HCV replicon system where
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ERstress response mechanismsare integral to viral infections [142, 144, 146,
155);
There are still some fundamental issues that need to be addressed concerning
potential resistance mechanisms of G. lamblia that might not be detected by
either DIGE or by the microarray experiments used in this study. A closer look
at the underlying genetic sequences of resistant pathogen strains can in many
cases reveal mutations that are responsible for resistance. A recent study using
high resolutiontiling arrays to discover resistance conferring mutations to MET
in H. pylori [100] is a good example of this. Whole transcriptome shotgun
sequencing (WTSS) techniques such as RNA-seq which provide both transcript
sequence data and transcript abundance could nowalso be used to improve on
the tiling array method and identify genes that might carry mutations. However
since resistance to NTZ can belost after a round of en- and excystation, the
mechanism of resistance may be mediated by an epigenetic mechanism rather
than permanent genetic change such as a mutation. Techniques such as ChIPseq,
which is a combination of chromatin immunoprecipitation of proteins suspected
of interactions with DNA combined with sequencing of the DNA fragments to
which they bind, could also have a place in determining if epigenetic
mechanismsare involved in resistance. Other epigenetic mechanisms such as
PTMs(histone acetylation for example) could also be investigated using 2DE,
and MS.With this data in hand, a more complete picture ofhow the thiazolides
affect cells on a global scale could be built. Sequence analysis of a recently
created HCVreplicon cell line, resistant to NTZ through whatare believed to be
host cell mediated means [12], could also be beneficial to the discovery ofNTZs
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targets. Future studies of the mechanism of action of the thiazolides against
HCVshould also consider using genomic length replicon expression systems
that include the structural proteins of HCV [205]. These newerreplicon systems
that include HCV glycoproteins El and E2 might be especially important in
light of evidence that NTZ affects the maturation of Influenza A, viral
haemmaglutinin [201] and the effects of glycoprotein maturation in Rotavirusis
also being investigated. The process of glycoprotein maturation is an ER
initiated process that continuesinto the golgi, again highlighting the importance
of protein metabolism as a potential target of action ofthe thiazolides
There were someareas of the present study, which were ultimately hindered by
limitations currently imposed on them. The bioinformatic aspects of studying G.
lamblia presented considerable challenges. After identifying proteins that were
modulated in NTZ resistant G. /amblia, functional annotations for these proteins
were sought. The only functional annotation currently available for G. lamblia
are GO terms, and only 25 % ofproteins in the 1.2 release of GiardiaDB have
GO annotations assigned to them. Even for relatively large datasets such as
microarrays, reducing the numberofsignificant results by this proportion leads
to rather small sample sizes for hypergeometric overrepresentation analysis.
Furthermore, obtaining the mappings of GO termsto the GiardiaDB identifiers
and transcribing them into a form useable by other tools was a difficult task,
requiring at least some basic knowledge of regular expressions (a method
commonly found in text editors or programming languages for of identifying
characters, words, or patterns of characters etc). This is in contrast to other
organisms such as Saccharomyces cerevisiae for which the information is
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readily available. Although there are now manytools available for GO term
enrichmentanalysis, these tools often exclude all but the most commonspecies.
G. lamblia was even excluded from DAVID,despite obtaining its information
from several databases that do contain gene information for this species, such as
NCBI(althoughthe current private beta release addresses this [202]).
Whilst microarrays have a clearly defined background population set and thus
are highly amenable to statistical analysis, most proteomic techniques suffer
from an unknown background population. The main reason forthis, particularly
in parasitic organismsbutthatis likely true of any organism that can survive in
more than one environment, is the potential for unknown differences in the
expressed proteome that is subject to fluctuations from cellular differentiation
and life cycle stages [206, 207]. A method to account for post-translational
modification (PTMs) and alternative splicing also needs to be factored into
statistical models before they can be considered accurate. One wayto solve this
problem whilst taking into account the technical biases of DIGE(i.e. protein
solubility and dynamic range in a gel based system) might be to pick and
identify every detectable protein on the analytical DIGE gel, thus quantifying
the background against which, statistical analysis of the proteins can be
performed. The time required to identify the several thousand resolvable protein
spots that are detectable on the gel however meansthis is somewhat impractical.
Gel-free techniques such as multidimensional protein identification technology
(MudPIT)that can identify hundreds of proteins in a sample [208, 209] could be
used to achieve similar statistical gains, however this would not incorporate
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some of the advantages of gel-based methods such asthe ability to recognise
phosphorylation simply [210].
Perhaps the best approach to the statistical challenges that are faced by most
current proteomic techniques is not to develop new statistical analytical
methods, but to create or adapt methods that can be analysed using the existing
robust methods. There are some emerging proteomic techniques that do not
suffer from the statistical challenges that techniques such as DIGE do; protein
arrays use a defined set of proteins as the background population, and thus
eliminate the uncertainty in the statistical analysis. Two methodsin particular
stand out as promising techniques for the discovery of drug mechanism of
action. Global effects of drugs on the protein expression could be quantified by
using antibody arrays (or capture arrays) that possess specificity for individual
proteins. By detecting the concentration of protein bound by each spot, the
concentration can easily be determined. The bottle-neck to this is clearly the
availability of specific antibodies for every protein of interest. Howeverby using
the results of global proteomic techniques, such as DIGE, iTRAQ, SILAC or
ICAT in combination with protein-protein interaction resources such as
Reactome, Biogrid or STRING, protein arrays that are targeted to sub-
proteomes and would benefit from straight forward statistical analysis could be
created. A functional protein array meanwhile, with proteins immobilised to the
array, could be used to directly observe which proteins the drugs bind to. Protein
synthesis and capture is the main obstacle to this, but improvements in
recombinant expression have led to the ability to perform in situ synthesis of
proteins directly on the array. Nucleic acid programmable protein arrays
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(NAPPA) [211] are an exampleofthis, as is synthesis of proteins directly from a
DNA microarray, “DNA to protein array” (DAPA) [212] for example. The
implications of these techniques to the field of drug target discovery could be
immense and in combination with techniques such as ChIP on chip and
CHIPseq which can determine the interactions between DNAandproteins, the
improvements in dynamic range, resolution, reliability and interoperability of
the techniquestakesthe field a step closer to realising the goal of global systems
biology. Increases in the capacity of techniques such as multiple reaction
monitoring (MRM) [213], a mass spectrometric technique which use single
peptides as representatives of protein concentration, is also helping to establish
this technique as a useful method for multiplexing the quantitation of individual
proteins and their turnover.
The pull down assay was confirmed as a good wayofidentifying interactions
but establishing the nature of the interaction took several weeks. With higher
throughput methodsthat could result in many candidate proteins, expressing the
recombinant protein and testing the interactions with a target would be very
lengthy and laborious. There may be waysofprioritising the analyses of these
interactions. Protein arrays in combination with biosensing techniques such as
dual polarisation interferometry (DPI) [214, 215] could potentially be used to
rapidly assess the binding of small molecules to many different proteins without
the need for tagging and labelling strategies. DPI uses the principles of surface
plasmon resonance to detect distortions in evanescent wavesthat results from
changes in the conformation of molecules at the surface of chip. The technical
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limitations of this are unknown,but could be a fast way offinding the targets of
small molecules.
Using proteomic, transcriptomic, bioinformatic and classical biochemical and
enzyme kinetic techniques, the present study has identified areas for further
research in the discovery of the mechanism ofaction ofthe thiazolides. Testable
hypotheses can now be generated on the basis of the ‘omic’ results for both G.
lamblia and HCV andtherelative contribution towards the mechanism ofaction
that each of the putative areas of significance makes can be assessed. Most
significantly, this study has identified a novel target of the thiazolides, NQO1
has been identified; the importance of this interaction should be assessed by
further studies. There are howeverstill several, yet-to-be investigated areas,
such as the potential for genetic mutations and how epigenetic mechanisms
might contribute to mechanism of action that must be also be addressed if we
are to completely understand the complex biochemistry that underpins the
activity of the thiazolides.
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Appendix A
“TOPTABLE” RANKEDLIST OF DIFFERENTIALLY EXPRESSED
GENESIN NTZ RESISTANT GIARDIA LAMBLIA
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 locus [Product Description] logFC
113797 VSP with INR -3.3826208
4078 Hypothetical protein 1.9680186
16501 VSP with INR 1.8392107
111874 VSP -2.1392015
99493 hypothetical protein -2.6984578
114122 VSP -1.6893063
41212 Hypothetical protein 1.40183 16
5435 Cyst wall protein 2 -1.4520654
137612 VSP 1.3231786
114672 VSP -1.5510569
101811 Hypothetical protein -1.5329691
114065 VSP -1.788614
40591 VSP -1.2666862
40621 VSP -1.3834347
17249 Coiled-coil protein 1.4868398
36493 VSP -1.6011802
98799 Hypothetical protein 1.9836519
10429 Wos2 protein 2.2770209
32450 hypothetical protein -1.2008322
32426 Hypothetical protein 1.4082055
111873 VSP -1.2664834
27310 Stress-induced-phosphoprotein 1 1.4193631
7593 Hypothetical protein 1.2907629
118532 hypothetical protein -1.1511618
101326 Hypothetical protein 1.2746888
118156 hypothetical protein -1.4314666
13520 VSP -1.1932273
12143 hypothetical protein -1.0693958
97733 Hypothetical protein -1.618966
3218 hypothetical protein -1.1842615
7260 Aldose reductase 1.1169795
4812 Beta-giardin 2.1184591
12139 Protein 21.1 2.2388346
9861 Hypothetical protein 1.1166114
8722 Myb1-like protein -1.1381169
34030 hypothetical protein -1.2260634
115200 Hypothetical protein -1.002655
137672 High cysteine membrane protein VSP-like -1.2245806
27925 Protein 21.1 2.448497
137740 VSP 1.4999011
13272 Hypothetical protein -1.5441317
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112103
10193
41476
17043
28748
106300
26971
16745
8174
5188
18877
115598
33004
1206
38862
15026
92941
137713
24590
29774
101498
19098
97820
8173
32711
13783
16125
102012
8726
38553
16906
14043
5638
134773
114653
34196
17551
17570
16648
11865
4410
16283
Arginine deiminase
WD-repeat membraneprotein, putative
VSP
Glyceraldehyde 3-phosphate dehydrogenase
Hypothetical protein
hypothetical protein
hypothetical protein
Axoneme-associated protein GASP-180
Protein 21.1
Protein 21.1
hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
Src-associated protein-like protein
hypothetical protein
Hypothetical protein
Protein 21.1
Hypothetical protein
Variant-specific surface protein VSP4A1 precursor
hypothetical protein
VSP,putative
Glycerol kinase
hypothetical protein
Hypothetical protein
Glycerol-3-phosphate dehydrogenase
Hypothetical protein
Actin related protein
Hypothetical protein
Phosphatidate cytidylyltransferase
VSP
Cyst wall protein 1
hypothetical protein
VSP
VSP
Protein 21.1
Elongation factor 2
Hypothetical protein
Hypothetical protein
SALP-1
Aminoacid transporter family
245
1.6544307
-1.2746311
-1.3313304
-1.0129174
1.0772775
-1.0371954
-1.1695203
1.253151
1.4127078
1.6739594
-1.8815889
-1.2910638
-1.4381026
1.1189112
-1.0444742
1.1591176
1.1637746
-2.1353091
1.0980898
-1.2976241
-1.4840273
-3.4584075
-2.2375817
-1.4510159
1.067822
-1.0429467
-1.2392267
-1.0581393
1.6191699
1.2161621
1.0845438
-1.343418
-1.1015245
-1.0466678
-1.2179331
-1.03784
2.2383348
1.0974692
1.1729272
1.0868362
1.30995
-1.4905046
135831
13627
19663
103983
11997
21444
32265
15455
16532
137726
14262
117476
23876
34867
6334
137614
17053
88369
13651
10401
31692
10255
16412
113622
114623
125386
16867
112445
98058
4852
31366
9515
13584
10219
88765
15499
86648
86484
135918
9978
10133
38906
VSP
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Spindle pole protein, putative
Hypothetical protein
E04F6.2 like protein
Protein 21.1
ABCtransporter ABCA.1, putative
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
VSP AS12
Protein 21.1
Protein 21.1
Hypothetical protein
hypothetical protein
Hypothetical protein
Translationinitiation factor elF-4A, putative
Heat-shockprotein, putative
Protein 21.1
Hypothetical protein
hypothetical protein
AAA family ATPase
Hypothetical protein
VSP
Hypothetical protein
Hypothetical protein
Coiled-coil protein
Hypothetical protein
Protein 21.1
Cytosolic HSP70
Hypothetical protein
Hypothetical protein
Hypothetical protein
VSP
Hypothetical protein
Hypothetical protein
Hypothetical protein
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-1.018952
1.0077234
-1.1426454
-1.6084021
-1.0510821
1.6790508
1.6550273
1.0677176
2.3858302
-1.1373928
1.4405229
1.0310408
1.1565427
1.1266217
-1.1877477
1.1781061
1.8847839
1.2958509
1.1767041
1.4399468
1.2881158
1.107429
1.0878148
1.7593508
1.0264678
-1.1708098
1.4665034
-1.0908036
-1.5229418
1.3981064
-1.7030155
1.3591797
1.1238364
1.0802242
2.5871322
1.1508821
1.5631548
1.3748453
-1.0393734
-1.1653574
-1.0019661
1.0061533
112048
5883
13329
9046
23492
1695
23017
109417
113954
35011
37538
115985
113450
3762
13323
93011
97839
17097
9720
10808
93585
16844
6637
28811
10238
14628
10524
8044
17046
14225
14940
98126
7439
119466
39024
8377
4587
10370
15410
16935
14568
116967
VSP
Hypothetical protein
Hypothetical protein
Sugar transport family protein
Protein 21.1
Rab11
Hypothetical protein
hypothetical protein
VSP
Hypothetical protein
Hypothetical protein
hypothetical protein
VSP with INR
Protein 21.1
Hypothetical protein
Protein 21.1
hypothetical protein
Protein 21.1
Protein 21.1
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Phosphatidylinositol-4-phosphate 5-kinase, putative
Hypothetical protein
Seven transmembraneprotein 1
Protein 21.1
CXC-rich protein
Hypothetical protein
High cysteine protein
Ser/Thr phosphatase 2A, 65kDa reg sub A
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
ATP/GTPbinding protein, putative
Ser/Thr protein kinase
Hypothetical protein
Ser/Thr protein phosphatase PP1-alpha 2 catalytic
subunit
Hypothetical protein
247
1.4267342
1.556997
1.2893323
-1.1510486
1.3657967
1.0229949
1.516429
-1.0348212
-1.0442842
1.2213966
1.3461582
-1.2471546
-2.7001563
1.1465729
1.0192144
1.3267276
-1.2776117
1.0327236
1.1685414
1.0376391
-1.094157
1.6260784
-1.3347951
-1.9846866
1.4219284
1.0022832
1.0858196
1.1686363
2.0505091
-1.0050698
1.0329953
-1.4017662
1.6941958
-1.1417615
-1.3802749
-2.4310123
1.0597201
1.0744608
1.2220712
1.4373532
1.2900581
1.746827
2616
114662
3545
20810
23790
36567
13948
16376
106224
38761
103807
24108
102142
20170
9787
32052
24781
17060
24279
96818
41401
28302
9062
112112
16367
3079
14859
6967
30947
17585
16267
40390
117118
15048
95451
117908
86676
17571
38009
28626
39098
11309
Hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
ATP-dependent RNA helicase p47, putative
hypothetical protein
Hypothetical protein
Protein 21.1
hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Protein 21.1
Hypothetical protein
Hypothetical protein
VSP
hypothetical protein
Longchain fatty acid CoA ligase 5
Hypothetical protein
Hypothetical protein
Hypothetical protein
Protein 21.1
hypothetical protein
hypothetical protein
Protein 21.1
Hypothetical protein
Protein 21.1
hypothetical protein
ATP-dependent RNAhelicase-like protein
Hypothetical protein
hypothetical protein
Delta giardin
Trichohyalin
Hypothetical protein
VSP
Hypothetical protein
High cysteine membrane protein Group 1
248
1.1234678
1.0958169
-1.1242322
-2.004941
-1.0262794
1.5390717
-1.3783046
1.0479762
-1.0196269
-1.1520153
1.049963
-1.4281621
-1.4407456
-1.0494125
-1.0788858
-1.0582137
-1.0170255
1.8379919
1.05349
1.0959669
-1.1236116
-1.1938622
1.0569044
1.5300598
1.2941586
-1.3326145
2.0746506
-1.169392
-1.0787223
1.3168111
1.1280021
1.0964091
-1.0488257
1.5600422
-1.9826522
-1.022446
1.2288563
1.3361601
-1.2123463
-1.1149377
-1.5422948
1.6655639
11165
103107
8855
7268
6242
15823
14553
41288
89117
26121
11204
28829
40376
27896
16478
38910
5804
12229
32111
31341
114820
118283
10706
5278
88181
36036
8364
32051
3582
34505
96043
28348
103818
17230
27830
102662
28761
12066
33935
10171
17120
4355
Protein 21.1
Hypothetical protein
P115, putative
Protein 21.1
Translationally controlled tumorprotein-like protein
1,4-alpha-glucan branching enzyme
CCAAT-bindingtranscription factor subunit C
Mucin-like protein
Hypothetical protein
hypothetical protein
Plant adhesion molecule 1
hypothetical protein
High cysteine non-variant cyst protein
hypothetical protein
Hypothetical protein
VSP
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Thymidine kinase
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Gammagiardin
hypothetical protein
VSP
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
CEGP1 protein
Nif3-related protein
249
1.0531813
-1.6750535
1.0241137
1.4136421
1.1911214
1.2206884
-1.2477901
1.001736
-1.0714499
-1.0621025
-1.4158823
1.1731792
-1.0214051
1.1167383
1.3779455
2.350619
-1.950971
-1.7484415
-1.7396331
-1.8716566
-1.1366388
-1.3118835
-1.0180786
-1.0865194
-1.2919539
-1.1481444
2.1832573
-1.7035587
1.2514338
-1.7591143
-1.9836693
-1.4336243
1.0735893
2.2381868
-1.0955445
1.0911661
-1.3022835
-1.8361274
-1.0825331
-2.6249601
-1.1624368
-1.1613566
114674
87941
20386
38412
2178
111809
92037
93369
14438
27760
32192
13268
14971
5302
36798
16001
102051
114833
113021
10361
10229
92449
37897
105663
92990
94534
12068
86401
32354
135991
37641
3273
13464
29599
33978
38396
24169
39564
14821
31504
8101
6602
Hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Glutamate-cysteine ligase
Aminoacid transporter family
hypothetical protein
Acetyl-CoA carboxylase/pyruvate carboxylase fusion
protein, putative
P60 katanin
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Splicesome-associated protein
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
HesB domain-containing protein
hypothetical protein
Hypothetical protein
Protein 21.1
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1.7982051
-2.1591043
-1.1488136
-1.9033777
-1.0011942
-1.0273758
-2.5301086
-1.1380863
-1.0177607
-1.110506
-3.2889784
-1.7255415
1.2278697
-1.5575743
-1.1813553
-1.5789414
-2.0948855
1.2520665
-1.1265481
-1.4344822
-1.124833
-1.0525987
-1.7525784
-1.8173938
-4.1855426
1.0702163
-1.6567428
-1.3783849
-1.3289421
-2.3683503
-1.0067555
-1.68979
-1.4899715
-2.4587618
-1.0322838
-1.2888904
-1.1897364
1.3632847
-1.2796581
-3.4109045
-1.4910123
-1.5423632
9238
39487
38901
117147
103164
5513
36178
102184
31541
34559
10666
7053
21438
3202
38130
105786
16630
16689
21160
33083
90306
31903
105642
16502
5657
11953
35575
35090
33917
38149
34431
32454
112866
34642
15011
32460
32363
37931
5130
11624
16841
6147
hypothetical protein
hypothetical protein
VSP
hypothetical protein
H-SHIPPO1
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
Histone acetyltransferase GCN5
Hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Mlh2-like protein
hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
Coatomeralpha subunit
hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
Reverse transcriptase/endonuclease, putative
hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
DinF protein
hypothetical protein
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-1.3456202
-1.326162
1.2140658
-1.2377587
1.5361031
-1.393345
-1.0159547
1.927578
-1.1088954
-1.3525332
-1.2064225
-2.0003323
-1.7091078
-1.2743657
-1.2842142
-1.8152152
-1.8074216
1.4950658
-3.144422
-1.1201041
-4.5215798
-2.1003543
1.2706796
-1.1714333
1.0940093
-1.9776048
1.3882571
-1.1286587
-1.0027848
-1.2810748
-2.0990681
-2.4075854
1.1906261
-1.8626408
-1.1753689
-2.4147782
-1.125929
-1.7678753
-2.1164767
-2.2750638
-1.1070488
-1.5921621
35241
37871
1519
27806
16751
39044
36095
37713
37737
16693
3465
16635
27623
33931
104925
87793
113610
14863
39084
16638
15135
98218
15248
94673
8516
16247
5013
35161
38903
92245
3855
8454
11862
37700
19642
10850
90305
8650
14872
28779
hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
GlcNAc-PIsynthesis protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
hypothetical protein
Spindle protein, putative
hypothetical protein
Hypothetical protein
hypothetical protein
Endothelin-converting enzyme 2
hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
hypothetical protein
Hypothetical protein
Hypothetical protein
hypothetical protein
Hypothetical protein
Protein 21.1
Hypothetical protein
2o2
-2.3063583
-2.3355954
-1.0590267
-1.286117
-1.4994601
-1.4859341
-1.2937277
-2.3476927
-1.3040557
-1.2777013
-1.2670535
-2.2588046
-1.155534
-2.2159347
-1.2991321
-3.8747034
-1.5576588
-1.5202013
-3.078483 1
-1.9674039
-1.5383418
-3.169746
-1.2792175
-1.0927331
-1.5694599
-2.7714092
-1.6208002
-1.113097
-1.5419471
-1.0573451
-1.2329531
1.7424329
-2.0230963
-1.513302
-1.111936
-1.4337166
-1.0280951
-1.2748754
-2.6225089
-1.3983511
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National Institute of Allergy and Infectious Diseases (NIAID), NIH
 
Functional Annotation Clustering
Help and Manual
Current Gene List: Downregulated
7 DAVID IDs
 
Options Classification Stringency High
[ Rerun using options ] [ Create Sublist ] fi DownloadFile
[] GOTERM_CC_ALL organelle lumen RT inccnnacacmcdisans 3 4.4E-2 1.0E0
CJ GOTERM_CC_ALL membrane-enclosed lumen RT ‘cecamncenaaaiins 3 4.4E-2 1.0E0
[lb SOLERRecah guclear Tt — 3 5.6E-2 1.00
Cl GOTERM_CC_ALL macromolecular complex RT Snaasranenenmmannees 6 6.2E-4 4.2E-1
co binding RI cnsceencastasesanaaaamaaiid 6 5.8E-1 1.0E0
Cl GOTERM_BP_ALL cellular process RT _ 6 7.6E-1 1.0E0
C} GOTERM_MF_ALL structural molecule activity RT eT 3 3.6E-2 1.0E0
‘a GOTERM_CC_ALL cytoskeleton RT ee 3 6.4E-2 1.0E0
ol GOTERM_CC_ALL eenon-membrane-bound RT —_—_—_ 3 1.6£-1 1.0E0
[]=. SOTERMECCALL fon-membrane-bound RI nanan 3 1,.6E-1 1.0E0
{J SP_PIR_KEYWORDS phosphoprotein RT NL 6 6.4E-3 1,0E0
[J GOTERM_CC_ALL intracellular organelle RT 6 1.3E-1 1.0E0
CJ GOTERM_CC_ALL organelle RT ‘cam 6 1.3E-1 1.0E0
EI GOTERM=CC“AL intracellular RT ciaRaccaacaRasaiaR 6 2.7E-1 1.0E0
[] GOTERM_CC_ALL intracellular RT NN 6 3.5E-1 1.0E0
C] GOTERM_BP_ALL organelle organization and biogenesis RT scainciainass 3 7.4E-2  1.0E0
a GOTERM_BP_ALL cell development RT acne 3 7.9E-2 1.0E0
ir} SP_PIR_KEYWORDS nucleatide-binding RT —_—_n 3 8.5E-2 1.0E0
[| GOTERM_MF_ALL purine ribonucleotide binding RT ee 3 1.4E-1 1.0E0
C] GOTERM_MF_ALL ribonucleotide binding RT ee 3 1.4E-1 1,0E0
a GOTERM_MF_ALL purine nucleotide binding RT ee 3 1.5E-1 1.0E0
C GOTERM_BP_ALL cell differentiation RT iamamiamaaaaionnens 3 1.5E-1 1.0E0
i”| GOTERM_BP_ALL cellular developmental process RT ees S 1.5E-1 1.0E0
Cj GOTERM_MF_ALL nucleotide binding RT ‘ccna 3 1.9E-1 1.0E0
tC GOTERM_BP_ALL response to stimulus RT _—_— 3 3.4E-1 1.0E0
CI SoranKEY)ORES protein RT scimtaaintads 4 4.1E-2  1.0E0
MGEeCe nucleus TT aa é 2.4E-1 1.0E0
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O GOTERM_CC_ALL membrane-bound organelle RT a 4 5.7E-1 1.0E0
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INTERPRO Heat shock protein Hsp70 RT ee a 2.6E-6 1.5E-2
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GOTERM_CC_ALL organelle RT 23 6.0E-4 4.2E-2         Annotation Cluster 3 Pee reeloe) HUCESTea 
O
O
O
O
O
B
O
O
O
O
B
O
O
O
O
O
O
O
O
O
O
O
  
GOTERM_BP_ALL anti-apoptosis RT iene 5 2.4E-4 4.6E-1
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GOTERM_BP_ALL negative regulation of programmedcell RT a 5 7.9E-4 5.0E-1
death ine
GOTERM_BP_ALL requlation of apoptosis RI means 6 2.6E-3 6.5E-1
GOTERM_BP_ALL regulation of programmedcell death RT aaa 6 2.7E-3 6.4E-1
GOTERM_BP_ALL cellular protein metabolic process RT ‘ciiiaatieiaaarna 15 1.4E-3 6.5E-1
CoE lular macromolecule metabolic proce RT ‘anne 15 1.6E-3 6.6E-1
GOTERM_BP_ALL protein metabolic process RT amines 15 2.5E-3 7.0E-1
Pelee md eTeloaed
GOTERM_CC_ALL intracellular part RT ‘eciceeacaseaesld 26 8.0E-5 2.3E-2
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GOTERM_CC_ALL cell RT ay 27 2.4E-1 1.0E0
PeleGo eda Enrichment Score: 2.09 | Count i aeflit i PIa
O
O
O
O
O
U
B
O
O
O
O
B
O
O
O
GOTERM_BP_ALL spouioets kt =—_— 7 2.5E-3 7.3€-1
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GOTERM_BP_ALL requlation of programmedcell death RT mone 6 2.7E-3 6.4E-1
GOTERM_BP_ALL death RT —_— 7 3.4E-3 7.0E-1
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See cellular developmental process RT rane 7 1.1E-1 1.0E0
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J GOTERM_MF_ALL ribonucleotide binding RT mod 8 5.6E-2 1.0E0
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[-]  GOTERM_BP_ALL etch Goo 10 1.0E-1 1.00
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[7] SOTERM_MF_ALL RNA binding ao 3 4.0E-1 1.0E0
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GOTERM_MF_ALL hydrolase activity, acting on acid 9 4 1.2E-1 1.0E0J anhydrides a — ; 3
Annotation Cluster 13 EnrichmentScore: 0.92 Coree LEa
im GOTERM_BP_ALL intracellular protein transport RT as 4 3.7E-2 1.0E0
a GOTERM_BP_ALL protein transport RT ry A 1.3E-1 1.0E0
ir GOTERM_BP_ALL establishment of protein localization RT — 4 1.5E-1 1,0E0
Py GOTERM_BP_ALL protein localization RT oat A 1,7E-1  1.0€0
Py GOTERM_BP_ALL macromolecule localization RT iam 4 2.0E-1 1.0E0
Annotation Cluster 14 PeleseR eee
ry UP_SEQ_FEATURE transit peptide: Mitochondrion RT ‘i 3 1.5E-1 1.00
[-] $P-PIR.KEYWoRDS francepentiie Rt 3 1.6E-1 1.0E0
PCeaeae earneda MED 1 Count { P_Value i Benjamini
 
[] SPPIR_KEYWoRDS Taian Rt aa 3 3.6E-1 1.0E0
Annotation Cluster 15 eaenear
i] GOTERM_BP_ALL nervous syste elopment RT ny a 1.7E-1 1.0E0
I eeee system development RT = 5 4.0E-1 1.0E0
[| GOTERM_BP_ALL anatomical structure development RT as 5 5.7E-1 1.0E0
{| GOTERM_BP_ALL multicellular organismal development RT —_—1 5 6.4E-1 1.0E0
IF SERNEE multicellular organismal process RT ame 6 8.5E-1 1.0E0
[| GOTERM_MF_ALL fort oirdica i — 10 4.1E-1 1.0E0
[-]  GOTERM_MF_ALL Heealfiantbinding RT SEE 9 5.5E-1 1.0E0
[]  GOTERM_MF_ALL ton pnding ct 8 6.2E-1 1.0E0
Annotation Cluster 17 aametoy Herein i aeCe eatea
a GOTERM_BP_ALL requlation of metabolic process RT — 5 8.2E-1 1.0E0
| GOTERM_BP_ALL regulation of gene expression RT — 4 9.0E-1 1.0E0
Ir] GOTERM_BP_ALL requlation ofcellular metabolic process RT en 4 9.2E-1 1.0E0
t] GOTERM_BP_ALL regulation of transcription RT — 3 9.6E-1 1.0E0
GOTERM_BP_ALL nucleobase,Cc fucleotidenucleicacid metabolic gc —_ 3 9.7E-1 1.0E0process[7] SOTERM_BP_ALL tanecrnton RT (a 3 9.7E-1 1.0E0
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INTERPRO Heat shock protein Hsp70 RT esl 4 4.1E-6 2.4E-2
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SP_PIR_KEYWORDS chaperone RT — 5 1.6E-4 2.4E-2
SP_PIR_KEYWORDS stress response RT — 4 3.9E-4 5,1E-2
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GOTERM_BP_ALL regulation of apoptosis RT _— 7 8.9E-4 7.9E-1
GOTERM_BP_ALL regulation of programmedcell death RT —_ 7 9.4E-4 7.1E-1
GOTERM_BP_ALL apoptosis RT — 8 1.2E-3 5.8E-1
GOTERM_BP_ALL programmedcell death RT = 8 1.2E-3 5.6E-1
GOTERM_BP_ALL cell death RT neem 8 L7E-3" 9.5E-1
GOTERM_BP_ALL death RT — 8 1.7E-3 5.5E-1
GOTERM_BP_ALL cell development RT — 9 4.0E-3 7.4E-1
GOTERM_BP_ALL cellular developmental process RT acca 9 3.7E-2 1.0E0
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GOTERM_BP_ALL cellular protein metabolic process RT ney 16 3.1E-3 7.2E-1
GOTERMBTACL cellular macromolecule metabolic process RT iin 16 3.7E-3 7.5E-1
GOTERM_BP_ALL protein metabolic process RT ‘ccs 16 5.7E-3 8.1E-1
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[Pedensee intracellular
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RI ‘aati 7 3.7E-3 7.3E-1
a GOTERM_BP_ALL establishmentof cellular localization RT =e 7 L0E-2- S-1E-1
[| GOTERM_BP_ALE cellular localization RT ‘naan, 7 1.2E-2 9.2E-1
“| SP_PIR_KEYW ORDS nucleatide-binding RT canine 10 2.5E-3 2.1E-1
[] SPPIR_KEYWoRDS ito binding ee cece 8 8.1E-3 4.8E-1
~ | GOTERM_MF_ALL purine ribonucleotide binding RT ‘cas 10 1.7E-2 1.00
@ GOTERM_MF_ALL ribonucleotide binding RT kama 10 1.7E-2  1.0E0
GOTERM_MF_ALL purine nucleotide binding RT m/e 10 2.2E-2  1.0E0
GOTERM_MF_ALL ATP binding ct oa 8 4.1E-2 1.0E0
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eReom) eauecontae edl rae aeCEly
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GOTERM_MF_ALL hydrolase activity, acting on acid
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ee RRM RT nat 3 3.5E-2 1.0E0
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